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ABSTRACT	
Tailoring	medical	decisions	to	the	individual	patient	while	considering	the	scientific	evidence	has	always	
been	the	goal	of	evidence-based	medicine.	Similarly,	personalized	medicine	or	similar	terms	refer	to	the	
pursuit	 of	 health	 care	 that	 considers	 an	 individual’s	 predisposition,	 risk	 factors	 or	manifest	 illness	 but	
also	values	and	preferences	to	inform	medical	decisions.	A	possible	approach	for	personalized	medicine	
is	 to	 stratify	patients	 according	 to	 the	 risk	of	disease	or	 adverse	outcomes	as	estimated	by	prediction	
models	 that	 may	 include	 any	 indicators	 of	 the	 factors	 listed	 before.	 Estimated	 risks	 help	 balancing	
expected	benefits	and	harms	of	preventive	or	 therapeutic	 interventions	 for	an	 individual.	Hundreds	of	
prediction	 models	 have	 been	 developed	 across	 the	 medical	 field.	 Beside	 their	 clinical	 application,	
prediction	models	are	also	used	 in	research	to	control	 for	confounding,	to	efficiently	explore	subgroup	
effects	 or	 to	 identify	 patients	 that	 need	 to	 be	 in	 a	 predefined	 risk	 group	 in	 order	 to	 be	 eligible	 for	
randomized	controlled	trials.	
However,	prediction	models	often	 lack	external	validation	(to	ensure	generalizability)	and	comparisons	
among	each	other,	which	was	the	motivation	for	this	thesis.	This	thesis	focuses	on	prediction	models	for	
patients	with	Chronic	Obstructive	Pulmonary	Disease	(COPD)	to	predict	exacerbations	and	mortality	but	
had	 also	 the	 wider	 scope	 of	 methods	 development	 for	 externally	 validating	 prediction	 models	 and	
concurrently	comparing	their	performance.		
In	the	first	paper	of	this	thesis,	we	report	on	a	systematic	review	of	prediction	models	to	estimate	the	
risk	of	exacerbations	 in	patients	with	COPD.	We	included	25	studies	reporting	on	27	models	to	predict	
exacerbations.	 Outcome	 definitions,	 the	 number	 and	 type	 of	 predictors,	 time	 horizon,	 statistical	
methods	 and	 measures	 of	 prediction	 model	 performance	 were	 so	 heterogeneous	 that	 it	 was	 not	
possible	to	identify	the	most	accurate	prognostic	model	for	exacerbations.	We	identified	a	great	need	for	
external	validation	and	comparison	of	available	models	 in	order	to	inform	practice	on	which	models	to	
use.	 In	 the	 second	 paper,	 we	 describe	 the	 development	 of	 multiple	 score	 comparison	 (MSC)	 meta-
analysis	that	enables	external	validation	and	comparison	of	multiple	prediction	models	or	their	simplified	
versions	for	prognosis,	prognostic	scores.	We	provided	a	two-step	approach,	which	first	performs	meta-
analyses	 of	 the	 performance	 of	 prognostic	 scores	 among	 cohort	 studies	 that	 have	 data	 for	 the	 same	
prognostic	scores	and	then	aggregates	the	results	across	the	groups	of	cohorts.	The	method	builds	upon	
network	 meta-analytic	 techniques	 used	 for	 multiple	 treatment	 effect	 comparisons	 but	 deals	 with	 a	
number	of	challenges,	like	the	correlation	of	data	within	cohorts	(that	is	much	more	pronounced	than	in	
randomized	trials),	the	selection	of	the	predictive	performance	metric	(so	far	restricted	to	the	area	under	
the	 curve	 or	 discrimination,	 respectively)	 as	 well	 as	 the	 assessment	 of	 consistency,	 transitivity	 and	
heterogeneity.	 In	 the	 third	paper,	we	applied	our	methodology	 to	patients	with	COPD.	We	had	at	our	
disposal	a	large-scale	database	with	24	international	cohort	studies	and	15762	patients	(1871	deaths	and	
42203	person-years	of	follow-up)	from	primary,	secondary	and	tertiary	care	settings	that	provided	data	
to	 calculate	 between	 two	 and	 nine	 prognostic	 scores	 depending	 on	 the	 cohort	 study.	 The	ADO	 score	
(including	age,	dyspnea	and	forced	expiratory	volume	on	lung	function	measurement)	outperformed	all	
other	 scores	 to	 predict	 3-years	 mortality	 in	 COPD.	 The	 assumption	 of	 transitivity	 was	 not	 violated.	
Heterogeneity	across	direct	comparisons	was	small	and	we	did	not	identify	any	substantial	local	or	global	
inconsistency.	 Beside	 the	 predictive	 performance,	 the	 clinical	 applicability,	 namely	 the	 availability	 of	
predictors	and	associated	cost,	and	potential	harm	for	patients,	should	be	considered	to	recommend	any	
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prognostic	score	for	practice.	In	this	respect,	the	ADO	score	also	appeared	most	attractive	because	of	its	
simplicity	and	easy	availability	of	predictors.		
This	thesis	showed	that	prognostic	scores	to	estimate	the	risk	for	COPD	exacerbations	are	not	ready	for	
practice	 because	 they	 lack	 external	 validation	 and	 comparisons	 among	 each	 other.	 An	 accurate	
prediction	 model	 for	 exacerbations	 is,	 however,	 of	 great	 important	 for	 personalized	 care	 of	 COPD	
patients	since	prognostic	knowledge	provides	great	value	for	the	benefit-harm	assessment	of	drug	and	
non-drug	 therapies	 and	 supports	 the	prevention	of	 exacerbation	as	 a	 key	 goal	 of	 COPD	management.	
The	methodology	for	MSC	meta-analysis	developed	and	applied	here	shows	a	novel	and	much	needed	
way	 to	 externally	 validate	 and	 compare	 prognostic	 scores.	 While	 we	 showed	 an	 example	 of	 its	
application	for	prediction	models	to	estimate	the	risk	of	mortality	in	COPD	patients,	MSC	meta-analysis	
can	 be	 applied	 to	 any	 field	 of	 medicine	 and	 addresses	 the	 great	 need	 for	 external	 validation	 and	
comparison	of	prediction	models.	Thereby,	the	best	prediction	models	can	be	identified	paving	the	way	
for	risk-stratified,	personalized	medicine.	
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ZUSAMMENFASSUNG	
Das	Ziel	evidenzbasierter	Medizin	ist	es	seit	jeher,	medizinische	Entscheidungen	unter	Einbeziehung	der	
wissenschaftlichen	 Evidenz	 für	 den	 einzelnen	 Patienten	 zu	 finden.	 Gleichermassen	 verweisen	
personalisierte	Medizin	und	ähnliche	Begriffe	auf	eine	medizinische	Versorgung,	welche	die	individuelle	
Prädisposition,	Risikofaktoren	und	manifeste	Krankheiten,	aber	auch	Wertvorstellungen	und	Präferenzen	
bei	medizinischen	Entscheidungen	berücksichtigt.	Ein	möglicher	Ansatz	zur	personalisierten	Medizin	 ist	
die	 Stratifizierung	 von	Patienten	nach	Krankheitsrisiko	oder	dem	Risiko	 von	Ereignissen.	Diese	 können	
mittels	 	 Prognosemodellen	 geschätzt	 werden,	 die	 verschiedene	 der	 zuvor	 genannten	 Faktoren	 mit	
einbeziehen.	Risikoschätzungen	helfen	dabei,	den	erwarteten	Nutzen	und	die	Risiken	präventiver	oder	
therapeutischer	 Interventionen	 gegeneinander	 abzuwägen.	 Eine	 Vielzahl	 von	 Prognosemodellen	 ist	 im	
medizinischen	 Bereich	 entwickelt	 worden.	 Neben	 ihrer	 klinischen	 Anwendung	 finden	 sie	 auch	 in	 der	
Forschung	Verwendung,	etwa	zur	Kontrolle	von	Confounding	(Störgrössen),	zur	effizienten	Untersuchung	
subgruppenspezifischer	 Effekte	 oder	 zur	 Identifizierung	 von	 Patienten,	 welche,	 um	 in	 eine	 klinische	
Studie	 aufgenommen	 werden	 zu	 können,	 einer	 vorspezifizierten	 Risikogruppe	 angehören	 müssen.	
Jedoch	 fehlt	 es	 oft	 an	 einer	 externen	 Validierung	 der	 Prognosemodelle	 (um	 die	 Generalisierbarkeit	
sicherzustellen)	 sowie	 am	 Vergleich	 zu	 anderen	 Modellen.	 Dies	 stellt	 die	 Hauptmotivation	 für	 die	
vorliegende	Dissertation	dar.	 Ihr	Fokus	 liegt	auf	Prognosemodellen	 für	Exazerbation	und	Mortalität	bei	
Patienten	mit	chronisch	obstruktiver	Lungenerkrankung	(chronic	obstructive	pulmonary	disease,	COPD),	
sie	 behandelt	 aber	 auch	 allgemeiner	 Methoden	 zur	 externen	 Validierung	 und	 zum	 gleichzeitigen	
Vergleich	von	Prognosemodellen.	
Der	 erste	 Artikel	 dieser	 Dissertation	 stellt	 einen	 systematischen	 Review	 von	 Prognosemodellen	 zur	
Schätzung	des	Risikos	einer	Exazerbation	bei	COPD-Patienten	dar.	Insgesamt	25	Studien	mit	27	Modellen	
zur	Vorhersage	einer	Exazerbation	wurden	einbezogen.	Die	Definition	des	Outcomes,	Zahl	und	Art	der	
Prädiktoren,	 Zeithorizonte	 sowie	 statistische	 Methoden	 und	 Masse	 für	 die	 Prognosegüte	 waren	 so	
heterogen,	 dass	 es	 nicht	 möglich	 war,	 das	 genaueste	 Vorhersagemodell	 auszumachen.	 Es	 wurde	
deutlich,	 dass	 ein	 grosser	 Bedarf	 nach	 externer	 Validierung	 und	 dem	 Vergleich	 verfügbarer	 Modelle	
besteht,	um	zu	bestimmen,	welche	Modelle	in	der	Praxis	verwendet	werden	sollten.	Im	zweiten	Artikel	
beschreiben	wir	die	Entwicklung	der	Multiple	Score	Comparison	(MSC)	Meta-Analyse,	die	es	ermöglicht,	
verschiedene	Prognosemodelle	 oder	 -scores	 extern	 zu	 validieren	und	 zu	 vergleichen.	Wir	 schlagen	ein	
Zweischrittverfahren	vor:	Zunächst	wird	eine	Meta-Analyse	für	die	Güte	von	prognostischen	Scores	über	
verschiedene	Kohortenstudien,	deren	Daten	die	Berechnung	der	selben	Scores	erlauben,	durchgeführt.	
Die	 Ergebnisse	 werden	 über	 die	 verschiedenen	 Kohortenstudien	 aggregiert.	 Die	 Methode	 baut	 auf	
Techniken	 der	 Netzwerkmetaanalyse	 zur	 Kombination	 mehrerer	 Vergleiche	 von	 Behandlungseffekten	
auf.	 Sie	 muss	 jedoch	 mit	 verschiedenen	 Schwierigkeiten	 umgehen	 können,	 etwa	 der	 Korrelation	 von	
Daten	aus	der	selben	Kohorte	(welche	weitaus	stärker	ausgeprägt	ist	als	bei	randomisierten	Studien),	der	
Auswahl	 von	Massen	 für	 die	 Prognosegüte	 (bisher	 auf	 die	Area	under	 the	Curve	bzw.	Diskriminierung	
beschränkt)	sowie	der	Beurteilung	von	Konsistenz	und	Transitivität.	Im	dritten	Artikel	wenden	wir	unsere	
Methode	 auf	 COPD-Patienten	 an.	 Hierfür	 stand	 uns	 eine	 grosse	 Datenbank	 mit	 24	 internationalen	
Kohortenstudien	und	15762	Patienten	(1871	Todesfälle	und	42203	Personenjahre	Follow-up)	aus	Primär-
,	 Sekundär-	 und	 Tertiärversorgung	 zur	 Verfügung.	 Je	 nach	 Kohortenstudie	 erlaubten	 diese	 Daten	 die	
Berechnung	von	zwischen	zwei	und	neun	prognostischen	Scores.	Der	ADO	Score	(welcher	Alter,	Atemnot	
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und	 das	 forcierte	 exspiratorische	 Volumen	 aus	 einem	 Lungenfunktionstest	 beinhaltet)	 schnitt	 bei	 der	
Vorhersage	von	Dreijahresmortalität	bei	COPD-Patienten	am	besten	ab.	Die	Transitivitätsannahme	war	
nicht	 verletzt,	 die	 Heterogenität	 zwischen	 direkten	 Vergleichen	 war	 gering	 und	 wir	 konnten	 keine	
wesentliche	 lokale	oder	globale	 Inkonsistenz	 feststellen.	Neben	der	Vorhersagegüte	sollte	die	klinische	
Anwendbarkeit,	 insbesondere	 die	 Verfügbarkeit	 von	 Prädiktoren	 und	 die	 damit	 verbundenen	 Kosten,	
sowie	 potenzielle	 Risiken	 für	 den	 Patienten	 bei	 der	 Empfehlung	 eines	 Scores	mit	 einbezogen	werden.	
Auch	 in	 dieser	 Hinsicht	 erschien	 der	 ADO	 Score	 aufgrund	 seiner	 Einfachheit	 und	 der	 leichten	
Verfügbarkeit	der	Prädiktoren	am	attraktivsten.	
Die	 vorliegende	 Dissertation	 zeigt,	 dass	 prognostische	 Scores	 zur	 Schätzung	 des	 Risikos	 einer	
Exazerbation	 bei	 COPD-Patienten	 für	 die	 Praxis	 noch	 nicht	 bereit	 sind,	 da	 externe	 Validierung	 und	
Vergleiche	 zwischen	 Scores	 fehlen.	 Ein	 präzises	 Prognosemodell	 für	 Exazerbationen	 ist	 jedoch	 von	
grosser	 Wichtigkeit	 für	 die	 individuelle	 Behandlung	 von	 COPD-Patienten.	 Prognostisches	 Wissen	 ist	
wertvoll	 für	 Nutzen-Risiko-Analysen	 von	 medikamentösen	 und	 nicht-medikamentösen	 Behandlungen	
und	unterstützt	mit	der	Vermeidung	von	Exazerbationen	eines	der	Kernziele	des	COPD-Managements.	
Die	 hier	 entwickelte	 und	 angewandte	 MSC-Metaanalyse-Methode	 stellt	 ein	 neues	 und	 dringend	
benötigtes	Verfahren	 zur	externen	Validierung	und	 zum	gleichzeitigen	Vergleich	prognostischer	 Scores	
dar.	 Während	 unser	 Anwendungsbeispiel	 Prognosemodelle	 zur	 Schätzung	 des	 Mortalitätsrisikos	 von	
COPD-Patienten	behandelt	 kann	die	Methode	 in	 jedem	Teilgebiet	der	Medizin	Anwendung	 finden	und	
begegnet	dem	grossen	Bedarf	zur	externen	Validierung	und	zum	Vergleich	von	Prognosemodellen.	Auf	
diese	 Weise	 können	 die	 besten	 Prognosemodelle	 ausgemacht	 werden	 und	 den	 Weg	 für	
risikostratifizierte,	personalisierte	Medizin	bereiten.	
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Prediction	models	in	medical	practice	
Prediction	models	assess	a	person’s	 risk	of	developing	a	disease	or	an	adverse	outcome	 in	 the	 future.	
They	are	 supposed	 to	be	helpful	 in	 clinical	 practice,	 public	health	management	 and	medical	 research1	
and	 it	 has	 been	 shown	 that	 prediction	 models	 can	 be	 as	 accurate	 as	 physicians’	 assessments2,3	 and	
realistically	 complement	 them	 in	 a	 fruitful	 way.	 In	 some	 medical	 fields,	 leading	 guidelines	 strongly	
recommend	the	use	of	prediction	models	or	 the	underlying	 risk	prediction	scores	 for	clinical	practice.4	
For	 instance,	 in	 cardiovascular	medicine,	 risk	 scores	 are	 used	 in	 clinical	 practice	 to	 guide	 primary	 and	
secondary	 prevention	 of	 cardiovascular	 disease.5–8	 Many	 other	 clinical	 fields	 also	 know	 prediction	
models.9–15			
	
The	most	renowned	example	of	a	prognostic	model	 is	probably	the	Framingham	risk	score	to	estimate	
the	 risk	 of	myocardial	 infarction	 or	 stroke	 over	 10	 years.16	 Online,	 tablet	 or	 smartphone	 applications	
have	been	made	available	(Figure	1)	that	make	it	easy	for	clinicians	to	use	such	risk	scores.	For	example,	
it	 predicts	 a	 5%	 risk	 of	 a	myocardial	 infarction	 or	 stroke	 over	 10	 years	 for	 a	 50-year-old	 non-smoking	
male	with	210	mg/dL	total	cholesterol,	50mg/dL	High-Density	Lipoprotein	(HDL)	cholesterol,	130	mm/Hg	
systolic	blood	pressure	and	not	on	medication	for	high	blood	pressure	Figure	1.	
	
	
	
	
	
	
	
	
Figure	1	Framingham	score	assessment	(https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf)	
	
The	estimated	risk	supports	the	treating	physician	in	the	preventive	or	therapeutic	choice	according	to	
the	 expected	 benefit-harm	 balance,	 that	 is,	 to	 prescribe	 treatments	 only	 if	 the	 benefits	 (in	 terms	 of	
reduced	risk	of	adverse	outcome)	are	expected	to	outweigh	the	harms.	For	example,	 in	cardiovascular	
primary	prevention,	the	use	of	lipid	lowering	drugs	in	addition	to	a	healthy	lifestyle	is	only	recommended	
if	 the	10-year	 risk	of	 a	myocardial	 infarction	or	 stroke	exceeds	 some	 risk	 threshold	 (e.g.	10%)	 since	 in	
lower	risk	people	the	harms	from	these	drugs	outweigh	the	expected	benefit.		
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Risk	 thresholds	 for	 recommending	 for	 or	 against	 treatment	 can	 be	 determined	 using	 quantitative	
benefit-harm	 assessment	 that	 takes	 into	 account	 outcome	 risks	 of	 a	 population	 or	 its	 subgroups,	
treatment	 effects	 as	 estimated	 in	 randomized	 trials	 as	 well	 as	 the	 importance	 of	 benefit	 and	 harm	
outcomes.	For	example,	a	quantitative	benefit-harm	assessment	suggested	that	a	novel	drug	for	patients	
with	chronic	obstructive	pulmonary	disease	(COPD)	is	only	indicated	if	the	one	year	risk	for	very	severe	
exacerbations	 requiring	 a	 hospital	 admission	 is	 at	 least	 20%.17	 Below	 this	 risk,	 the	 harm	 from	
gastrointestinal,	 psychiatric	 and	neurological	 side	 effects	 is	 very	 likely	 to	outweigh	 the	benefits	 of	 the	
novel	drug.	 For	 clinicians	 to	act	on	 such	evidence	 it	 is	 a	prerequisite	 to	estimate	 risks	 for	 such	events	
accurately	 based	 on	 prediction	 models	 or	 their	 simplified	 version	 for	 prognosis,	 namely,	 prognostic	
scores.		
Prediction	Models	in	Medical	Research	
Prediction	models	can	also	serve	medical	research,	for	instance	for	the	design	of	randomized	controlled	
trials	 (RCT),	 for	 efficiently	 identifying	 subgroup	 effects,	 for	 statistical	 analysis	 (adjustment	 for	
confounders)	in	RCTs	and	observational	studies.	
RCT	should	define	eligibility	in	a	way	that	ensures	the	safety	of	patients	both	with	respect	to	benefit	and	
harm	 outcomes.	 In	 some	 situations,	 for	 example	 as	 described	 before	 for	 the	 novel	 drugs	 to	 prevent	
exacerbations	 in	 COPD	 patients,	 harms	 can	 be	 expected	 so	 that	 only	 patients	 at	 higher	 risk	 for	 the	
outcome	to	be	prevented	should	be	 included	 in	whom	the	benefit	harm	balance	may	be	 favorable.	 In	
other	instances,	there	may	be	a	specific	side	effect	certain	participants	are	susceptible	to	and	where	it	is	
not	safe	to	enroll	them	into	a	RCT.	For	example,	people	at	high	risk	for	gastrointestinal	bleeds	have	been	
excluded	from	RCTs	on	low	dose	aspirin	for	primary	cardiovascular	prevention	to	minimize	risks.	In	these	
situations,	 prediction	 models	 can	 help	 to	 explicitly	 estimate	 the	 risk	 of	 the	 outcome	 of	 interest	 and	
include	or	exclude	patients	accordingly.		
Another	application	is	pre-stratification	in	an	RCT,	in	order	to	control	for	confounding.	Confounders	are	
defined	 as	 variables	 that	 are	 associated	with	 both	 the	 exposure	 and	 the	 outcome	 and	 do	 not	 act	 as	
mediators,	 possibly	 biasing	 the	 relationship	 of	 exposure	 and	 outcome.	 In	 small	 RCTs	 or	 even	 in	
moderately	sized	RCTs	with	populations	that	have	diverse	outcome	expectations,	randomization	may	not	
yield	 balanced	 groups.	 Pre-stratification	 offers	 additional	 control	 for	 confounding.	 Prediction	 models	
carry	more	information	than	single	characteristic	so	that	the	predicted	risk	can	be	used	for	more	efficient	
pre-stratification.	 Similar	 efficiency	 considerations	 apply	 to	 the	 statistical	 control	 for	 confounding	
through	adjustment	or	for	the	identification	of	effect	modification	in	RCTs	or	observational	studies.	If	the	
number	of	events	is	limited	statistical	models	may	not	afford	many	covariates	to	adjust	for	confounding	
or	 to	 identify	 differences	 in	 effects	 across	 subgroups.	 Prediction	 models,	 by	 combining	 pertinent	
outcome	 predictors,	 carries	 more	 information	 than	 single	 characteristics	 and	 offer	 a	 way	 for	 more	
parsimonious	models	without	losing	(much)	information.		
The	problem	of	lacking	validations	and	comparisons	of	prediction	models	
Most	 clinical	 fields	 have	 still	 a	 long	way	 to	 go	 on	 the	 path	 between	model	 development	 and	 clinical	
application	since	 the	generalisability	of	 the	models	and	their	clinical	effectiveness	must	be	ensured.	 In	
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particular,	 the	 generalisability	 of	 a	 prediction	model	 is	 ensured	 by	 demonstrating	 good	 accuracy	 (i.e.	
prognostic	 properties	 in	 its	 derivation	 cohort,	 namely	 the	 cohort	 in	 which	 it	 was	 developed),	 good	
reproducibility	 (i.e.	a	good	performance	of	 the	model	 in	 the	same	source	population	of	 the	derivation	
cohort)	 and	 good	 transportability	 (i.e.	 a	 good	 performance	 of	 the	 model	 in	 a	 different	 population).18	
Researchers	often	develop	new	models	instead	of	checking	for	the	generalisability	of	the	existing	model	
and	the	need	for	a	new	model	at	all	first.	Steyerberg	provided	an	excellent	framework	for	how	to	build	
upon	existing	models	before	embarking	on	model	extensions	or	even	the	development	of	new	prediction	
models.1	
Prediction	models	 have	 been	 developed	 to	 assess	 the	 individual	 risk	 of	 adverse	 outcomes	 in	 various	
medical	 fields.	 For	 instance,	 over	 the	 past	 two	 decades,	 numerous	 prediction	 models	 have	 been	
developed	 to	 estimate	 the	 risk	 of	 developing	 cardiovascular	 disease.	 A	 recent	 systematic	 review	
concerning	 prediction	models	 for	 cardiovascular	 disease	 risk	 in	 the	 general	 population19	 included	 212	
studies,	referring	to	the	development	of	363	prediction	models	and	473	external	validations.	Only	132	of	
the	developed	models	 (36%)	were	 externally	 validated,	 and	only	 70	 (19%)	 of	 these	were	 validated	by	
independent	investigators.		
Even	 if	 many	 scores	 have	 been	 developed	 and	 published,	 they	 are	 sometimes	 not	 used	 in	 clinical	
practice.	One	 reason	 for	 general	 practitioners	not	using	 them	 is	 the	 lack	of	 external	 validation	 so	 that	
they	do	not	know	if	a	prognostic	model	predicts	a	risk	accurately	for	“their”	patients20,21,	a	prerequisite	
for	 generalizability18,22.	 Indeed,	 a	 prerequisite	 for	 the	 models’	 reliability	 is	 that	 the	 risk	 of	 adverse	
outcome(s)	can	be	accurately	predicted	by	a	prediction	model1,23,24	that	has	been	thoroughly	developed	
and	 validated.25–28	 In	 addition,	 Steyerberg’s	 framework	 for	 updating	 prediction	models	 starting	 with	 a	
scale	that	goes	from	simply	adjusting	the	intercept	to	developing	(and	validating)	an	entirely	new	model	
is	rarely	followed.1,29,30	Furthermore,	many	validation	studies	still	do	not	validate	(or	update)	the	original	
prognostic	score,	but	rather	develop	a	second	model.	This	practice	has	led	to	numerous	prognostic	scores	
for	the	same	conditions	that	have	not	been	externally	validated.	If	prognostic	scores	are	validated	at	all,	
there	is	usually	a	focus	on	a	single	score,	while	comparisons	with	other	prognostic	scores	are	lacking.	The	
applicability	 of	 prediction	models	 is	 hindered	 by	 the	 lack	 of	 comparisons	 among	 available	 prognostic	
scores.31	It	is	not	yet	clear	which	prediction	model	predicts	mortality	most	accurately	and	is	applicable	in	
daily	practice.		
Need	of	a	New	Methodology	
Ideally,	researchers	should	perform	an	external	validation	and	comparison	of	all	the	developed	scores.31	
Indeed,	 the	 collection	 of	 “big	 data”	 is	 becoming	 more	 common32	 as	 is	 the	 growing	 availability	 of	
individual	patient	data	(IPD).33–38	International	collaborative	efforts39–41	start	to	give	life	to	the	call	of	the	
medical	 community	 for	 data	 sharing.42	 Thus,	 researchers	 are	 provided	 with	 new	 opportunities	 (and	
challenges)43,44.	For	example,	there	may	be	the	possibility	of	checking	a	model’s	predictive	performance	
across	 clinical	 settings,	 populations,	 and	 subgroups43	 or	 of	 updating	 (or	 recalibrating)	 models,1	 or	
allowing	 for	head-to-head	comparisons;43,45	a	challenge	 is	 checking	 the	 transportability	associated	with	
external	 validation	 studies.46	A	 possible	 approach	 to	 compare	 several	 scores	 together	 across	 different	
cohorts	 is	 to	pool	available	databases	and	then	perform	the	comparative	analysis	on	 the	single	pooled	
cohort.	 A	 recent	 example	where	 available	 databases	 are	 pooled	 together	 in	 order	 to	 compare	 all	 the	
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available	prediction	scores	together	is	the	COCOMICS	study	that	compared	several	scores	to	estimate	the	
risk	of	mortality	in	patients	with	COPD.47		
Extending	 the	 simple-pooling	 approach	 to	 pool	 direct	 comparisons	 taken	 from	 different	 studies	 is	 a	
logical	next	step,	to	explore	heterogeneity	and	its	effects	on	the	usefulness	of	prognostic	scores.	Indeed,	
in	prognostic	performance	comparison,	simply	reporting	a	model’s	overall	performance	(averaged	across	
all	 clusters	 and	 individuals)	 is	 not	 sufficient	 because	 it	 can	mask	 differences	 across	 these	 clusters	 and	
subgroups	(in	the	same	way,	as	analyzing	pooled	data	not	weighting	them,	would	ignore	characteristics	
of	 the	 subgroups	 and	 individual	 studies	 being	 pooled	 in	 comparison	 to	 a	meta-analysis)48,49.	 Potential	
users	need	to	know	whether	or	not	a	model	is	reliable	or	transportable	to	all	the	settings,	populations,	
and	groups	represented	in	the	data,43	relying	as	well	on	a	careful	interpretation	of	the	external	validation	
studies.46		
Prediction	models	in	COPD	
COPD	 is	 a	 complex	 disease	 and	 medical	 literature	 indicates	 management	 guidelines	 that	 categorize	
patients	according	to	the	severity	of	airflow	limitation	(GOLD	1,	2,	3,	4)	according	to	the	FEV1	%	of	the	
predicted	value	for	COPD	patients	with	of	a	specific	sex,	age	height	and	ethnicity).50–53	However,	there	is	
weak	 correlation	 between	 this	 categorization	 and	 symptoms	 of	 a	 COPD	 patient.	 Thus,	 a	 more	
comprehensive	 categorization	 (GOLD	 A,	 B,	 C,	 D)	 was	 created,	 to	 have	 a	 better	 understanding	 of	 the	
impact	 of	 the	 disease	 on	 COPD	 patients.	 This	 new	 tool	 includes,	 not	 only	 the	 spirometric	 grade	 (i.e.	
airflow	limitation),	but	also	the	exacerbation	risk	of	the	patient,	in	order	to	highlight	the	importance	of	
prevention	and	quality	of	life.50	Both	of	these	assessments	were	proven	to	poorly	perform	for	prediction	
of	 mortality	 and	 other	 health-related	 outcomes.40	 Thus,	 for	 the	 purpose	 of	 prediction,	 without	
considering	the	symptom	assessment,	specific	prediction	models	have	to	be	developed.		
Indeed,	starting	in	2004	with	the	BODE	index,54	several	prognostic	scores	incorporating	clinical	and	non-
clinical	factors	(including	symptoms,	patient	history,	functional	capacity	tests	and	biomarkers)	have	been	
developed	 to	estimate	 the	 risk	of	mortality,54–67	 or	 exacerbations60,61,68–95,	 the	 course	of	health-related	
quality	of	life70	or	resource	utilisation91	in	patients	with	COPD.	For	COPD,	surveys	show	that	the	majority	
of	physicians	do	not	consider	the	patient's	prognosis	(i.e.	 in	terms	of	exacerbations	or	mortality)	when	
prescribing	 COPD	 treatments	 unless	 the	 patients	 have	 very	 severe	 disease	 (e.g.	 requiring	 oxygen	 or	
surgery)	 and	 that	 current	 medical	 practice	 deviates	 substantially	 from	 the	 GOLD	 and	 other	
guidelines.39,96–99		
Exacerbations	 are	 an	 ideal	 target	 for	 risk-stratified	 treatment	 since	 they	 are	 one	 of	 the	most	
important	outcomes	for	COPD	patients	and	avoiding	them	leads	to	a	higher	health-related	quality	of	life,	
longer	life	and	lower	health-care	costs.	“All-cause	mortality”	is	a	more	consolidated	outcome	because	of	
the	hard	endpoint	definition	and	has	a	longer	history	in	the	medical	literature;	the	first	developed	score	
dates	back	to	200454.	Today,	no	treatments	to	 lower	the	risk	of	mortality	are	yet	available	for	patients	
with	COPD;	thus,	for	this	outcome,	prediction	scores	cannot	provide	risk-stratified	treatment	guidance.	
However,	 prognostic	 scores	may	help	 to	make	 randomized	 trials	with	 all-cause	mortality	 as	 a	 primary	
outcome	 more	 efficient	 by	 only	 including	 patients	 at	 higher	 risk.100,101	 Furthermore,	 for	 such	 multi-
morbid	 patients,	 as	 COPD	 patients	 (where	 cardiovascular	 disease,	 diabetes,	 renal	 disease	 and	 lung	
cancer	can	contribute	to	death)102,103	high	risk	of	death	for	COPD	has	implications	on	which	could	be	the	
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optimal	 prevention	 and	 treatment	 of	 cardiovascular	 prevention,	 lung	 cancer	 screening	 or	 other	
treatments.	Thus,	over-	and	under-treatment	in	COPD	could	be	avoided.	
	
	
Thesis	Outline	
This	 thesis	 focuses	 on	 prediction	 models	 for	 patients	 with	 Chronic	 Obstructive	 Pulmonary	 Disease	
(COPD)	to	predict	exacerbations	and	mortality	but	had	also	the	wider	scope	of	methods	development	for	
externally	validating	prediction	models	and	concurrently	comparing	their	performance.		
In	 the	 second	 chapter,	we	 report	 on	 a	 systematic	 review	of	prediction	models	 to	 estimate	 the	 risk	 of	
exacerbations	in	patients	with	COPD.	Chapter	3	describes	the	development	of	multiple	score	comparison	
(MSC)	meta-analysis	 that	enables	external	validation	and	comparison	of	multiple	prediction	models.	 In	
chapter	 4,	 the	 first	 application	 of	MSC	meta-analysis	methodology	 is	 described.	 For	 that	 purpose,	we	
used	a	large-scale	database	with	24	international	cohort	studies	and	15762	patients	that	provided	data	
to	 calculate	 and	 compare	 between	 two	 and	 nine	 prognostic	 scores	 depending	 on	 the	 cohort	 study.	
Finally,	chapter	5	includes	a	discussion	of	findings,	their	implication	for	the	practice	as	well	as	for	further	
research	in	COPD	and	beyond.	
	
A	brief	introduction	of	the	chapters	follows:	
	
CHAPTER	1:	General	Introduction	
	
CHAPTER	2:	Prediction	models	for	exacerbations	in	patients	with	COPD:	A	systematic	review	
This	paper	illustrates	a	systematic	review	of	models	predicting	exacerbations	in	patients	with	COPD.	We	
identified	 25	 studies	 reporting	 on	 27	 statistical	 prediction	 models	 for	 exacerbation	 in	 patients	 with	
COPD.	The	prediction	models	differ	greatly	 in	terms	of	how	they	were	developed	and	which	predictors	
and	measures	for	their	predictive	performance	were	used.	Most	studies	were	of	good	quality	concerning	
the	clinical	settings	and	tests	(i.e.	selection,	definition	and	measurement	of	predictors	and	outcomes	and	
in	 terms	of	how	patients	were	selected).	However,	most	of	 the	prediction	models	were	at	high	 risk	of	
bias	because	of	unsound	statistical	methods	used	to	develop	prediction	models	and	a	lack	of	validation.	
The	overall	assessment	of	 readiness	of	 the	27	prediction	models	 for	use	 in	practice	showed	that	none	
were	ready	for	clinical	application.	
	
CHAPTER	3:	Multiple	Score	Comparison:	A	network	meta-analysis	approach	to	comparison	and	external	
validation	of	prognostic	scores	
This	paper	 illustrates	a	novel	methodology	that	we	named	“Multiple	Score	Comparison	meta-analysis”,	
that	 allows	 one	 to	 externally	 validate	 different	 prognostic	 scores	 and	 concurrently	 compare	 their	
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predictive	 performance.	 It	 is	 a	 frequentist	 two-stage	 network	 meta-analytic	 approach	 to	 compare	 all	
scores	within	a	single	analytical	 framework	accounting	 for	correlations	between	scores	within	cohorts.	
We	 assessed	 heterogeneity,	 inconsistency	 and	 transitivity	 and	 provided	 a	 performance	 ranking	 of	 the	
prognostic	scores.		
CHAPTER	 4:	 A	 novel	 comprehensive	 approach	 for	 large-scale	 external	 validation	 and	 comparison	 of	
prognostic	models:	An	application	to	chronic	obstructive	pulmonary	disease	
This	paper	refers	to	the	clinical	application	of	the	MSC	meta-analysis	to	a	large-scale	database	of	patients	
with	COPD.	This	study	was	based	on	26	cohort	studies	of	the	COPD	Cohorts	Collaborative	International	
Assessment	(3CIA)	consortium.	Our	study	had	2	main	findings.	Firstly,	our	results	indicated	that	the	ADO	
index	 has	 the	 best	 ability	 to	 predict	 3-year	mortality	 in	 patients	with	 COPD,	 followed	 by	 the	 updated	
BODE	and	eBODE	indices.	Given	its	simplicity,	the	ADO	index	may	be	the	most	attractive	option	across	
care	settings	to	inform	patients	and	health	care	professionals	about	prognosis	and	to	inform	treatment	
decisions	 whose	 effectiveness	 may	 depend	 on	 life	 expectancy.	 Secondly,	 we	 showed	 how	 our	 novel	
methodology	(MSC	meta-analysis)	meets	the	call	of	top	medical	journals	for	new	approaches	for	external	
validation	and	concurrent	comparison	of	risk	prediction	models	and	scores	that	should	take	advantage	of	
data	sharing,	individual	patient	data	(IPD)	and	advanced	analytical	techniques.	
	
CHAPTER	5:	General	Discussion	
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Abstract	
Personalised	medicine	aims	to	tailor	medical	decisions	to	the	individual	patient.	A	possible	approach	is	to	
stratify	patients	according	to	the	risk	of	adverse	outcomes	such	as	exacerbations	in	COPD.	Risk-stratified	
approaches	 are	 particularly	 attractive	 for	 drugs	 like	 inhaled	 corticosteroids	 or	 phosphodiesterase-4	
inhibitors	 that	 reduce	 exacerbations	 but	 are	 associated	with	 harms.	 However,	 it	 is	 currently	 not	 clear	
which	models	are	best	to	predict	exacerbations	in	patients	with	COPD.	Therefore,	our	aim	was	to	identify	
and	 critically	 appraise	 studies	 on	 models	 that	 predict	 exacerbations	 in	 COPD	 patients.	 Out	 of	 1382	
studies,	 25	 studies	 with	 27	 prediction	 models	 were	 included.	 The	 prediction	 models	 showed	 great	
heterogeneity	 in	 terms	 of	 number	 and	 type	 of	 predictors,	 time	 horizon,	 statistical	 methods	 and	
measures	of	prediction	model	performance.	Only	2	out	of	25	studies	validated	the	developed	model,	and	
only	1	out	of	27	models	provides	estimates	of	 individual	exacerbation	risk,	only	3	out	of	27	prediction	
models	used	high	quality	statistical	approaches	for	model	development	and	evaluation.	Overall,	none	of	
the	existing	models	 fulfilled	 the	requirements	 for	 risk-stratified	 treatment	 to	personalise	COPD	care.	A	
more	harmonised	approach	to	develop	and	validate	high	quality	prediction	models	 is	needed	to	move	
personalised	COPD	medicine	forward.	
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Introduction	
Personalised	medicine	 aims	 to	 tailor	medical	 decisions	 to	 the	 individual	 patient	 104,105.	 The	 interest	 in	
personalised	respiratory	medicine	has	risen	recently	but	 it	has	not	been	introduced	much	into	practice	
yet	106,107.	For	patients	with	Chronic	Obstructive	Pulmonary	Disease	(COPD)	108,	a	possible	approach	for	
personalising	medical	treatments	is	to	stratify	patients	according	to	the	risk	of	exacerbations	in	order	to	
prescribe	 treatments	 	 such	 as	 inhaled	 corticosteroids	 or	 phosphodiesterase-4	 inhibitors	 only	 if	 their	
benefits	 in	 terms	of	 reduced	risk	of	exacerbations	109	are	expected	to	outweigh	the	harms	17,110,111.	For	
example,	a	recent	benefit	harm	assessment	of	the	phosphodiesterase-4	 inhibitor	roflumilast	suggested	
that	 the	risk	 for	severe	exacerbations	requiring	hospital	admissions	needs	to	be	at	 least	20%	over	one	
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year	 so	 that	 the	 expected	 benefits	 (in	 terms	 of	 reducing	 severe	 exacerbations)	 overcome	 the	
gastrointestinal,	psychiatric	and	neurological	side	effects	of	roflumilast	17.	
Exacerbations	 are	 an	 ideal	 target	 for	 risk-stratified	 treatment	 since	 it	 is	 one	 of	 the	 most	 important	
outcomes	for	COPD	patients	and	avoiding	them	is	likely	to	lead	to	a	higher	health-related	quality	of	life,	
longer	life	and	less	health-care	cost.	However,	a	prerequisite	for	risk-stratified	treatment	is	that	the	risk	
of	 exacerbations	 can	 be	 accurately	 predicted	 by	 a	 prediction	 model	 1,23,24	 that	 has	 been	 thoroughly	
developed	and	validated	25–28.	A	number	of	models	predicting	exacerbations	in	COPD	patients	have	been	
published	reporting	on	combinations	of	information	from	patient	history,	clinical	characteristics	and	test	
results	 including	biomarkers	 to	predict	 exacerbations.	 It	 is	 still	 not	 clear	 yet,	 though,	which	prediction	
model	predicts	exacerbations	most	accurately	and	 is	applicable	 in	daily	practice.	For	this	reason,	along	
with	the	lack	of	other	systematic	reviews,	the	aim	of	this	systematic	review	was	to	identify	and	critically	
appraise	 studies	 presenting	models	 predicting	 exacerbations	 in	 COPD	 patients	 that	may	 support	 risk-
stratified	and	personalised	treatment.	
	
Materials	and	Methods	
The	authors	 followed	the	Center	 for	Reviews	and	Dissemination	guidance	 for	 the	methodology	 112	and	
the	PRISMA	statement	for	the	reporting	113,114.		
Protocol	
We	wrote	a	detailed	study	protocol	in	advance	(see	online	material).	We	carefully	followed	the	protocol	
and	recorded	any	deviations	from	it.	
Search	methods	
We	 identified	 eligible	 papers	 through	 a	 search	 of	 the	 databases	Medline	 (from	 1949),	 Embase	 (from	
1974)	and	Scopus	(from	1996).	The	search	was	performed	by	an	information	specialist	of	the	University	
of	 Zurich	 (Zurich,	 Switzerland).	 Additional	 studies	were	 identified	 through	 the	Pubmed-related	 articles	
function	and	reference	list	of	included	studies,	author	contacts,	narrative	reviews	or	the	grey	literature	
(reports,	dissertation,	conference	abstracts	or	papers).		
Participants	
To	be	eligible	for	inclusion,	patients	were	required	to	have	a	COPD	diagnosis	according	to	GOLD	criteria	
(i.e.	 the	 ratio	 between	 forced	 expiratory	 volume	 (FEV1)	 and	 forced	 volume	 capacity	 (FVC)	 had	 to	 be	
smaller	than	0.7	after	bronchodilation).		
Outcome	definition		
The	outcome	of	interest	was	exacerbation.	Exacerbations	could	be	event-based	(e.g.	course	of	antibiotics	
and/or	 oral	 corticosteroids	 or	 admission	 to	 hospital)	 or	 symptom-based	 (patient-reported	 change	 in	
symptoms	with	or	without	use	of	diary	charts).		
General	selection	criteria	
Publication	status,	year	of	publication	and	language	were	not	subject	to	exclusion	criteria.	
CHAPTER	2:	Systematic	Review	of	Prediction	Models	
	
	33	
Study	design		
We	included	studies	with	a	longitudinal	design	(prospective	or	retrospective	cohorts)	or	control	arms	of	
randomised	control	trials	(that	can	be	regarded	as	cohort	studies).	Length	of	follow-up	was	not	subject	
to	exclusion	criteria.	
Selection	criteria	for	prediction	models		
For	 inclusion,	 the	 analysis	 section	 of	 the	 paper	 had	 to	 refer	 to	 a	 prediction	model	 1	 or	multivariable	
association	 115,116	of	a	 set	of	predictors	with	 the	outcome	exacerbation.	By	 including	also	multivariable	
models	 without	 explicit	 reference	 to	 prediction	 models	 we	 broadened	 the	 eligibility	 of	 models	
substantially	in	order	to	learn	as	much	from	the	literature	as	possible.	But	in	order	to	foresee	the	use	of	
such	multivariable	models,	that	often	focused	on	a	single	predictor	of	 interest	(e.g.	a	biomarker)	while	
adjusting	 for	 other	 predictors	 (e.g.	 previous	 exacerbations	 or	 FEV1%	 predicted)	 a	 requirement	 for	
inclusion	 was	 that	 the	 model	 also	 included	 four	 commonly	 used	 and	 easily	 available	 predictors	 (i.e.	
previous	 exacerbations,	 smoking,	 age,	 FEV1%	 predicted)	 beside	 the	 predictor	 of	 interest.	 Indeed,	
analyses	not	accounting	for	these	four	common	predictors	may	over-estimate	the	predictive	value	of	a	
particular	 single	 predictor	 (such	 as	 a	 biomarker)	 and	 there	 is	 general	 consensus	 that	 the	 use	 of	more	
sophisticated	 predictors	 is	 justified	 only	 if	 they	 provide	 additional	 value	 when	 added	 to	 commonly	
available	predictors.	A	further	requirement	for	the	inclusion	in	the	systematic	review	was	the	presence	
of	 at	 least	 one	 performance	 of	 the	 prediction	 model	 (e.g.	 area	 under	 the	 curve	 -or	 AUC-	 for	
discrimination).	 If	 information	 needed	 to	 decide	 on	 inclusion	 was	 not	 available	 from	 the	 papers	 we	
contacted	the	authors	up	to	two	times	to	obtain	them.	The	studies	could	also	be	included	if	exacerbation	
was	not	the	only	outcome	of	the	study.		
Procedure	
Two	review	authors	(BG	and	CB)	independently	assessed	titles	and	abstracts	of	all	references	retrieved.	
Two	 review	 authors	 (BG	 and	 VG)	 independently	 reviewed	 full-text	 versions	 of	 potentially	 relevant	
studies,	 and	 selected	 the	 studies.	 Disagreement	 was	 resolved	 by	 discussion	 between	 the	 two	 review	
authors.	If	consensus	was	not	reached,	a	third	review	author	was	consulted	(MP).	
Data	extraction	and	management	
Two	 review	 authors	 (BG	 and	 VG)	 independently	 extracted	 the	 following	 data	 from	 included	 studies:	
demographic	characteristics	of	the	study	population,	disease	severity,	clinical	settings,	definition	of	the	
outcome,	duration	of	the	follow-up,	details	of	the	statistical	method	as	well	as	of	the	predictors	of	the	
final	 model.	 All	 missing	 information	 was	 searched	 for	 in	 the	 references	 indicated	 in	 the	 papers	 (if	
available),	 or	 asked	 for	 by	 email	 to	 the	 authors.	 Some	 missing	 information	 was	 retrieved	 from	
pharmaceutical	companies	involved	in	the	studies	(if	needed,	by	formal	requests).		
Quality	assessment	concerned	6	categories	of	potential	bias	(participant	selection	as	shown	in	the	study	
flow,	measurement	 of	 predictors,	measurement	 of	 outcome	 (i.e.	 exacerbation),	 statistical	 analysis	 for	
model	 development,	 performance	measures	 and	 validation,	 based	 on	 guidance	 from	Cochrane	 117,	 an	
early	version	of	 the	PROBAST	guidelines	 	 (http://www.systematic-reviews.com/probast)	and	 the	needs	
of	this	particular	systematic	review.	The	criteria	for	rating	studies	at	low,	high	or	unclear	risk	of	bias	as	
well	as	a	description	for	each	bias	category	of	each	included	study	are	shown	in	the	online	material.		
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Some	studies	reported	on	small	variations	of	the	same	prediction	model.	Since	these	models	performed	
in	general	very	similarly,	we	considered	1	prediction	model	per	study	for	the	main	analysis	(for	details,	
see	 online	 material).	 We	 only	 considered	 more	 than	 one	 prediction	 model	 per	 study	 if	 they	 were	
substantially	different,	as	in	Almagro	et	al.	72,	where	the	predictive	performance	of	the	CODEX,	ADO	and	
BODEX	 indices	 were	 assessed	 (thus,	 we	 will	 speak	 in	 this	 systematic	 review	 of	 25	 studies	 and	 27	
prediction	models).	
In	order	to	evaluate	the	readiness	of	the	prediction	models	for	practice	we	defined	a	priori	three	criteria	
for	the	clinical	applicability	of	the	models.			
1. Availability	predictors:	We	deemed	the	set	predictors	in	each	prediction	model	to	be	easily	(E)	
available	 if	most	 of	 them	were	 based	 on	 questions	 or	 information	 from	medical	 charts,	 to	 be	
moderately	 (M)	 available	 if	 some	 (at	 least	 2)	 were	 based	 on	 tests	 routinely	 done	 in	 non-
specialised	and	 specialised	 settings	and	 to	be	difficult	 (D)	 to	be	available	 if	 at	 least	one	of	 the	
predictor	was	based	on	a	test	usually	performed	in	specialised	settings	only	(details	concerning	
the	assessment	are	explained	later	in	the	text	and	in	the	online	material).	
2. External	 validation:	 In	 order	 to	 be	 confidently	 used	 in	 practice	 prediction	 models	 require	
validations	in	populations	other	than	the	populations	in	which	it	was	developed.	We	deemed	to	
have	high	confidence	in	the	performance	if	the	model	had	been	validated	(with	a	small	decrease	
of	 performance	 between	 derivation	 and	 validation	 cohort)	 in	 an	 external	 cohort	 of	 COPD	
patients	and,	accordingly,	low	confidence	if	an	external	validation	was	lacking.	
3. Practical	applicability:	To	be	useful	 for	risk-stratified	treatment	 in	practice	we	deemed	models	
to	be	useful	if	they	provided	a	simple	point	system	like	the	BODE	or	ADO	indices	(e.g.	54,56])	with	
corresponding	 risks	 of	 exacerbations	 (e.g.	 4	 points	 =	 25%	 probability	 of	 exacerbation	 for	 a	
specified	 time-horizon),	 an	 online	 calculator	 or	 other	 means	 to	 easily	 derive	 the	 risk	 of	
exacerbations	 for	 an	 individual	 patient.	 We	 deemed	 prediction	 models	 not	 ready	 for	 risk-
stratified	 treatment	 yet	 if	 only	 the	 statistical	 methods	 (e.g.	 regression	 coefficients)	 were	
reported.		
Statistical	analysis	
Given	the	heterogeneity	of	the	studies	we	deemed	meta-analyses	not	a	sensible	approach	and	reported	
the	findings	using	descriptive	summary	statistics.		
Results	
Selection	of	studies		
Figure	1	shows	 the	study	selection	process	and	 the	main	 reasons	 for	exclusion	at	 the	different	stages.	
From	the	database	searches	we	included	20	from	a	total	of	1345	studies.	From	additional	searches	we	
included	 another	 5	 studies	 and	 thus	 a	 total	 of	 25	 papers	 68–79,81,82,84–90,92–95	 reporting	 on	 27	 prediction	
models	(see	online	material	for	details	concerning	each	stage	of	the	selection	process).		
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Figure	1	Flow	diagram	of	the	study	selection	process	
	
Study	characteristics	
The	 included	 studies	 (Table	 1)	 were	 conducted	 in	 countries	 around	 the	 world.	 They	 are	 ordered	
according	to	categories	of	exacerbation	 incidence.	Acknowledging	the	 lack	of	standard	 in	 literature	 for	
the	individual	cut-off	value	(or	more	cut-off	values)	for	the	frequent	exacerbator	phenotype,	and	given	
the	commonly	used	cut-off	of	2	exacerbations	per	person-years	73,52	we	categorised	each	cohort	as	low	
(<1	 exacerbation	 per	 person-year),	 moderate	 (1-2	 exacerbations	 per	 person-year)	 or	 high	 (>=2	
exacerbations	 per	 person	 year)	 incidence	 of	 exacerbations.	 3	 cohorts	 with	 high	 incidence	 of	
exacerbations,	4	cohorts	with	moderate	incidence	of	exacerbations	and	19	cohorts	with	low	incidence	of	
exacerbations	were	included	(for	1	of	the	27	cohorts	the	related	data	were	not	retrieved).	Sample	sizes	
ranged	 from	109	 to	8020.	The	definition	and	measurement	of	exacerbations	was	 symptom-based	 in	7	
(out	 of	 27	 cohorts:	 25	 derivation	 cohorts	 plus	 2	 validation	 cohorts),	 event-based	 in	 17	 and	 unclear	
definition	 in	3	cases.	Exacerbations	were	not	adjudicated	by	a	committee	 in	any	study.	The	prediction	
models	were	mainly	based	on	prospective	cohort	studies	 (control	arm	of	a	randomised	controlled	trial	
for	one	model	78),	while	two	prediction	models	were	based	on	retrospective	cohort	studies	93,94).	Follow-
up	periods	ranged	from	14	days	to	up	to	9	years	(the	most	common	follow-up	was	up	to	1	year).	21	out	
of	 the	25	 included	studies	had	 the	explicit	aim	 to	 find	a	combination	of	predictors	 strongly	associated	
with	exacerbations,	while	4	studies	69,79,82,84	focused	on	a	particular	predictor	but	adjusted	for	age,	FEV1%	
predicted,	smoking	and	previous	exacerbation	(making	them	eligible	for	the	inclusion	in	this	review).	
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Table	1	Study	characteristics	 		 		 		 		 		 		 		 		 		 		 		
Incidence	of	
exacerbations	
category	
Study	(year)	 Country	 Settings	of	the	care	 Cohort	study	
#	
patients	
(included	
in	the	
cohort	
study)	
#	
patients													
(included	
in	the	
analysis)	
Average	
age	
Average	
FEV1%	
predicted	
Males	
(%)	
Definition	of	
exacerbation	
Follow-
up	
(years)	
#	
events	
in	the	
analysis	
Person-
years	
of	
follow-
up	
Incidence	
(exacerbations	per	
year	per	person)	
Low	 Bertens	(2013)	
The	
Netherlands	 Outpatient	primary	care	 Prospective		 243	 240	 73	 71	 68	 Event-based	 up	to	2	 >70	
1	 480	 >0.15	
Low	 Bertens	(2013)	
(validation)	
The	
Netherlands	
Outpatient	primary	care	 Prospective		 793	 793	 67	 71	 53	 Event-based	 up	to	2	 >222	2	 1586	 >0.14	
Low	 Parshall	(2008)		 UK	 Outpatient	primary	care	 Prospective		 309	 127	 70	 50	 56	 Symptom-
based	3	
up	to	1	 >98	4	 127	 >0.77	
Low	 Motegi	(2013)	 Japan	 Outpatient	secondary	care	 Prospective		 232	 183	 71	 56	 93	
Symptom-	and	
event-based	 up	to	2	 193	 366	 0.53	
Low	 Almagro	(2014)	 Spain	 Outpatient	secondary	
care	
Prospective		 679	 606	 73	 45	 90	 Event-based	
up	to	
0.25	
and	1		
>98	5	 139.3	 >0.70	
-	 Almagro	(2014)	
(validation)	
Spain	 Outpatient	secondary	
care	
Prospective		 395	 377	 72	 41	 94	 Event-based	 1	 -	 -	 -	
Low	 Jones	(2009)	 England	 Outpatient	secondary	
care	
Prospective		 297	6	 175	7	 67	 42	 71	 Symptom-
based	
up	to	9	 50	 1575	 0.03	
Low	 Suetomo	(2014)		 Japan	 Outpatient	secondary	or	tertiary	care		 Prospective		 -	 123	 67	 64	 87	
Symptom-
based8	 up	to	1	 106	
9	 123	 0.87	
Low	 Müllerova	(2015)	
12	
Countries	
Secondary	and	tertiary	
care	 Prospective		 2164	 2138	 63	 48	 65	 Event-based	 up	to	3	 1452	 5725	
10	 0.25	
Low	 Thomsen	(2013)	 Denmark	 Outpatient	tertiary	care	 Prospective	11	 8020	 6574	 67	 80	 47	 Event-based	 4	12	 3083	 26296	
0.12	
	
Low	 Moberg	(2014)	 Denmark	 Outpatient	tertiary	care	 Prospective		 695	 674	 69	 37	 36	 Unclear	 5.5	13	 >421	14	 3822	15	 >0.11	
Low	 Ong	(2005)	 Singapore	 Outpatient	tertiary	care	 Retrospective	 127	 127	 71	 44	 91	 Symptom-
based	
1.35	16	 318	17	 171	18	 0.08	
Low	 Takahashi	(2012)	 Japan	 Outpatient	tertiary	care	 Prospective		 109	 93	 73	 55	 100	 Symptom-based	 up	to	1	 92	
19	 93	 0.88	
Low	 Faganello	(2010)	 Brazil	 Outpatient	tertiary	care	 Prospective		 120	 120	 65	 61	 71	 Event-based	 up	to	1	 >95	20	 120	 >0.79	
Low	
Garcia-Aymerich	
(2003)		 Spain	
Out-	and	inpatient	
tertiary	care	 Prospective	 346	 312	 69	 36	 92	
Symptom-
based	 1.1	
21	 >197	22	 343	 >0.57	
Low	 Ko	(2011)	 China	 Inpatient	tertiary	care	 Prospective	 327	 243	 74	 52	 86	 Event-based	 up	to	3	 >186	23	 729	 0.26	
Low	 Brusse-Keizer	
(2011)	
The	
Netherlands	
Inpatient	tertiary	care	 Control	arm	of	
RCT	
121	 121	 65	 58	 84	 Event-based	 up	to	1	 >62	24	 121	 >0.51	
Low	 Echave	(2010)	 Spain	 Inpatient	tertiary	care	 Prospective		 120	 93	 71	 43	 89	 Event-based	 up	to	1	 >61	25	 93	 >0.65	
Low	 Gudmundsson	
(2005)	
Sweden,	
Norway,	
Finland,	
Iceland,	
Denmark	
Inpatient	tertiary	care	 Prospective		 416	 406	 69	 34	 49	 Event-based	 up	to	1	 >246	26	 406	 >0.61	
Low	 Amalakuhan	
(2012)	
USA	 -	 Retrospective		 -	 106	 -	 -	 -	 Unclear	27	 up	to	1	 >100	28	 106	 >0.94	
Moderate	 Lee	(2014)	
China,	
Taiwan,	
Korea,	
Australia		
Outpatient	secondary	or	
tertiary	care	 Prospective		 545	 495	 69	 47	 88	
Symptom-
based		
up	to	
0.5	 >338	
29	 247.5	 >1.37	
Moderate	 Moy	(2014)	 USA	
Outpatient	secondary	or	
tertiary	care		 Prospective		 173	 167	 71	 54	 99	 Event-based	
30	 1.25	31	 263	30	 210	 1.25	
Moderate	 Marin	(2009)	 Spain	 Outpatient	tertiary	care	 Prospective	 275	 275	 65	 49	 100	 Event-based	 5.1	32	 2735	33	 1402	34	 1.95	
Moderate	 Hurst	(2010)	 12	
Countries	
Inpatient	tertiary	care	 Prospective		 2164	 2138	 63	 48	 65	 Event-based	 up	to	3	 6927	35	 5725	36	 1.21	
High	 Chen	(2005)	 Taiwan	 Outpatient	secondary	
care	
Prospective	 150	 143	 72	 49	 73	 Event-based	 14	
days37	
31	 5.5	 5.65	
High	 Jakob	(2013)	 Canada	
Outpatient	secondary	or	
tertiary	care	 Prospective		 115	 115	 67	 43	 47	 Event-based	 1.5	
38	 683	39	 207	 3.30	
High	 Almagro	(2006)	 Spain	 Inpatient	tertiary	care	 Prospective		 156	 129	 72	 36	 93	 Event-based	 1	 335	40	 129	 2.60	
"-"	stays	for	not	reported	and	not	straightforward	to	evaluate;	The	incidence	of	exacerbations	category	is	indicated	as	low,	moderate	or	high	when	the	exacerbation	rate	is,	respectively,	<1	exacerbation	per	person-year,	between	1	and	2	exacerbations	per	person-year	or	>2	exacerbations	per	person-year;	
FEV1:	forced	expiratory	volume	in	1	second;	Age	and	FEV1%predicted	are	referring	to	the	mean	in	the	study	population;	170	patients	with	at	least	1	event;	2222	patients	with	at	least	1	event;	3Slightly	different	data	are	provided	for	the	other	outcome	analyzed	in	the	paper	(health	care	use);	498	patients	with	at	
least	1	event;	5Number	of	exacerbators	to	3	months	of	follow-up	period.	Data	found	in	the	cited	article:	CHEST	2012;	142(5):1126–1133;	6From	the	reference	Am	J	Respir	Crit	Care	Med	Vol	179.	pp	369–374,	2009;	7For	which	DOSE	Index	scores	were	available;	8The	outcome	hospital	readmission	for	exacerbation	
was	analyzed	as	well	in	the	paper;	9Obtained	from	the	data	event	per	patients	in	each	of	the	two	categories	(high-CAT	and	low-CAT	groups);	10Proxy	considering	the	patients	included	in	the	analysis	(2138)	and	the	ones	completing	the	three	years	of	follow-up	(1679);	11From	a	population-based	cohort	was	
randomly	selected	a	subgroup	of	individuals	with	COPD;	12Median	follow	up;	13Mean	follow-up;	14421	patients	with	at	least	1	event;	15Obtained	multiplying	the	number	of	patients	in	the	study	by	the	mean	follow-up;	16Mean	follow-up;	17Calculated	considering	the	mean	number	of	admissions	(2.5);	18Calculated	
using	the	mean	follow-up	value;	19Proxy	obtained	using	the	mean	exacerbation	frequency	per	year	in	the	two	categories	(normal	IgG-titer	and	high	IgG-titer);	2032	patients	(27%)	experienced	1	episode,	21	patients	(18%)	2	episodes,	and	7	patients	(6%)	3	or	more	episodes	of	exacerbation,	thus	at	least	95	
exacerbations;	21Mean	follow	up;	2263%	of	the	patients		(197)	with	at	least	one	exacerbation;	23186	patients	with	at	least	1		readmission	for	AECOPD;	2431	patients	with	at	least	2	events;	2561	patients	with	at	least	1	event;	 	26Patients	with	at	least	1	readmission;	27Presumably	event-based;	2850	patients	with	
multiple	 (>=2)	events;	 29338	patients	with	at	 least	1	exacerbation;	226	patients	had	 instead	at	 least	1	moderate	 to	 severe	exacerbation;	 30Two	different	outcomes	analyzed:	number	of	acute	exacerbation	and	COPD	related	hospitalization.	 In	 this	 table	are	only	presented	 the	data	 for	 the	outcome	acute	
exacerbations	and	not	 for	 the	outcome	COPD	related	hospitalization;	 31Mean	of	 follow-up;	 32Median	 follow-up;	 33Obtained	multiplying	the	 incidence	by	person-years;	 34Proxy	obtained	 from	the	median	value	 for	 the	 follow-up;	 35Obtained	multiplying	the	 incidence	by	person-years;	 36Proxy	considering	the	
patients	included	in	the	analysis	(2138)	and	the	ones	completing	the	three	years	of	follow-up	(1679);	37A	follow-up	of	three	months	was	analyzed	as	well	in	the	paper;	38Mean	follow-up;	39Obtained	multiplying	the	incidence	by	person-years;	40Obtained	multiplying	the	incidence	by	person-years.		
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Predictors	included	in	the	prediction	models	
More	than	50	different	predictors	were	used	across	the	included	prediction	models	(see	online	material).	
Airways	obstruction	(FEV1%	predicted	or	FEV1	or	GOLD	stage)	was	the	most	common	predictor	(12	times	
out	 of	 27	 models.	 The	 next	 most	 common	 predictors	 were	 previous	 exacerbations	 (9	 times),	 age	 (9	
times),	smoking	(8	times)	and	health-related	quality	of	life	(8	times).	More	than	half	of	predictors	were	
included	only	once.	
Quality	assessment	
21	out	of	25	studies	 reported	with	 low	risk	of	bias	on	 the	study	 flow	and	 the	selection	of	participants	
(Figure	2),	23	out	of	25	studies	were	deemed	at	 low	risk	of	bias	for	how	they	measured	the	predictors	
and	22	out	of	25	studies	were	deemed	at	 low	risk	of	bias	for	how	they	measured	exacerbations	(given	
our	broad	definition	of	exacerbation).	14	studies	were	at	low	risk	of	bias	for	how	the	prediction	models	
were	developed	statistically	and	how	the	statistical	analysis	was	performed	 (the	 remaining	11	were	at	
high	risk).	6	studies	were	at	low	risk	of	bias	in	terms	of	the	performance	measures	used	(while	19	studies	
were	at	high	risk).	19	studies	out	of	25	were	of	good	quality	concerning	the	clinical	data	(i.e.	the	three	
bias	categories	selection,	definition	and	measurement	of	predictors	and	outcomes	and	in	terms	of	how	
patients	were	selected).	3	out	of	25	models	were	of	good	quality	from	a	statistical	point	of	view	(i.e.	the	
two	 categories	 statistical	 method	 and	 performance	 evaluation).	 Finally,	 2	 studies	 78,93	 performed	 an	
internal	validation	118	and	2	studies	72,87	an	external	validation	(other	studies	had	a	validation	cohort,	but	
they	made	a	prediction	 for	other	outcomes	or	 they	did	not	provide	any	performance	measure	 for	 the	
outcome	exacerbation).	
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Statistical	methods		
Table	2	shows	a	description	of	 the	27	prediction	models	ordered	by	underlying	statistical	method	(the	
details	of	 the	 two	validation	cohorts	are	 shown	as	well,	 for	a	 total	of	29	 rows);	 some	papers	 included	
different	analyses,	 in	one	case	92	different	statistical	methods	were	shown;	 in	order	to	avoid	confusion	
for	the	reader,	we	have	included	in	Table	2	only	1	statistical	method	per	study,	apart	from	the	already	
discussed	 72	 (where	we	 included	 the	 three	 indices	as	 three	 independent	prediction	models).	 The	most	
common	statistical	method	was	logistic	regression	(11	out	of	25	different	statistical	methods	analysed)	
followed	by	Cox	regression	(10),	and	correlation	analysis	between	an	index	(or	a	multivariable	regression	
equation)	with	the	outcome	(3).	Finally,	Poisson	regression	model,	negative	binomial	regression	model,	
and	random	forest	model	were	each	used	once.		
Most	of	the	prediction	models	(18	out	of	27)	were	directly	presenting	a	model	with	a	predefined	index	or	
regression	equation	with	predefined	predictors.	The	remaining	9	prediction	models	used	some	selection	
procedure	 of	 the	 variables	 (i.e.	 univariable	 selection	 process	 relying	 on	 p	 values,	 stepwise	 selection	
Figure 2 Quality Assessment 
1) Study flow description from screening of the patients to patients included in the statistical analysis  
2) Definition and measurement of the predictors 
3) Definition and measurement of the outcome 
4) Statistical method used and eventual procedure of predictors’ selection 
5) Separated evaluation of discrimination and calibration of the model 
6) Validation in an external cohort 
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process	 relying	 on	 p	 values,	 combinations	 of	 both	 or	 selection	 process	 driven	 by	 the	 Area	Under	 the	
Curve).	
For	5	prediction	models	(out	of	27)	performance	related	to	both	discrimination	(e.g.	AUC)	and	calibration	
(e.g.	Hosmer-Lemeshow	test)	were	reported	(in	87	this	is	true	for	both	derivation	and	validation	cohort).	
A	measure	of	discrimination	(always	AUC)	was	the	most	common	performance	provided	(21	times	out	of	
27	 prediction	 models).	 Measures	 of	 overall	 performance	 (like	 R2	 or	 log-likelihood)	 and	 of	 calibration	
(Hosmer-Lemeshow	p-value	or	chi-square)	were	less	common	(provided,	respectively,	for	12,	3,	6	and	5	
models).	 The	performance	provided	 for	 the	2	 validation	 cohorts	 are	 the	 same	 than	 the	ones	 for	 their	
respective	derivation	cohorts.	
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Table	2	Description	of	prediction	models	ordered	by	underlying	statistical	method		 		 		 		 		 		 		
Study	 Statistical	Method	
Follow-up	
(years)	
Outcome	of	the	
prediction	model	
Derivation/	
validation	
Procedure	for	
variable	selection	
Initial	#	predictors	 Final	#	predictors	
Measure	of	
association	 AUC	(95%CI)	
HL	chi-
square	 HL	p	value	 r^2	 	-2	Log	L	
Parshall	(2008)	86	
Correlation	
analysis	
up	to	1	
Exacerbation	
(symptom-based)	1	
Derivation	
Predefined	
variables	2	
-	 1	 -	 0.65-0.70	2	 -	
0.355-0.974	
2	
0.043-0.081	2	 -	
	Marin	(2009)	75	
Correlation	
analysis	
5.1	3		
Outpatient-treated	
exacerbation	4	
Derivation	 Predefined	index		 -	 1	 OR	 0.78	(0.73-0.84)	 -	 -	 0.31	 -	
Jones	(2009)	70	
Correlation	
analysis	 up	to	9	
Hospital	Admission	for	
exacerbation		 Derivation	 Predefined	index		 -	 1	 -	 0.755	5	 -	 -	 -	 -	
Chen	(2006)	89	
Logistic	
regression	 14	days	6	
Hospital	Readmission	
for	exacerbation		 Derivation	
Predefined	
variables	 -	 9	 OR	 -	 -	 -	 0.10	 139.49	
Almagro	(2006)	68	
Logistic	
regression	
up	to	1	
Hospital	Readmission	
for	exacerbation	
Derivation	
Univariable	
selection		
6	 3	 OR	 -	 1.9964	 0.8496	 0.146-0.194	7	 -	
Brusse-Keizer	(2011)	78	
Logistic	
regression	
up	to	1	
Patient	with	>=2	
exacerbations	
Derivation	8		
Univariable	and	
stepwise	selection		
15	 2	 OR	 0.717	(0.595-0.839)	 7.512	 0.483	 0.099-0.15	9	 -	
Faganello	(2010)	77	
Logistic	
regression	
up	to	1	 Exacerbation	 Derivation	 Predefined	index		 -	 1	 OR	 0.69	10	 -	 -	 -	 -	
Suetomo	(2014)	85	
Logistic	
regression	
up	to	1	 Exacerbation	11	 Derivation	
Predefined	
variables	
3	 3	 OR	 0.77	 -	 -	 -	 -	
Takahashi	(2012)	79	
Logistic	
regression	
up	to	1	
Patient	with	>=2	
exacerbations	
Derivation	
Predefined	
variables	
-	 11	 RR	 0.81	 66.64	 0.56	 0.22	 -	
Hurst	(2010)	73	
Logistic	
regression	
up	to	1	
Increased	
exacerbation	
frequency	
Derivation	 Stepwise	selection	 31	 5	 OR	 -	 -	 -	 0.22	 -	
Bertens	(2013)	(derivation)	87	
Logistic	
regression	
up	to	2	
Patients	with	>=1	
exacerbation	
Derivation	
Backward	
stepwise	selection	
6	 4	 OR	 0.75	(0.69-0.82)	 8.66	 0.37	 0.26	 -	
Bertens	(2013)	(validation)	 x	12	 up	to	2	
Patients	with	>=1	
exacerbation	
Validation	 x	12	 x	12	 x	12	 x	12	 0.66	(0.62-0.71)	 32.98	 0.00	 0.09	 -	
Motegi	(2013)	81	
Logistic	
regression	
up	to	2	 Exacerbation	 Derivation	 P	value	selection	 14	 2	 OR	 0.76-0.78	13	 -	 -	 0.15-0.18	13	 -	
Thomsen	(2013)	69	
Logistic	
regression	
up	to	1	
14	
Frequent	exacerbator	
15	
Derivation	
Predefined	
variables	
-	 8-11	16	 OR	 0.71-0.73	16	 -	 -	 -	 -	
Lee	(2014)	92	
Logistic	
regression	
up	to	0.5	 Any	exacerbation	17	 Derivation	
Predefined	
variables	
-	 1-9	18	 RR	 0.64-0.79	18	 -	 -	 -	 -	
Almagro	(2014)	(derivation)		
(CODEX)	72	
Cox	regression	
up	to	1	
19	
Hospital	Readmission	
for	exacerbation	
Derivation		 Predefined	index		 -	 1	 HR	 0.583	 -	 -	 -	 -	
Almagro	(2014)	(derivation)	
(ADO)	
Cox	regression	
up	to	1	
19	
Hospital	Readmission	
for	exacerbation	
Derivation	20	 Predefined	index	 -	 1	 HR	 0.533	 -	 -	 -	 -	
Almagro	(2014)	(derivation)	
(BODEX)	
Cox	regression	
up	to	1	
19	
Hospital	Readmission	
for	exacerbation	
Derivation	20	 Predefined	index		 -	 1	 HR	 0.633	 -	 -	 -	 -	
Almagro	(2014)	(validation)	
(CODEX)	
x	21	 up	to	1	
Hospital	Readmission	
for	exacerbation	
Validation	 x	21	 x	21	 x	21	 x	21	 0.590	 -	 -	 -	 -	
Echave-Sustaeta	(2010)	95	 Cox	regression	 up	to	1	
Hospital	Readmission	
for	exacerbation		
Derivation	
Univariable	and	
stepwise	selection	
6	 2	 HR	 0.7601	 -	 -	 0.334	 -	
Gudmundsson	(2005)	82	 Cox	regression	 up	to	1	
Hospital	Readmission	
for	exacerbation		
Derivation	
Predefined	
variables	
Unclear	 5	 HR	 -	 -	 -	 -	 2175.6	
Garcia-Aymerich	(2003)	88	 Cox	regression	 1.1	22	
Hospital	Readmission	
for	exacerbation	
Derivation	
Univariable	
selection	
23	 7	 HR	 0.71	 -	 -	 -	 -	
Jakob	(2013)	84	 Cox	regression	 1.5	23	 Any	exacerbation	24	 Derivation	
Predefined	
variables	
-	 7	 RR	 -	 -	 -	 -	 833.372	25	
Müllerova	(2015)	71	 Cox	regression	 up	to	3	
Hospital	admission	for	
exacerbation		
Derivation	
Predefined	
variables	
Unclear	 6	 HR	
0.742	(0.718-0.766)	
26	
5.57	26	 0.696	26	 0.15	26	 -	
Ko	(2011)	76	 Cox	regression	 up	to	3	
Hospital	Readmission	
for	exacerbation		
Derivation	 Predefined	index	 -	 1	 HR	 0.58	27	 -	 -	 -	 -	
Moberg	(2014)	74	 Cox	regression	 5.5	28	
Hospital	admission	for	
exacerbation		
Derivation	
Univariable	
selection	
Unclear	 18	 HR	 0.62	(0.59-0.65)	 -	 -	 -	 -	
Ong	(2005)	94	
Poisson	
Regression	
1.35	29	
Hospital	Admission	for	
exacerbation	
Derivation	 Predefined	index	 -	 1	 IRR	 -	 -	 -	 0.16	30	 -	
Moy	(2014)	90	
Negative	
binomial	
regression	
1.25	31	 Exacerbation	32	 Derivation	
Predefined	
variables	
-	 4-5	33	 RaR	 0.59-0.62	33	 -	 -	 -	 -	
Amalakuhan	(2012)	93	 Random	Forest	 up	to	1	
Hospital	Readmission	
for	exacerbation		
Derivation	34	
Variables	of	
importance	
evaluated	with	
AUC	
60	 5	 -	 0.75	35	 -	 -	 -	 -	
In	this	table	only	the	data	and	analyses	related	to	one	outcome	(in	general	the	one	deemed	to	be	closer	to	the	definition	of	exacerbation)	are	reported,	with	exception	of	Almagro	(2014),	where	three	different	rows	(for	the	three	different	predefined	indices:	CODEX,	ADO,	BODEX)	are	used.	"-"	stays	for	not	reported	and	not	
straightforward	to	evaluate;	AUC:	Area	Under	the	Curve;	-2	log	L:	-2	logarithmic	likelihood;	HL:	Hosmer-Lemeshow	test;	OR:	odds	ratios;	RR:	relative	risk;	RaR:	Rate	Ratios;	HR:	hazard	ratios;	IRR:	Incidence	Rate	Ratios;	The	number	of	initial	predictors	is	often	a	proxy	evaluated	by	the	authors	of	this	review;	1The	outcome	health	
care	use	was	analysed	as	well	in	the	paper;	24	domain	subscales	of	the	Medical	Outcomes	Study	short-form	health	survey	[36	items]	(SF-36)		(GH:	General	Health	perceptions;	MH:	Mental	health,	RP:	Role	limitation-Physical,	MCS:	Correlated	Mental-health	Score)	were	evaluated	as	separated	prediction	models;	3Median	follow-
up;	4The	outcome	hospitalisation	was	analysed	as	well	in	the	paper;	5	The	performance	refers	to	the	DOSE	index	(a	performance	is	provided	for	MRC	Dyspnoea	Scale	and	FEV1%predicted	as	well	in	the	text);	6A	follow-up	of	three	months	was	analysed	as	well;	7Cox-Snell-Nagelkerke	definition	of	R-square	;	8To	assess	over-fitting	
jackknife	cross	validation	technique	was	applied	to	the	prediction	rule	;	9Cox-Snell-Nagelkerke	definition	of	R-square;	10The	performance	refers	to	the	BODE	index	(a	performance	is	provided	for	GOLD	stage	as	well	in	the	text).	Other	multivariable	models	are	also	shown	but	no	performance	was	provided;	11	The	outcome	hospital	
readmission	for	exacerbation	was	analysed	as	well	in	the	paper;	12Not	expected	since	it	refers	to	validation	process;	13According	to	the	model	used	(4	different	ones	are	presented);	14The	authors	of	the	paper	(Thomsen	2013)	report	in	the	online	material	the	data	for	a	median	follow-up	of	4	year	(range	of	performances	with	and	
without	the	three	biomarkers	evaluated	in	the	study:	0.92-0.92);	15At	least	2	exacerbations	more	than	1	year	apart;	16According	to	the	inclusion	in	the	final	model	of	three	inflammatory	biomarkers	as	predictors;	Net	Reclassification	Index	used	to	evaluate	(40%;	22%-57%)	the	improvement	in	performances	with	the	inclusion	of	
the	three	biomarkers;	17Other	two	outcomes	(moderate-severe	exacerbation	with	a	logistic	regression	model	and	time	to	first	exacerbation	with	Cox	regression	model)	were	analysed	in	the	text;	18According	to	if	CAT	was	categorised	or	not	and	if	there	was	or	not	adjustment	for	other	variables	(age,	BMI,	duration	of	COPD,	
current	smoking	status,	number	of	comorbidities,	history	of	influenza	vaccination,	Country);	19For	the	derivation	cohort	the	follow-up	of	3	months	is	analysed	as	well	in	the	paper;	20Validation	is	performed	but	no	performance	is	provided;	21Not	expected	since	it	refers	to	validation	process;	22Mean	follow-up;	23Mean	follow-up;	
24The	outcomes	outpatients-treated	exacerbation	and	inpatient-treated	exacerbation	are	analysed	as	well	in	the	paper;	25Provided	as	well	AIC	and	SBC,	but	not	reported	in	the	table;	26Data	provided	upon	request	by	the	authors;	27The	performance	refers	to	the	BODE	index	(a	performance	is	provided	for	the	BODE's	4	component	
as	well	in	the	text);	28Mean	follow-up;	29Mean	follow-up;	30The	performance	refers	to	the	BODE	index	(a	performance	is	provided	for	the	GOLD	stage	as	well	in	the	text);	31Mean	follow-up;	32The	outcome	hospital	readmission	for	exacerbation	is	analysed	as	well	in	the	paper;	33Different	models	evaluated	(Step_CRP,	STEP_IL-6	or	
BODE);	34Internal	validation	performed;	35Mean	AUC	for	200	runs	
	
Clinical	applicability	of	the	models	
The	use	of	prediction	models	 in	practice	needs	to	balance	the	clinical	availability	of	predictors,	 i.e.	 the	
effort	 to	 obtain	 the	 information,	 the	 easiness	 with	which	 doctors	 can	 obtain	 a	 risk	 for	 the	 individual	
patients	and	the	predictive	performance	of	the	models.	Ideally,	predictors	would	be	easily	available,	the	
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model	easy	to	obtain	individual	probabilities	from,	and	the	model	would	predict	the	risk	of	exacerbations	
accurately	as	shown	by	an	external	validation.		
Table	 3	 shows	 the	 assessment	 of	 the	 readiness	 of	 the	 prediction	 models	 for	 clinical	 practice.	 The	
availability	of	 predictors	was	based	on	 the	assessment	of	 the	availability	of	 single	predictors	 and	how	
many	of	them	were	in	different	categories	of	availability	(as	shown	in	the	online	material,	"1"	refers	to	a	
simple	 test	or	simple	questions	or	medical	charts,	 "2"	 refers	 to	 routine	 tests,	 	 "3"	 refers	 to	specialised	
tests).	 12	 out	 of	 27	 models	 were	 deemed	 to	 have	 an	 easily	 available	 set	 of	 predictors	 across	 non-
specialised	and	specialised	health	care	settings,	4	out	of	27	to	have	an	moderately	easy	available	set	of	
predictors	and	11	out	of	27	to	have	a	set	of	predictors	whose	data	is	difficult	to	obtain	across	health	care	
settings.	Only	2	models	72,87	can	be	confidently	used	in	other	populations	because	an	external	validation	
was	performed	to	assess	the	transportability	of	the	prediction	model	18.	Also,	only	1	study	68	provided	a	
way	to	easily	obtain	an	estimate	of	the	risk	of	an	exacerbation	for	an	individual	patient	and	thus	a	basis	
for	risk-stratified	treatment.	Overall,	none	of	the	existing	models	fulfilled	all	criteria	for	being	ready	for	
clinical	application	and	use	for	risk-stratified	treatment	to	personalise	COPD	care.	
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Table	3	Readiness	of	prediction	models	for	clinical	practice		
Study	 Availability	predictors	 External	validation	 Practical	applicability	
Bertens	(2013)	87	 E	 Y	 N	
Almagro	(2014)	72	 E	 Y	 N	
	
E	 Y	 N	
	
E	 Y	 N	
Almagro	(2006)	68	 D	 N	 Y1	
Brusse-Keizer	(2011)	78	 E	 N2	 N	
Amalakuhan	(2012)	93	 E	 N3	 N	
Jones	(2009)	70	 E	 N4	 N	
Echave-Sustaeta	(2010)	95	 E	 N	 N	
Jakob	(2013)	84	 E	 N	 N	
Motegi	(2013)	81	 E	 N	 N	
Lee	(2014)	92	 E	 N	 N	
Parshall	(2008)	86	 E	 N	 N	
Chen	(2006)	89	 M	 N	 N	
Gudmundusson	(2005)	82	 M	 N	 N	
Hurst	(2010)	73	 M	 N	 N	
Suetomo	(2014)	85	 M	 N	 N	
Faganello	(2010)	77	 D	 N	 N	
Ko	(2011)	76	 D	 N	 N	
Ong	(2005)	94	 D	 N	 N	
Garcia-Aymerich	(2003)	88	 D	 N	 N	
Marin	(2009)	75	 D	 N	 N	
Moberg	(2014)	74	 D	 N	 N	
Moy	(2014)	90	 D	 N	 N	
Müllerova	(2015)	71	 D	 N	 N	
Takahashi	(2012)	79	 D	 N	 N	
Thomsen	(2013)	69	 D	 N	 N	
The	field	“Availability	predictors”	refers	 to	how	easy	 is	 to	obtain	the	data	related	to	the	predictors:	E	 (easy),	M	(medium),	D	
(difficult);	the	field	“External	validation”	refers	to	the	reliability	of	the	model	in	terms	of	comparison	of	performance	between	
derivation	 and	 eventual	 validation	 cohort:	 Y	 (yes),	 N	 (no).	 The	 field	 “Practical	 applicability”	 indicates	 if	 it	 is	 easy	 to	 extract	
individual	likelihoods	of	exacerbation	from	the	model:	Y	(yes),	N	(no).	Studies	presenting	different	models	are	considered	only	
once,	with	 exception	of	Almagro	 (2014)	where	different	predefined	 indices	 are	 shown.	 1The	paper	 explains	how	 to	 you	 can	
obtain	probabilities	starting	from	the	logistic	regression	equation	and	indicates	how	to	calculate	individual	probabilities	starting	
from	 the	 predictors;	 2The	 jackknife	 cross	 validation	 was	 applied	 but	 no	 performance	 is	 indicated;	 3Internal	 validation	 was	
applied	but	no	performance	is	indicated;	4Validation	is	performed	for	other	outcomes.	
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Discussion	
Our	systematic	review	identified	25	studies	reporting	on	27	statistical	prediction	models	for	exacerbation	
in	patients	with	COPD.	The	prediction	models	differ	greatly	 in	 terms	of	how	they	were	developed	and	
which	predictors	and	measures	for	their	predictive	performance	were	used.	Most	studies	were	of	good	
quality	concerning	the	clinical	settings	and	tests	(i.e.	selection,	definition	and	measurement	of	predictors	
and	 outcomes	 and	 in	 terms	 of	 how	patients	were	 selected).	 However,	most	 of	 the	 prediction	models	
were	at	high	risk	of	bias	because	unsound	statistical	methods	to	develop	prediction	models,	and	a	lack	of	
validation.	The	overall	assessment	of	readiness	of	the	27	prediction	models	for	use	 in	practice	showed	
that	none	were	ready	for	clinical	application.	
Strengths	and	limitations	
Strengths	of	 this	 systematic	 review	are	 the	adherence	 to	 rigorous	systematic	 review	methodology	and	
reporting	guidelines,	apart	from	a	thorough	search	strategy	and	a	great	effort	for	retrieving	the	needed	
information	 from	the	authors.	A	 limitation	could	be	considered	the	broad	 inclusion	criteria	concerning	
the	definition	of	 exacerbation,	 potentially	 introducing	heterogeneity	 among	models.	 Furthermore,	 the	
adopted	broad	definition	of	prediction	model	could	have	allowed	the	inclusion	of	studies	not	meant	to	
concern	 prediction,	 but	 only	 evaluating	 the	 association	 of	 an	 index	 (or	 a	 multivariable	 regression	
equation)	with	 the	outcome.	Nevertheless,	we	deemed	our	broader	approach	 suitable	 in	order	not	 to	
miss	prediction	models	that	may	be	useful	for	clinical	practice.	Finally,	the	big	heterogeneity	of	statistical	
methods	used	in	literature	makes	probably	not	valuable	to	overall	compare	all	the	models	even	if	they	
are	providing	the	same	performance	measure	(e.g.	AUC),	since	they	are	often	too	different	 in	terms	of	
definition	of	exacerbations,	time	horizon,	statistical	method	and	outcome	of	the	prediction	model.	
Future	research		
In	order	to	come	up	with	high-quality	prediction	models	for	exacerbations	in	COPD	patients,	a	standard	
methodology	 for	 developing	 the	models	 should	 be	 adopted	 119.	 For	 instance,	 in	 certain	medical	 fields	
some	 indices	were	validated	and	are	currently	used	 in	clinical	 setting	 for	 risk-stratified	prevention	and	
treatment.	The	cardiovascular	field,	for	example,	has	a	long	tradition	that	started	with	the	Framingham	
Risk	Score	predicting	the	risk	of	cardiovascular	disease	16	and	led	to	clinical	guidelines	that	heavily	rely	on	
risk-stratified	 prevention	 of	 cardiovascular	 disease	 7,8.	 In	 COPD,	 high	 quality	 prediction	 models,	 for	
example	the	BODE	and	ADO	indices,	have	been	developed	and	externally	validated	for	the	outcome	of	
mortality	54–56.	There	is	also	a	research	need	to	better	understand	how	prediction	models	could	be	made	
as	 attractive	 as	 possible	 to	 use	 in	 practice.	 The	 optimal	 balance	 between	 availability	 of	 predictors,	
practical	 applicability	 and	 predictive	 measurement	 properties	 is	 not	 yet	 well	 understood	 20,120.	 It	 is	
paramount	 that	 prediction	 models	 are	 validated	 thoroughly	 in	 order	 to	 make	 sure	 that	 the	 risk	
predictions	 are	 accurate	 across	 different	 populations	 and	 could	 be	 used	 with	 confidence	 for	 risk-
stratified	treatment	18,26.	Finally,	it	would	be	ideal	if	the	COPD	community	agreed	on	a	single	or	very	few	
different	 exacerbation	 prediction	 models	 since	 validations	 and	 implementation	 research	 are	 more	
efficient	if	there	is	a	common	prediction	model	as	compared	to	having	many	different	prediction	models	
121.	 Such	a	prediction	model	 can	always	be	 improved	by	opportunely	updating	 it	 (if	 necessary)	 in	new	
cohorts	 1,29	 and	 by	 adding	 promising	 predictors,	 but	 it	 needs	 to	 build	 upon	 prior	 knowledge	 on	 other	
datasets.	Of	course,	separate	models	are	justified	if	the	decisions	they	inform	are	distinct,	for	example,	
in	terms	of	time	horizon.	
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Conclusions	
Overall,	none	of	the	existing	prediction	models	fulfilled	the	criteria	for	being	ready	for	clinical	application	
and	 use	 for	 risk-stratified	 treatment	 to	 personalise	 COPD	 care.	 The	 available	 COPD	 cohorts	 contain	
relevant	populations,	predictors	and	exacerbation	measurements	but	a	more	harmonised	approach	 to	
develop	and	validate	high	quality	predictions	is	needed	to	move	personalised	COPD	medicine	forward.	
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Abstract	
Background:	Prediction	models	and	prognostic	scores	have	been	increasingly	popular	in	both	clinical	
practice	and	clinical	research	settings,	for	example	to	aid	in	risk-based	decision	making	or	control	for	
confounding.	In	many	medical	fields,	a	large	number	of	prognostic	scores	are	available,	but	practitioners	
may	find	it	difficult	to	choose	between	them	due	to	lack	of	external	validation	as	well	as	lack	of	
comparisons	between	them.		
Methods:	Borrowing	methodology	from	network	meta-analysis,	we	describe	an	approach	to	Multiple	
Score	Comparison	meta-analysis	(MSC)	which	permits	concurrent	external	validation	and	comparisons	of	
prognostic	scores	using	individual	patient	data	(IPD)	arising	from	a	large-scale	international	collaboration.	
We	describe	the	challenges	in	adapting	network	meta-analysis	to	the	MSC	setting,	for	instance	the	need	
to	explicitly	include	correlations	between	the	scores	on	a	cohort	level,	and	how	to	deal	with	many	multi-
score	studies.		We	propose	first	using	IPD	to	make	cohort-level	aggregate	discrimination	or	calibration	
scores,	comparing	all	to	a	common	comparator.	Then,	standard	network	meta-analysis	techniques	can	be	
applied,	taking	care	to	consider	correlation	structures	in	cohorts	with	multiple	scores.	Transitivity,	
consistency	and	heterogeneity	are	also	examined.	
Results:	We	provide	a	clinical	application,	comparing	prognostic	scores	for	3-year	mortality	in	patients	
with	chronic	obstructive	pulmonary	disease	using	data	from	a	large-scale	collaborative	initiative.	We	
focus	on	the	discriminative	properties	of	the	prognostic	scores.	Our	results	show	clear	differences	in	
performance,	with	ADO	and	eBODE	showing	higher	discrimination	with	respect	to	mortality	than	other	
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considered	scores.	The	assumptions	of	transitivity	and	local	and	global	consistency	were	not	violated.	
Heterogeneity	was	small.	
Conclusions:	We	applied	a	network	meta-analytic	methodology	to	externally	validate	and	concurrently	
compare	the	prognostic	properties	of	clinical	scores.	Our	large-scale	external	validation	indicates	that	the	
scores	with	the	best	discriminative	properties	to	predict	3	year	mortality	in	patients	with	COPD	are	ADO	
and	eBODE.		
	
Keywords:	prognostic	scores,	external	validation,	multiple	score	comparison,	chronic	obstructive	
pulmonary	disease	
	
	
	
Background	
Prediction	models,	which	combine	predictors	using	regression	coefficients,	and	simpler	prognostic	
scores,	which	typically	assign	point	values	to	predictors	based	on	prediction	models,	have	become	
increasingly	popular	1,122.	They	aid	in	decision	making	in	public	health,	clinical	research	and	clinical	
practice	123	by	estimating	a	person’s	risk	of	developing	a	disease	or	other	outcome.	In	several	medical	
fields,	a	variety	of	prediction	models	have	been	developed	to	assess	the	individual	risk	of	adverse	
outcomes.	A	great	example	for	this	was	a	very	recent	systematic	review	regarding	validated	risk	factor	
models	for	neurodevelopmental	outcomes	in	children	born	very	preterm	or	with	very	low	birth	weight	
124;	78	original	studies	(including	222	prediction	models)	were	extracted.	Most	of	the	models	were	not	
intended	to	be	used	for	clinical	practice	and	only	4	studies	(5%)	had	performed	a	validation.	Another	
example	regards	models	predicting	risk	of	type	2	diabetes	mellitus	with	genetic	risk	models	on	the	basis	
of	established	genome-wide	association	markers;	a	systematic	review	deemed	to	be	eligible	21	articles	
representing	23	studies	125.	Concerning	the	risk	of	developing	cardiovascular	disease,	over	the	past	two	
decades,	numerous	prediction	models	have	been	developed,	to	estimate	the	risk	of	developing	
cardiovascular	disease	19.		Only	36%	of	them	were	externally	validated	and	only	19%	by	independent	
investigators.	In	the	case	of	chronic	obstructive	pulmonary	disease	(COPD),	several	prognostic	scores	
have	been	developed	to	predict	mortality,	starting	with	the	BODE	score	54.	but	scores	also	exist	to	predict	
exacerbations	126,	or	the	course	of	health-related	quality	of	life	62,70.	Prognostic	scores	suffer	from	a	
reluctance	of	general	practitioners	to	use	them	20,98	as	well	as	from	scepticism	because	they	lack	internal	
and	external	validation	which	are	requirements	for	generalizability	18,127.	The	external	validation	studies	
are	often	simply	poorly	designed	or	reported	22.	The	lack	of	comparisons	among	available	prognostic	
scores	provides	an	additional	hurdle	to	their	widespread	applicability,	as	practitioners	may	not	be	able	to	
decide	among	them	based	on	the	information	available	128.	
Luckily,	 the	collection	of	 “big	data”	 32	and	 the	growing	availability	of	 individual	patient	data	 (IPD)	data	
analyses	33–38	provide		researchers	with	new	opportunities	and	challenges	43,44.	Furthermore,	the	call	of	
the	medical	 community	 for	 data	 sharing	 42	 improves	 the	 possibilities	 of	 checking	 a	model’s	 predictive	
performance	 across	 clinical	 settings,	 populations,	 and	 subgroups	 43.	 The	 COCOMICS	 study	 47	 is	 a	 rare	
example	 of	 prognostic	 scores	 being	 directly	 compared	with	 each	 other	 and	 simultaneously	 externally	
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validated	after	pooling	all	the	databases	in	a	single	cohort	128.	Our	approach,	multiple	score	comparison	
network	meta-analysis	 (MSC),	 extends	 the	 simple	 pooling	 approach	 to	 pool	 direct	 comparisons	 taken	
from	different	studies,	as	a	meta-analysis	across	studies	provides	 in	general	higher	quality	 information	
compared	 to	 the	 analysis	 of	 a	 database,	 constituted	 pooling	 together	 the	 single	 studies	 48,49.	 This	
methodology	 allows	 to	 take	 into	 account	 heterogeneity	 of	 the	 individual	 studies	 and	 obtain	 more	
generalizable	results	43.	
Methods	
Various	methodological	approaches	have	been	proposed	for	network	meta-analysis	for	comparison	of	
treatments	129–135,	which	is	sometimes	referred	to	as	network	meta-analysis,	multiple	(or	mixed)	
treatment	comparisons	meta-analysis	(MTC	meta-analysis)	or	multiple	treatments	meta-analysis	136,137.	
For	diagnostic	test	performance,	the	first	steps	of	network	meta-analysis	were	undertaken	(e.g.	in	terms	
of	sensitivity	and	specificity)	138,139.	No	similar	methodology	exists	to	compare	the	performance	of	
prognostic	scores	or	prediction	models.	Nevertheless,	network	meta-analysis	may	provide	an	attractive	
solution	to	the	problem	of	comparing	the	performance	of	prognostic	scores.		
Changing	from	comparing	effects	of	treatments	to	comparing	performance	of	prediction	models	or	
prognostic	scores,	however,	reveals	a	number	of	differences	between	the	two	settings,	and	care	must	be	
taken	to	ensure	that	the	unique	features	of	multiple	score	comparison	(MSC)	meta-analysis	(as	we	will	
refer	to	this	new	method)	are	considered	properly	in	the	analysis.		
A	number	of	features	distinguish	a	MSC	meta-analysis	of	prognostic	scores	from	a	meta-analysis	of	
treatments.	In	network	meta-analysis	of	treatments	outcomes	are	summarized	separately	within	each	
treatment	arm	of	a	randomized	trial,	and	combined	to	obtain	estimates	of	treatment	effect	(for	example,	
mean	difference	or	log	odds	ratio);	instead,	the	MSC	meta-analysis	uses	performance	measures	of	each	
score	in	a	cohort	that	can	be	calculated	on	the	same	sample	of	patients.	Additionally,	the	number	of	
prognostic	scores	assessed	in	a	given	cohort	is	not	limited	by	the	practicalities	of	study	design,	so	that	it	
would	be	easily	possible	to	have	more	than,	say,	four	scores	within	one	cohort,	while	such	a	large	
number	of	treatment	arms	in	an	RCT	is	relatively	unlikely	due	to	considerations	of	power	and	sample	size	
along	with	practical	aspects	of	conducting	clinical	trials.	Consideration	of	multi-score	studies	properly,	
including	the	correlations	inherent	in	such	comparisons,	in	MSC	is	therefore	of	great	importance.		
We	 developed	 a	 comprehensive	 approach	 to	MSC	 to	 assess	 various	 prediction	models	 using	 network	
meta-analysis	with	 individual	patient	data,	providing	external	validation	and	concurrent	comparison	of	
the	 scores,	 and	 applied	 it	 to	 risk	 prediction	 scores	 for	 mortality	 in	 COPD	 40,140.	 After	 careful	
methodological	 issues	 (see	 also	 online-only	 material,	 where	 we	 go	 deeper	 into	 the	 statistical	
background)	 the	 following	 approach	was	 developed:	 we	 calculated	 aggregated	 summary	 statistics	 for	
each	cohort	and	score.	Then,	we	examined	the	network	structure	by	grouping	the	cohorts	according	to	
which	 scores	 could	 be	 evaluated.	 We	 adapted	 methodology	 from	 network	 meta-analysis	 134	 to	
concurrently	 externally	 validate	 and	 compare	 prognostic	 scores	 from	 individual	 patient	 data	 across	
different	cohorts,	explicitly	including	correlations	141	between	the	scores	on	a	cohort	level.		
	We	will	also	re-interpret	NMA	as	a	two-stage	meta-regression	model,	as	proposed	in	134:		
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1. Ordinary	meta-analysis	 to	 gain	 the	 direct	 estimates	 for	 corresponding	 pooled	 effect	 estimates	
(using	 the	 inverse-variance	 weighted	 means	 of	 the	 corresponding	 cohorts).	 Cohorts	 at	 our	
disposal	are	classified	into	“groups”	according	to	which	scores	it	is	possible	to	evaluate	by	their	
data.	
2. Based	on	 the	direct	estimates	and	 their	 variances	 from	 the	 first	 stage,	 they	obtain	 to	 find	 the	
optimal	 estimate	 of	 the	 pooled	 effect	 parameters	 that	 obeys	 the	 fundamental	 consistency	
equations.	 In	 this	 stage	we	merge	 the	group	estimates,	 looking	 for	 the	weighted	 least	 squares	
solution	to	the	regression	problem	equation.	
The	last	steps	were	to	confirm	that	transitivity	is	a	plausible	assumption	and	to	check	for	possible	
inconsistency	and	heterogeneity.		
	
Calculation	of	aggregated	summary	statistics	
First,	the	performance	measure	for	comparison	of	the	various	prognostic	scores	was	defined	as	the	area	
under	the	curve	(AUC)	of	the	corresponding	receiver	operating	characteristic	curve	(ROC).	This	is	
a	graphical	plot	that	illustrates	the	ability	of	a	binary	classifier	system	(diagnostic	or	prognostic)	as	its	
discrimination	threshold	is	varied	(in	particular	plotting	true	vs	false	positive	rate).	Differences	in	AUC,	
denoted	ΔAUC,	provided	an	estimate	of	the	relative	discrimination	ability	when	comparing	scores.	For	
this	purpose,	we	use	of	a	common	comparator	(CC)	model	(in	our	case	the	GOLD	classification,	since	it	is	
a	variable	supposed	to	be	present	in	each	COPD	cohort);	it	constitutes	a	reference	value	for	the	
performance	of	other	scores,	the	value	from	which	to	subtract	the	possibly	common	biases	142.	
Variance	and	covariance	estimates	for	the	ΔAUC	values	were	estimated	numerically	using	bootstrapping.	
We	also	confirmed	consistency	of	bootstrapped	variance	estimates	to	those	of	the	analytical	formula	for	
variances	of	paired	differences	in	AUC	143	(results	not	shown).		
Aggregated	data	on	the	cohort	level	for	a	cohort	with	k	scores	consist	therefore	of	k	–	1	ΔAUC	estimates	
and	a	corresponding	(k	–	1)	x	(k	–	1)	variance-covariance	matrix.	
	
To	further	clarify	the	methodology,	we	show	the	main	steps	with	a	small	fictional	example.	Suppose	we	
had	2	cohorts	where	score	A	and	B	could	be	evaluated	(group	1:	AB;	cohorts	P,	R),	2	cohorts	where	A	and	
C	could	be	evaluated	(group	2:	AC;	cohort	S,	T),	2	cohorts	where	A,	B	and	D	could	be	evaluated	(group	3:	
ABD;	cohorts	U,	V),	and	a	final	2	cohorts	where	A,	B,	C,	and	D	could	be	evaluated	(group	4:	ABCD,	cohorts	
X	and	Y).	Let	us	focus	on	group	3,	constituted	by	the	cohorts	X	and	Y	in	which	the	scores	A,	B,	and	D	can	
be	used.	We	would	obtain	performance	difference	of	the	scores	B	and	D	in	comparison	to	the	score	A	for	
each	of	the	cohorts,	as	reported	in	Table	1.	
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Table	1	Point	estimate	of	the	difference	of	AUC	of	the	scores	B	and	D	with	the	score	A	in	the	group	3	of	
the	fictional	example	
Cohort	 ΔAUC	–	AB	 ΔAUC	-	AC	 ΔAUC	-	AD	
X,	 0.05	 --	 0.07	
Y	 0.06	 --	 0.18	
	
	
Analogously,	in	group	3,	we	would	obtain	variance-covariance	matrices,	like	the	ones	reported	in	Table	2.	
	
Table	2	Variance-covariance	matrices	of	the	difference	of	AUC	of	the	scores	B	and	D	with	the	score	A	in	
the	group	3	of	the	fictional	example.	
Cohort	X	 	 	
	 0.0012	 0.0005	
	 0.0005	 0.0009	
	
Cohort	Y	 	 	
	 0.0068	 0.0051	
	 0.0051	 0.0109	
	
Examination	of	network	structure		
Once	the	aggregated	summary	statistics	were	computed,	we	explored	the	structure	of	the	network.	In	a	
first	step,	we	divided	the	cohorts	into	groups	based	on	which	sets	of	scores	could	be	evaluated.		
Each	group	is	represented	by	a	polygon,	that	passes	by	all	the	scores	(i.e.	the	vertices)		which	can	be	
evaluated	in	the	cohorts	constituting	that	group.	The	thickness	of	the	polygon	is	directly	proportional	to	
the	number	of	deaths	in	the	group	(Figure	1).	
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Figure	1	Network	representation	of	the	fictional	example		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Head-to-head	comparisons	within	a	group	can	be	performed	between	any	two	scores	connected	in	the	
same	polygon.		
For	example,	in	group	4,	A	and	D	can	be	compared	because	they	are	both	connected	by	the	same	
polygon,	even	though	there	is	no	line	directly	connecting	the	two	scores	in	that	group.	
According	to	Table	3,	group	1,	group	2,	group	3	and	group	4	have	a	cumulative	number	of	4000,	1000,	
3000	and	2000	patients,	respectively.		
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Table	3	Group	Characteristics	of	a	fictional	network	(g	identifies	the	group.	n	is	the	total	number	of	
subjects	and	d	is	the	total	number	of	deaths	in	each	group.	Additional	characteristics	are	also	listed:	the	
Q	statistic	describing	heterogeneity	has	df	degrees	of	freedom,	and	τ	gives	the	square	root	of	the	τ2	
statistics	for	between	cohort	heterogeneity)	
G	 Scores	 Cohorts	 n	 D	 Q	 df	 τ	
1	 A,	B	 R	 4000	 350	 28	 0	 0.019	
2	 A,	C	 S,	T	 1000	 200	 15.5	 1	 0.014	
3	 A,	B,	D	 U,	V	 			3000	 300	 13.4	 2	 0.004	
4	 A,	B,	C,	D	 X,	Y	 2000	 300	 9.6	 3	 0.036	
	 	
	
	
Multiple	score	comparison		
The	method	of	Lu	et	al.	2011	134	was	used	to	perform	the	multiple	score	comparison	meta-analysis	with	
Der	Simonian-Laird	random	effects	144–147.	This	method,	which	reinterprets	frequentist	NMA	as	a	two-
stage	meta-regression	model	(using	inverse	variance	weighted	least	squares	estimation)	,	was	chosen	as,	
compared	to	most	of	the	network	meta-analytic	techniques,	it	can	easily	handle	multi-score	cohorts,		and	
does	not	make	unnecessary	simplifications	with	respect	to	the	correlations	inherent	in	such	trials,	as	
discussed	above.	In	the	first	stage,	cohorts	in	which	the	same	set	of	scores	have	been	assessed	are	
grouped	together	and	meta-analysed	separately.		
An	estimation	𝑇!	of	the	between-cohort	variance	(𝜏!)	(i.e.,	the	variance	of	the	true	performance	
difference	across	all	studies)	is	the	Der	Simonian-Laird	method	145	adapted	to	the	network	meta-analysis	
case	134.	Indeed,	the	Q	statistic	(adapted	to	network	meta-analysis)	is	referred	to	a	χ	distribution	with	
degrees	of	freedom	dfg=(Mg−1)(Ng−1),	where	Mg	is	the	number	of	scores	compared	in	the	group	g	and	Ng	
is	the	number	of	cohorts	belonging	to	the	group	g.	Thus,	the	degrees	of	freedom	are	df1=1*0=	0,	
df2=1*1=1,	df3=2*1=2,	df4=3*1=3.	Table	3	allows	us	to	calculate	pooled	τ2	(according	to	the	methods	of	
moments)144	with	which	we	evaluate	the	weights	used	to	obtain	the	weighted	average	of	the	
performance	estimate	for	the	whole	network	(reported	in	the	first	4	rows	in	Table	4).			
	
Analogously,	extending	the	definitions	from	meta-analysis	144	to	network	meta-analysis	134	we	calculate	
the	variables	C,	Q	and	τ	(τ	represents	the	heterogeneity	and	deserves	further	discussion	in	the	text	later).		
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In	Stage	II	the	inverse	variance	weighted	least	square	solution	across	all	groups	is	found,	thus	we	obtain	
the	performance	vector	related	to	each	score,	best	fitting	the	results	of	Stage	I	(for	more	details	see	
Appendix	A).	In	the	last	row	of	Table	4.	The	final	results	of	the	MSC	meta-analysis	for	the	fictional	
example	of	are	reported.		
	
	
	
	
Table	4	Stage	I	and	Stage	II	Results	of	the	MSC	Meta-Analysis	in	the	fictional	example	of	Table	1	
(comparison	with	the	A	score)	
Stage	 G	 B	 C	 D	
I	 1	
0.09																							
(0.07,	0.12)	
	
	
I	 2	 	
0.18																							
(0.07,	0.29)	
	
I	 3	
0.10																						
(0.08,	0.12)	
	
0.22																													
(-0.05,	0.50)	
I	 4	
0.08															
(0.04,	0..12)	
0.15																													
(0.01,	0.29)	
0.18																													
(0.05,	0.31)	
II	 	
0.09																							
(0.06,	0.13)	
0.17																															
(0.10,	0.25)	
0.21																															
(0.07,	0.35)	
	
	
	
	
	
Transitivity,	heterogeneity	and	inconsistency.	The	main	assumptions	to	be	met	for	performing	a	network	
meta-analysis	 are	 transitivity	 (a	 key	 assumption	 related	 to	 consistency),	 heterogeneity	 (differences	 in	
estimates	 of	 the	 same	 treatment	 or	 score	 contrasts	 coming	 from	 different	 studies)	 and	 inconsistency	
(comparing	direct	and	indirect	estimates,	sometimes	referred	to	as	incoherence)	142,148.	A	key	assumption	
of	 consistency	 is	 transitivity	 (sometimes	 referred	 to	 as	 similarity	 149)	 among	 the	 treatment	 effects	
133,142,149–153,	 that	 is,	 that	 indirect	 comparisons	 are	 valid	 estimates	 of	 (unobserved)	 direct	 comparisons.	
Therefore	 one	 statistical	 approach	 to	 check	 for	 transitivity	 in	 our	 case	 is	 to	 explore	 the	 distribution		
variables	 giving	 case-mix	 across	 groups	 154,155,	 which	we	 have	 adopted	 here	 using	meta-regression.	 In	
practice,	we	used	the	definition	of	transitivity	from	a	review	paper	on	the	topic	142	better	matching	our	
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methodology,	 namely	 that	 the	 different	 sets	 cohorts	 do	 not	 differ	with	 respect	 to	 the	 distribution	 of	
variables	that	could	generate	case	mix	variation.	Thus,	we	evaluated	by	meta-regression	analysis	156	the	
distribution	of	the	variables	that	could	generate	case	mix	variation	(like	median	and	variability	of	age	43,	
range	and	variance	of	obstruction	severity	(i.e.,	FEV1%	pred.),	exercise	capacity,	size,	mortality	rate).		
In	 case	 of	 variables	 directly	 affecting	 the	 performance,	 we	 used	 analysis	 of	 variance	 (ANOVA)	 to	 see	
whether	 the	 distribution	 of	 the	 identified	 variables	 was	 imbalanced	 in	 the	 groups	 and	 could	
consequently	generate	 imbalance	 in	 the	performance	group	by	group.	 In	case	of	homogenous	groups,	
we	cannot	reject	the	null	hypothesis	of	transitivity.	With	this	method	we	assess	as	well,	the	eventuality	
that	within-cohort	heterogeneity	could	affect	the	analysis	when	“case-mix”	is	present	(i.e.	heterogeneity	
in	 the	variables	 representing	heterogeneity	 in	 the	cohorts,	 like	FEV%predicted	 range,	 that	could	affect	
the	discriminative	properties	in	the	specific	cohorts).”	
Heterogeneity	could	be	described	using	a	multivariate	version	of	the	usual	τ2	statistic,	which	in	the	Lu-
Ades	(2011)	approach	is	considered	on	a	group	level	at	stage	1.	They	suggest	that	a	pooled	τ2	may	be	a	
natural	solution	to	situations	where	there	are	singleton	groups	(i.e.	constituting	only	a	cohort).		
Inconsistency	was	primarily	assessed	visually	by	comparing	direct	and	indirect	comparisons	from	node-
splitting	side	by	side	157.	As	a	further	check	of	inconsistency,	we	further	examined	the	Q	statistic	(that	is,	
the	residual	sum	of	squares)	which	can	be	used	to	reject	the	hypothesis	of	inconsistency	between	direct	
and	indirect	estimates	if	Q	is	greater	than	the	χ2	statistic	with	N	–	K	+	1	degrees	at	freedom	at	the	100(1	-	
α)%	level	134,	where	N	is	the	sum	of	the	number	of	contrasts	in	each	group,	and	K	is	total	number	of	
scores.	Furthermore	local	consistency	could	be	assessed	at	the	group	level	by	examining	residuals	and	
leverage	statistics.	Furthermore,	we	considered	ways	to	calculate	direct	and	indirect	evidence	within	the	
network.	Direct	comparisons	were	computed	by	including	only	cohorts	where	both	scores	under	
consideration	were	present,	and	then	performing	the	usual	random	effects	meta-analysis	144.	However,	
defining	loops	of	any	order	for	indirect	comparisons	proved	to	be	difficult	in	our	setting,	where	the	
network	is	highly	connected,	and	most	cohorts	have	between	4	and	9	scores	being	assessed.	Due	to	the	
various	difficulties	presented	by	studies	with	multiple	scores,	we	chose	to	examine	inconsistency	in	the	
network	using	“node-splitting”	157.	This	approach	avoids	the	need	to	define	loops	of	any	order,	and	
includes	all	possible	indirect	evidence.		
Consideration	of	missing	data.	The	main	analysis	was	performed	without	any	imputation	technique.	A	
sensitivity	analysis,	using	multiple	imputation	was	also	performed	and	it	is	shown	in	the	online-only	
material.	The	results	were	not	significantly	different	in	the	two	cases.	
	
COPD	Data	Description.	Following	the	recommendation	for	large	prospective	studies	140,	we	based	our	
analysis	on	a	large-scale	database	(provided	by	the	COPD	Cohorts	Collaborative	International	
Assessment	(3CIA)	consortium	40)	from	a	diverse	set	of	24	cohort	studies	and	15,762	patients	with	COPD	
(1,871	deaths	and	42,203	person-years	of	follow-up).	The	cohorts	were	heterogeneous	concerning	
geographic	location,	sample	size,	number	of	events	and	correspond	to	a	broad	spectrum	of	patients	with	
COPD	from	primary,	secondary	and	tertiary	care	settings.	Mean	FEV1	ranged	from	30	to	70%	of	the	
predicted	values,	mean	modified	Medical	Research	Council	(mMRC)	dyspnea	scores	from	1.0	to	2.8	(the	
CHAPTER	3:	Development	of	MSC	Meta-Analysis	
	
	67	
scale	goes	from	0	to	4,	with	4	being	the	worst),	mean	number	of	exacerbations	in	the	previous	year	
(where	available)	from	0.2	to	1.7	and	mean	6-minute	walk	distance	(where	available)	from	218	to	487	
meters.	The	follow-up	period	varied	from	cohort	to	cohort,	thus	we	decided	to	use	a	minimum	common	
time	frame	of	3	years.	The	mean	age	varies	between	58	and	72	years.	The	outcome	of	interest	was	3-
year	all-cause	mortality.	A	table	summarizing	the	clinical	characteristics	of	the	cohorts	is	reported	in	the	
supplementary	material.	
Results	
To	illustrate	an	MSC	meta-analysis,	we	compared	the	prognostic	ability	of	various	scores	to	predict	
mortality	in	patients	with	COPD.	The	COPD	Cohorts	Collaborative	International	Assessment	(3CIA)	40	
initiative	contains	individual	data	for	around	16000	patients	(approx.	70000	person	years)	with	COPD	
from	26	cohorts	in	7	countries.	Patients	were	considered	to	have	COPD	if	the	ratio	of	forced	expiratory	
volume	in	one	second	(FEV1)	to	forced	vital	capacity	(FVC)	was	less	than	70%,	regardless	of	the	Global	
Initiative	for	Chronic	Obstructive	Lung	Disease	(GOLD)	(2007)	stage	(I-IV)	52.	The	minimum	required	set	of	
variables	for	each	cohort	included	vital	status	(up	to	death,	loss	to	follow-up,	or	last	data	collection	in	
June	2013),	age,	sex,	pre-bronchodilator	and	post-bronchodilator	FEV1	and	dyspnoea	MRC	grade	40.	Most	
cohorts	included	many	more	variables	allowing	for	the	calculation	of	a	total	of	10	prognostic	scores:	
GOLD	(2007),	GOLD	(2011),	updated	ADO,	BODE,	updated	BODE,	eBODE,	BODEx,	DOSE,	SAFE	and	
optimised	B-AE-D	50,54,56,57,64,70,80.	
	
Examination	of	network	structure	
We	apply	the	MSC	network	meta-analysis	of	prognostic	scores	for	3-year	mortality	from	the	3CIA	data.		
Based	on	the	availability	of	the	10	scores	in	each	cohort,	the	cohorts	could	be	divided	into	6	groups.	The	
network	structure	is	shown	in	Table	5	and	in	Figure	2.	
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Figure	2	Depiction	of	network	structure	with	lines	weighted	by	the	total	number	of	deaths	in	the	group	
Abbreviations:	GOLD,	Global	initiative	for	chronic	Obstructive	Lung	Disease;	BODE,	Body	mass	index,	
airflow	Obstruction,	Dyspnoea	and	severe	Exacerbations;	BODE	upd.,	BODE	updated;	ADO,	Age,	
Dyspnoea,	airflow	Obstruction	(we	use	the	updated	version	of	the	ADO	score	in	our	analysis);	e-BODE,	
severe	acute	exacerbation	of	COPD	plus	BODE;	BODEx,	Body	mass	index,	airflow	Obstruction,	Dyspnoea,	
severe	acute	Exacerbation	of	COPD;	DOSE,	Dyspnoea,	Obstruction,	Smoking	and	Exacerbation	frequency;	
SAFE,	Saint	George’s	Respiratory	Questionnaire	(SGRQ)	score,	Air-Flow	limitation	and	Exercise	capacity;	
B-AE-D,	Body-mass	index,	Acute	Exacerbations,	Dyspnoea.	
aCohorts	belonging	to	the	ADO	or	COCOMICS	groups	are	marked	with	*	or	†	respectively.		
bThe	thickness	of	the	lines	is	proportional	to	the	number	of	deaths	of	the	respective	cohort.	
cBelow	we	report	the	composition	of	the	group;	each	of	them	is	identified	by	a	specific	color:	
Copenhagen*,	HUNT,		Japan	-	SEPOC*	(378	deaths	in	4323	patients)	
Barmelweid*,	Basque*,	Galdakao†,		Pamplona†,	Zaragoza	I†	(215	deaths	in	1208	patients)	
Mar	de	Plata	Argentina,	PACECOPD*,	Son	Espases	Mallorca	(61	deaths	in	556	patients)	
COPDgene	(337	deaths	in	4484	patients)	
Genkols,	ICE	COLD	ERIC,		Initiatives	BPCO,	Sevilla†,	Terrassa	I†,	Terrassa	III†,	Zaragoza	II†	(722	deaths	in	
4346	patients)	
La	Princesa	Madrid,	Requena	II†,	Tenerife†,	Terrassa	II†	(125	deaths	in	845	patients)	
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Table	5	Group	Characteristics	of	the	Network		
g	 Scores	 Cohorts	 n	 #d	 Q	 df	 Τ	
1	 GOLD	–	ADO	
Copenhagen*,	HUNT,		
Japan	-	SEPOC*	
4323	 378	 2.8	 3	 0	
2	
GOLD	-	ADO	-	BODE	–	
BODEupd	
Barmelweid*,	Basque*,	
Galdakao†,		Pamplona†,	
Zaragoza	I†	
1208	 215	 15.5	 12	 0.014	
3	
GOLD	-	GOLD	(2011)	-	ADO	-	
BODE	-	BODEupd	
Mar	de	Plata	Argentina,	
PACECOPD*,	Son	Espases	
Mallorca	
556	 61	 10.9	 8	 0.025	
4	
GOLD	-	GOLD	(2011)	-	ADO	-	
BODE	-	BODEupd	-	SAFE	
COPDgene	 4484	 337	
7.46E-
29	
0	 2.26E-09	
5	
GOLD	-	GOLD	(2011)	-	ADO	-	
BODEx	-	DOSE	–	BAED	
Genkols,	ICE	COLD	ERIC,		
Initiatives	BPCO,	Sevilla†,	
Terrassa	I†,	Terrassa	III†,	
Zaragoza	II†	
4346	 722	 48.1	 30	 0.011	
6	
GOLD	-	GOLD	(2011)	-	ADO	-	
BODE	-	BODEupd	-	eBODE	-	
BODEx	-	DOSE	–	BAED	
La	Princesa	Madrid,	
Requena	II†,	Tenerife†,	
Terrassa	II†	
845	 125	 34.5	 24	 0.014	
Abbreviations:	n,		number	of	subjects;	d,	number	of	deaths;	c,	number	of	cohorts;	Q,	likelihood	ratio	statistic;	df,	degrees	
of	freedom;	τ,	heterogeneity	within	the	group;	GOLD,	Global	initiative	for	chronic	Obstructive	Lung	Disease;	BODE,	Body	
mass	index,	airflow	Obstruction,	Dyspnoea	and	severe	Exacerbations;	BODE	upd.,	BODE	updated;	ADO,	Age,	Dyspnoea,	
airflow	Obstruction	(we	use	in	the	our	analysis	the	updated	version	of	the	ADO	score);	e-BODE,	severe	acute	exacerbation	
of	COPD	plus	BODE;	BODEx,	Body	mass	index,	airflow	Obstruction,	Dyspnoea,	severe	acute	Exacerbation	of	COPD;	DOSE,	
Dyspnoea,	Obstruction,	Smoking	and	Exacerbation	frequency;	SAFE,	Saint	George’s	Respiratory	Questionnaire	(SGRQ)	
score,	Air-Flow	limitation	and	Exercise	capacity;	B-AE-D,	Body-mass	index,	Acute	Exacerbations,	Dyspnoea.	
aCohorts	belonging	to	the	ADO	or	COCOMICS	groups	are	marked	with	*	or	†	respectively	We	notice	that	for	group	4	the	
value	of	heterogeneity	tau	is	not	available	(NA);	indeed,	that	is	a	singleton	group,	where	we	cannot	evaluate	heterogeneity	
	
	
Even	if	it	would	make	sense	to	use	absolute	performance,	we	used	relative	performance	of	each	score	in	
comparison	to	a	Common	Comparator	score,	in	order	to	get	rid	of	possible	common	biases.	We	chose	as	
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Common	Comparator	score	the	GOLD	classification.	One	cohort	(COCOMICS	Requena	I)	was	excluded	
from	the	analysis	because	it	only	had	sufficient	variables	to	evaluate	a	single	score	(GOLD)	and	it	would	
not	contribute	to	the	analysis.	We	had	to	further	exclude	the	cohort	A1ATD	because	there	were	no	cases	
in	the	follow-up	considered	for	our	analysis	(3	years)	and	the	lack	of	events	does	not	allow	calculating	an	
AUC.	Of	the	remaining	24	cohorts,	4	had	two	scores	(GOLD	(2007),	updated	ADO),	and	the	other	20	had	
between	3	and	9	scores	assessed.	We	note	that	in	no	cohort	all	the	10	scores	could	be	evaluated.	
As	GOLD	(2007)	is	commonly	used	to	classify	the	grade	of	severity	of	COPD	patients,	it	could	be	assessed	
in	all	cohorts	52.	We	note	that	direct	evidence	was	available	for	41	of	45	score	comparisons,	indirect	
evidence	was	available	for	other	16	comparisons	(among	which	the	4	cases	in	which	the	direct	
comparison	was	missing).	
Multiple	score	comparison	meta-analysis	(MSC)		
Transitivity,	heterogeneity	and	inconsistency.	To	examine	whether	transitivity	was	fulfilled,	we	analysed	
the	distribution	of	a	number	of	possible	variables	potentially	generating	case-mix,	following	
epidemiological	reasoning	and	literature	(age	median	and	variability	43,	FEV1	percent	predicted	range	
and	variance,	mortality		percentage,	exercise	capacity	range,	number	of	events)	across	the	groups	using	
meta-regression.	For	the	variables	generating	case-mix	(whose	meta-regression	analysis	were	
significant),	the	ANOVA	analysis	showed	that	the	variables	were	balanced	in	the	groups.	Thus,	we	cannot	
reject	the	null	hypothesis	of	transitivity.		
Stage	I	group	level	results	are	presented	in	the	top	of	Table	6,	while	the	bottom	rows	show	the	stage	II	
overall	results	from	the	network	meta-analysis.	GOLD	(2007)	scores	ranged	from	0.481	to	0.731,	with	a	
median	of	0.614,	and	interquartile	range	(0.587,	0.641).	Of	the	scores,	the	one	that	predicted	mortality	
best	was	updated	ADO	with	an	average	AUC	0.083	higher	than	that	of	GOLD	(2007)	(95%	confidence	
interval:	0.069,	0.097),	followed	by	the	updated	BODE	which	was	associated	with	a	0.072	better	AUC	
than	GOLD	(95%	confidence	interval:	0.051,	0.093)	and	eBODE	(+0.069,	95%	confidence	interval:	0.044,	
0.093).	DOSE	(+0.027,	95%	confidence	interval:	0.010,	0.045),	optimised	B-AE-D	(+0.016,	95%	confidence	
interval:	-0.007,	0.038)	and	GOLD	(2011)	(+0.014,	95%	confidence	interval:	0.001,	0.028)	and	showed	the	
worst	performance	in	predicting	mortality,	only	slightly	better	than	GOLD	(2007).	The	other	scores,	
BODE,	SAFE	and	BODEx	showed	moderate	performance,	between	+0.045	and	+0.064	improvement	in	
AUC	over	GOLD.	
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Table 6 Stage I and Stage II Results of the MSC Meta-Analysis (Comparison With the GOLD Classification) 
Stage g ADO BODEupd eBODE BODE SAFE BODEx DOSE BAED newGOLD 
I 1 0.097                       
(0.07, 0.123) 
        
I 2 
0.098                      
(0.057, 
0.139) 
0.124                       
(0.078, 0.17) 
 
0.098                      
(0.059, 
0.137) 
     
I 3 
0.044                              
(-0.03, 
0.117) 
0.023                            
(-0.054, 
0.099) 
 
0.019                           
(-0.054, 
0.091) 
    
-0.011(-0.053, 
0.03) 
I 4 0.042                         
(0.01, 0.074) 
0.043                          
(0.008, 0.078) 
 
0.049                        
(0.017, 
0.081) 
0.037                      
(0.005, 
0.069) 
   
-0.008(-0.038, 
0.022) 
I 5 
0.099                          
(0.076, 
0.123) 
    
0.056                         
(0.035, 
0.076) 
0.036                          
(0.015, 
0.057) 
0.032                         
(0.005, 
0.058) 
0.028                        
(0.008, 0.047) 
I 6 
0.076                     
(0.027, 
0.126) 
0.043                            
(-0.006, 
0.092) 
0.048                         
(0.004, 
0.093) 
0.043                       
(0.001, 
0.085) 
  
0.030                                     
(-0.015, 
0.074) 
0.021                    
(-0.023, 
0.065) 
-0.017(-
0.079, 0.045) 
0.008                             
(-0.031, 0.047) 
II  
0.083                       
(0.069, 
0.097) 
0.072                          
(0.051, 0.093) 
0.069                       
(0.044, 
0.093) 
0.064                       
(0.045, 
0.082) 
0.052                           
(0.022, 
0.082) 
0.045                      
(0.029, 
0.061) 
0.027                        
(0.010, 
0.045) 
0.016                                  
(-0.007, 
0.038) 
0.014                      
(0.001, 0.028) 
Abbreviations:	MSC,	Multiple	Score	Comparison;	GOLD,	Global	initiative	for	chronic	Obstructive	Lung	Disease;	BODE,	Body	
mass	index,	airflow	Obstruction,	Dyspnoea	and	severe	Exacerbations;	BODE	upd.,	BODE	updated;	ADO,	Age,	Dyspnoea,	
airflow	Obstruction	(we	use	in	the	our	analysis	the	updated	version	of	the	ADO	score);	e-BODE,	severe	acute	exacerbation	
of	COPD	plus	BODE;	BODEx,	Body	mass	index,	airflow	Obstruction,	Dyspnoea,	severe	acute	Exacerbation	of	COPD;	DOSE,	
Dyspnoea,	Obstruction,	Smoking	and	Exacerbation	frequency;	SAFE,	Saint	George’s	Respiratory	Questionnaire	(SGRQ)	score,	
Air-Flow	limitation	and	Exercise	capacity;	B-AE-D,	Body-mass	index,	Acute	Exacerbations,	Dyspnoea.	
aThe	first	6	rows	show	the	Stage	I	results	(group	by	group).	The	last	row	shows	the	Stage	II	results	(namely	the	final	results	
of	the	multiple	score	comparison	meta-analysis).		
bThe	score	ordered	by	performance	of	the	prognostic	scores	in	the	Stage	II 
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Concerning	heterogeneity,	due	to	the	group	containing	only	a	single	cohort	(group	6),	we	primarily	
considered	a	random	effects	analysis	calculated	using	a	pooled	estimate	of	τ2	for	all	groups,	which	was	
0.00015,	indicating	a	relatively	low	heterogeneity.	The	results	of	the	MSC	network	meta-analysis	were	
not	substantially	different	when	using	the	group-specific	τ2	estimates.	
Possible	inconsistency	between	direct	and	indirect	comparisons	was	assessed	using	the	Q	statistic	as	
described	above.	Overall,	Q	for	the	random	effects	analysis	was	22.1	with	16	degrees	of	freedom.	
Keeping	in	mind	that	in	this	case	(as	in	classical	network	meta-analysis)	the	inconsistency	test	has	low	
power,	since	Q	was	smaller	than	the	corresponding	χ2	statistic	of	26.3,	we	do	not	reject	the	hypothesis	of	
consistency	(P	=	0.14).		
Both	direct	and	indirect	estimates	of	the	score	comparisons	were	calculated	using	node-splitting	157,	and	
compared	visually.	The	results	are	similar	to	each	other	and	to	the	estimates	provided	by	the	network	
meta-analysis	(see	supplementary	material	for	further	discussion).		
	
Consideration	of	missing	data.	As	a	secondary	analysis,	the	entire	meta-analysis	was	repeated	in	a	
multiple	imputation	framework,	as	described	above.	The	results	were	similar	to	the	main	analysis	
without	imputation	(see	supplementary	material)	1,158,159.		
	
Discussion	
To	the	best	of	our	knowledge,	the	MSC	meta-analysis	proposed	in	this	paper	represents	the	first	
methodology	to	evaluate	the	comparative	prognostic	properties	of	prediction	models	that	synthesizes	all	
available	(direct	and	indirect)	evidence.	The	application	of	the	MSC	meta-analysis	could	provide	different	
clinical	fields	with	a	clear	indication	of	which	is	the	best-performing	prediction	model,	paving	the	way	for	
a	standardized	clinical	application.	While	there	are	a	number	of	issues	when	adapting	usual	NMA	
methodology	to	MSC,	they	can	be	addressed	in	a	straightforward	manner.	Multi-score	studies	are	
considered	in	our	approach	by	explicitly	using	covariance	estimates	for	the	various	prognostic	scores.	
Calculation	of	such	estimates	using	bootstrapping	may	be	computationally	intensive	but	is	not	difficult	to	
implement.	The	approach	presented	here	can	be	used	to	compute	prognostic	score	comparisons	for	the	
entire	network	of	evidence,	as	well	as	both	direct	and	indirect	comparisons	between	scores.		
Despite	these	adaptations,	the	results	of	the	MSC	meta-analysis	are	clear,	and	may	be	interpreted	in	a	
fashion	similar	 to	 standard	network	meta-analysis	 results.	The	only	difference	 is	 that	 the	performance	
measure	 is	not	mean	difference	between	treatments,	or	 log	odds	 ratio,	but	difference	 in	performance	
measure	 such	 as	 AUC.	 Measures	 of	 heterogeneity	 and	 inconsistency	 can	 however	 be	 calculated	 and	
interpreted	 in	 the	 usual	 fashion	 142.	 For	 instance,	 a	 definition	 similar	 to	 the	 one	 used	 for	 the	
heterogeneity	 for	meta-analysis	 of	 direct	 comparisons,	 can	 be	 used	 for	 the	 heterogeneity	 of	 network	
meta-analysis,	 adapting	 a	 definition	 used	 for	multi-arm	 trials	 to	multiple	 score	 comparison.	 	 Since	we	
have	singleton	groups	in	our	MSC	data	(group	6	in	our	database),	it	is	recommended	in	our	case	to	use	
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pooled	 estimate	 of	 the	 τ2	 (τ2pooled)	 134,	 i.e.	 a	 multivariate	 version	 of	 the	 pooled	 estimate	 for	 the	
heterogeneity	variance	(more	technical	details	are	provided	in	the	supplementary	material).	
	We	used	one	of	the	scores	as	a	common	comparator,	which	would	not	generally	be	necessary,	but	may	
be	easily	possible	in	this	MSC	setting.	
Performance	of	the	considered	prognostic	scores	can	be	computed	from	the	individual	patient	data	(IPD)	
directly;	this	is	how	we	approach	the	problems	having	at	our	disposal	a	large-scale	IPD	database.	The	
group	results	(Stage	I)	arise	from	averaging	the	cohort	results,	that,	in	turn,	are	calculated	using	the	IPD	
of	each	cohort.	If	no	IPD	are	available,	instead,	there	are	two	possibilities:	use	published	results,	or	send	
cohorts	code	to	extract	the	aggregated	performance	measures	individually.	Use	of	published	results	
requires	that	comparisons	have	been	reported	for	more	than	one	score,	which	in	practice	may	almost	
never	be	the	case.	Sending	code	to	obtain	aggregated	measures	may	be	an	optimal	approach	in	cases	
where	no	large-scale	collaboration	exists,	and	published	results	are	not	detailed	enough.	
We	used	all-cause	mortality	as	outcome.	Apart	from	being	clinically	relevant,	mortality	is	the	easiest	
outcome	that	we	can	expect	to	evaluate	in	a	cohort,	with	a	hard	definition.	This	makes	it	easier	to	reduce	
the	problems	related	to	miss-classification	or	missingness	of	the	outcome	160,161.	
Given	the	patterns	of	missing	data	(in	general,	the	variables	are	completely	or	almost	completely	missing	
or	not	missing	at	all)	a	sensitivity	analysis	performed	after	multiple	imputation	is	providing	similar	results	
to	the	analysis	without	imputation	(a	comparison	is	provided	in	the	supplementary	material).	
Analogously,	a	sensitivity	analysis	using	heterogeneity	group	by	group	gives	similar	results	than	using	a	
pooled	heterogeneity	(here	recommended	because	of	the	network	structure;	more	details	are	available	
in	the	supplementary	material).	
There	are	a	few	limitations	to	this	approach	to	MSC.	Although	the	analysis	can	be	implemented	as	
outlined	by	Lu	et	al	134	(Appendix	A),	creating	an	input	dataset	in	a	spreadsheet	may	be	less	than	
straightforward.		We	have	therefore	provided	example	R	code	to	convert	a	dataset	of	prognostic	scores	to	
a	MSC	meta-analysis,	without	first	making	a	table	of	cohort-level	summary	statistics,	as	is	often	
performed.	We	note	however	that	such	a	dataset	including	a	column	for	each	cell	of	the	variance-
covariance	matrices	could	be	analysed	using	mvmeta	in	Stata.	Creating	that	kind	of	summary	dataset	
might	be	useful	to	go	along	with	the	network	meta	set	of	commands	in	Stata	162.	We	focused	on	
implementing	this	approach	starting	from	the	raw	prognostic	scores	from	individual	patients,	which	had	
been	calculated	using	raw	data	from	the	international	collaboration	40.	
Conclusions	
In	summary,	we	have	adapted	methodology	from	network	meta-analysis	to	compare	prognostic	
scores	from	individual	patient	data	across	different	cohorts.	This	approach	permits	concurrent	external	
validation	of	the	scores	in	a	consistent	analysis	explicitly	including	correlations	between	the	scores	on	a	
cohort	level.	Estimates	of	differences	in	performance	can	be	estimated	for	the	entire	network,	as	well	as	
for	both	direct	and	indirect	comparisons	of	scores.	Results	of	the	MSC	analysis	can	be	interpreted	in	a	
manner	similar	to	that	of	the	usual	network	meta-analysis,	regardless	of	the	performance	measure	used.	
Our	application	to	prognostic	scores	showed	that	the	ADO	and	updated	BODE	scores	have	the	best	
discriminative	performance	to	predict	mortality	for	patients	with	COPD.	The	meta-analysis	could	also	be	
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repeated	for	a	number	of	different	performance	measures	in	order	to	describe	multiple	facets	of	the	
prognostic	scores	(e.g.	discrimination	and	calibration	1)	or	using	reclassification	methods	(like	the	net	
reclassification	index,	NRI	163)	or	to	aid	in	the	interpretation	of	the	results.	Development	of	clearer	data	
input	formats	as	well	as	more	automated	would	provide	opportunities	for	further	methodological	
research	in	MSC	meta-analysis.		
	
Abbreviations:	MSC:	multiple	score	comparison;	COPD:	chronic	obstructive	pulmonary	disease;	IPD:	
individual	patient	data.	
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Abstract	
Background:	External	validations	and	comparisons	of	prognostic	models	or	scores	are	a	pre-requisite	for	
their	use	in	routine	clinical	care	but	lacking	in	most	medical	fields	including	chronic	obstructive	
pulmonary	disease	(COPD).	Our	aim	was	to	externally	validate	and	concurrently	compare	prognostic	
scores	for	3-year	all-cause	mortality	in	mostly	multimorbid	patients	with	COPD.	
	
Methods:	We	relied	on	24	cohort	studies	of	the	COPD	Cohorts	Collaborative	International	Assessment	
(3CIA)	consortium,	corresponding	to	primary,	secondary	and	tertiary	care	in	Europe,	the	Americas	and	
Japan.	They	include	globally	15762	patients	with	COPD	(1871	deaths	and	42203	person-years	of	follow-
up).	We	used	network	meta-analysis	adapted	to	multiple	score	comparison	(MSC),	following	a	
frequentist	two-stage	approach;	thus,	we	were	able	to	compare	all	scores	in	a	single	analytical	
framework	accounting	for	correlations	among	scores	within	cohorts.	We	assessed	transitivity,	
heterogeneity	and	inconsistency	and	provided	a	performance	ranking	of	the	prognostic	scores.	
	
Results:	Depending	on	data	availability,	between	2	and	9	prognostic	scores	could	be	calculated	for	each	
cohort.	The	BODE	score	(body	mass	index,	airflow	obstruction,	dyspnea	and	exercise	capacity)	had	a	
median	AUC	of	0.679	[1st	quartile-3rd	quartile	=	0.655-0.733]	across	cohorts.	The	ADO	score	(age,	
dyspnea	and	airflow	obstruction)	showed	the	best	performance	for	predicting	mortality	(difference	
AUCADO	-	AUCBODE	=	0.015	[95%	confidence	interval	(CI)	=	-0.002	to	0.032;	p	=	0.08)	followed	by	the	
updated	BODE	(AUCBODE	updated	-	AUCBODE	=	0.008	[95%	CI	=	-0.005	to	+0.022;	p	=	0.23).	The	assumption	of	
transitivity	was	not	violated.	Heterogeneity	across	direct	comparisons	was	small	and	we	did	not	identify	
any	local	or	global	inconsistency.		
	
Conclusions:	Our	analyses	showed	best	discriminatory	performance	for	the	ADO	and	updated	BODE	
scores	in	patients	with	COPD.	A	limitation	to	be	addressed	in	future	studies	is	the	extension	of	MSC	
network	meta-analysis	to	measures	of	calibration.	MSC	network	meta-analysis	can	be	applied	to	
prognostic	scores	in	any	the	medical	field	to	identify	the	best	scores,	possibly	paving	the	way	for	
stratified	medicine,	public	health	and	research.	
	
Keywords:	COPD,	prognostic	 scores,	 large-scale	external	 validation,	performance	comparison,	network	
meta-analysis	
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Background	
Prognostic	scores,	commonly	based	on	coefficients	from	regression	models,	provide	a	probability	of	a	
certain	adverse	outcome	for	an	individual	over	a	specified	time	horizon.	Prognostic	scores	have	become	
increasingly	popular	over	the	last	two	decades	1,23,24,164,165.	They	serve	multiple	purposes	such	as	
informing	individuals	and	health	care	providers	about	disease	and	outcome	risks,	supporting	risk-
stratified	and	personalized	prevention	or	treatment	decisions,	identifying	participants	for	research	or	
adjusting	for	confounding	111,166–168.		
Numerous	prognostic	models	have	been	developed	in	various	fields	of	Medicine	169–172.	Just	for	
predicting	the	risk	of	cardiovascular	disease	in	the	general	population,	a	recent	review	identified	363	
prognostic	models	or	scores	19.	For	patients	with	Chronic	Obstructive	Pulmonary	Disease	(COPD),	
prognostic	scores	have	been	developed	mostly	to	predict	the	risk	of	death	54–58,60,61,63–67,70,80,173,174,	but	
scores	also	exist	to	predict	exacerbations	126,	or	deteriorating	of	health-related	quality	of	life	62,70.		
Major	obstacles	for	using	prognostic	scores	in	practice	and	research	are,	however,	the	frequent	
lack	of	external	validations,	comparisons	of	their	predictive	performance	and	assessments	of	their	
applicability	in	practice	23,27,31,43,120,175,176.	Practitioners	and	researchers	are	left	with	uncertainty	about	
which	prognostic	score	to	use	and	may	be	reluctant	to	use	them	at	all	177.	Ideally,	prognostic	scores	
would	be	externally	validated	in	several	different	populations	and	their	performance	summarized	178,179.	
However,	such	external	validations	and	concurrent	comparisons	are	rarely	performed	47.	In	addition,	for	
even	more	comprehensive	comparison,	the	performance	of	prognostic	scores	may	be	compared	
indirectly	using	common	comparator	scores	similar	to	network	meta-analysis	(NMA)	142,180–184	of	
randomized	trials.	
Our	aim	was	to	use	Multiple	Score	Comparison	(MSC)	in	order	to	externally	validate	and	
concurrently	compare	prognostic	scores	for	3-year	mortality	in	patients	with	Chronic	Obstructive	
Pulmonary	Disease	(COPD).	
	
	
Methods	
We	followed	a	pre-specified	study	protocol	and	described	the	detailed	statistical	methods	elsewhere.180		
Study	design	and	participants	
This	study	was	based	on	26	cohort	studies	of	the	COPD	Cohorts	Collaborative	International	Assessment	
(3CIA)	consortium.	Details	have	been	reported	elsewhere	and	summarized	in	Table	2	40.	All	cohorts	were	
approved	by	ethics	committees	and	participants	gave	written	informed	consent	40.	We	included	also	the	
PAC-COPD	and	Copenhagen	cohorts	in	the	final	database,	even	if	they	were	used	in	the	large-scale	
update	of	the	ADO	index	55.	We	considered	this	approach	reasonable,	since	they	form	only	small	part	of	
the	final	database	but	we	verified	in	a	sensitivity	analysis	if	they	affected	the	results.	
	
Prognostic	scores	
Starting	from	the	literature	review	of	two	studies	47,62	and	searching	among	their	references,	
Pubmed	related	articles	and	through	our	research	network,	we	identified	19	prognostic	scores,	of	which	
we	included	10	in	our	analysis	(in	the	appendix	the	whole	list	with	corresponding	scoring	rules).	The	
scores	(see	Table	1	for	details)	were	the	BODE	(Body	mass	index,	airflow	Obstruction,	Dyspnea	and	
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severe	Exacerbations)	54,	updated	BODE	56,	ADO	(Age,	Dyspnea,	airflow	Obstruction;	we	included	in	the	
analysis	only	the	updated	ADO	index	and	not	the	original	ADO	index	56	because	the	updated	ADO	was	
generated	from	large-scale	external	validation;	however	we	will	name	it	simply	ADO)	55,	eBODE	(severe	
acute	exacerbation	of	COPD	plus	BODE)	57,	BODEx	(Body	mass	index,	airflow	Obstruction,	Dyspnea,	
severe	acute	Exacerbation	of	COPD)	57,	DOSE	(Dyspnea,	Obstruction,	Smoking	and	Exacerbation	
frequency)	70,	SAFE	(Saint	George’s	Respiratory	Questionnaire		(SGRQ)	score,	Air-Flow	limitation	and	
Exercise	capacity)	80,	B-AE-D	(Body-mass	index,	Acute	Exacerbations,	Dyspnea;	we	used	the	optimized	
version	and	not	the	original	B-AE-D	score)	64.	The	GOLD	classification	50,52	and	the	2011-2016	GOLD	
classification	(often	referred	as	new	GOLD	in	the	recent	COPD	literature)	50	were	also	used	in	the	
analysis,	even	if	they	were	not	designed	for	prognostic	purposes.	Apart	from	original	ADO	and	original	B-
AE-D	score	(in	the	appendix	we	evaluated	also	their	performances)	the	other	7	identified	scores	from	
literature	were	excluded	from	the	analysis,	since	our	database	did	not	include	at	least	one	of	their	
predictors	or	did	not	include	them	simultaneously	in	at	least	1	cohort.	
	
	
Table	1	Scoring	rules	of	prognostic	scores	to	predict	mortality	in	patients	with	COPD	
														
Score	
	
Predictor	
	
GOLD	
50,52	
	
GOLD	
(2011-
2016)	
50	
	
BODE	
54	
	
BODE	
upd.	
56	
	
ADO	
55	
	
	
e-BODE	
57	
	
BODEx	
57	
	
DOSE	
70	
	
SAFE	
80	
	
B-AE-D	
64	
BMI	 	 	 0	(>21)	
1	(<=21)	
0	(>21)	
1	(<=21)	
	 0	(>21)	
1	(<=21)	
0	(>21)	
1	(<=21)	
	 	 0	(>=21)	
6	(18.5-
21)	
9	(<18.5)	
FEV1%	
pred.	
0	
(>=80%)	
1	(50-
79%)	
2	(30-
49%)	
3	(<30%)	
0	(if	
FEV1pp>=
50	
and	<=1	
exacerbati
ons	per	
year)	
2	
(otherwis
e)	
0	
(>=65%)	
1	(50-
64%)	
2	(36-
49%)	
3	(<=35)	
0	
(>=65%)	
1	(36-
64%)	
2	(<=35)	
	
0	
(>=81%)	
1	(65-
60%)	
2	(51-
64%)	
3	(35-
50%)	
4	
(<=35%)	
	
0	
(>=65%)	
1	(50-
64%)	
2	(36-
49%)	
3	(<=35)	
0	
(>=65%)	
1	(50-
64%)	
2	(36-
49%)	
3	(<=35)	
0	
(>=50%)	
1	(31-
49%)	
2	(<=30)	
	
0	
(>=80%)	
1	(50-
79%)	
2	(36-
49%)	
3	(<=35)	
	
mMRC	 	 0	(if	
mMRC	
>=2	and	
CAT	>=10)	
1	
otherwise	
0	(0-1)	
1	(2)	
2	(3)	
3	(4)	
0	(0-1)	
1	(2)	
2	(3)	
3	(4)	
0	(0)	
1	(1-2)	
2	(3)	
3	(4)	
0	(0-1)	
1	(2)	
2	(3)	
3	(4)	
0	(0-1)	
1	(2)	
2	(3)	
3	(4)	
0	(0-1)	
1	(2)	
2	(3)	
3	(4)	
	 0	(0-2)	
6	(3)	
10	(4)	
6-MWT	
(m)	
	 	 0	
(>=350)	
1	(250-
349)	
2	(150-
249)	
3	
(<=149)	
0	
(>=350)	
4	(250-
349)	
7	(150-
249)	
9	
(<=149)	
	 0	
(>=350)	
1	(250-
349)	
2	(150-
249)	
3	
(<=149)	
	 	 0	
(>=400)	
1	(300-
399)	
2	(200-
299)	
3	
(<=199)	
	
Age	(y)	 	 	 	 	 0	(40-49)	
2	(50-59)	
	 	 	 	 	
CHAPTER	4:	Application	of	MSC	Meta-Analysis	
	
	97	
Abbreviations:	 BMI=body-mass	 index;	 FEV1%	pred.=forced	 expiratory	 volume	 in	 1	 second	 percentage	 predicted;	
mMRC=modified	Medical	Research	Council	dyspnea	scale;	6MWT=6-minute	walk	test;	CAT=COPD	Assessment	Test;	
SGRQ=Saint	 George’s	 Respiratory	 Questionnaire;	 previous	 exacerbations	 are	 referred	 to	 the	 previous	 year.	
GOLD=Global	initiative	for	chronic	Obstructive	Lung	Disease;	BODE=Body	mass	index,	airflow	Obstruction,	Dyspnea	
and	severe	Exacerbations;	BODE	upd.=BODE	updated;	ADO=Age,	Dyspnea,	airflow	Obstruction	(we	use	in	the	our	
analysis	 the	 updated	 version	 of	 the	 ADO	 score);	 e-BODE=severe	 acute	 exacerbation	 of	 COPD	 plus	 BODE;	
BODEx=Body	 mass	 index,	 airflow	 Obstruction,	 Dyspnea,	 severe	 acute	 Exacerbation	 of	 COPD;	 DOSE=Dyspnea,	
Obstruction,	 Smoking	and	Exacerbation	 frequency;	 SAFE=Saint	George’s	Respiratory	Questionnaire	 (SGRQ)	 score,	
Air-Flow	 limitation	 and	 Exercise	 capacity;	 B-AE-D.=Body-mass	 index,	 Acute	 Exacerbations,	 Dyspnea	 (we	 use	 the	
optimized	version	of	 the	score,	 introduced	 in	 the	same	paper).	Missing	cells	 correspond	 to	variables	 that	do	not	
constitute	the	score	of	the	correspondent	column.	
	
	
Outcome	and	performance	measure	for	external	validation	and	comparison	of	prognostic	scores	
We	evaluated	a	number	of	performance	measures	commonly	used	to	assess	the	prognostic	
properties	of	prediction	models	and	scores.180		We	deemed	the	Area	Under	the	Curve	(AUC)	to	be	the	
most	appropriate	performance	measure	for	our	purposes,	mainly	because	its	range	is	independent	of	
the	data,	it	is	easy	to	interpret	and	an	analytic	formula	for	its	variance	is	available	185.	
	
Statistical	analysis	
We	followed	a	pre-specified	study	protocol.	We	first	performed	direct	head-to-head	
comparisons	using	random-effects	meta-analysis,	and	then	examined	the	network	evidence	merging	all	
available	direct	and	indirect	evidence	186.	We	used	a	novel	methodology,	i.e.	Multiple	Score	Comparison	
(MSC)	meta-analysis,		adapted		from	multiple	treatment	comparison	network	meta-analysis	134,187.	
Methodological	details	are	reported	in	the	section	“Detailed	Methods”	in	the	supplementary	material	
and	in	a	recent	paper	180.	R	codes	are	available	(provided	in	the	section	“R	Code	for	MSC	meta-analysis”	
in	the	supplementary	material).	
	
4	(60-69)	
5	(70-79)	
7	(>=80)	
Prev.	
exacerbati
on	
	 (See	
FEV1pp)	
	 	 	 0	(0)	
1	(1-2)	
2	(>2)	
0	(0)	
1	(1-2)	
2	(>2)	
0	(0-1)	
1	(2-3)	
2	(>3)	
	 0	(0)	
3	(1)	
7	(>=2)	
CAT	 	 (See	
mMRC)	
	 	 	 	 	 	 	 	
Smoking	 	 	 	 	 	 	 	 0	(non-	
smoker)	
1(curren
t	
smoker)	
	 	
Quality	of	
life	
(SGRQ)	
	 	 	 	 	 	 	 	 0	(<=30)	
1	(31-49)	
2	(50-64)	
3	(>=65)	
	
Total	
Score	
0-3	 0-3	 0-10	 0-15	 0-14	 0-12	 0-9	 0-8	 0-9	 0-26	
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Direct	comparisons	(random-effects	pairwise	meta-analysis)	
We	directly	compared	prognostic	scores	by	pairwise	random-effects	meta-analysis	145,188.	We	
used	forest	plots	to	visually	investigate	statistical	heterogeneity,	as	well	as	the	I²	statistic.	Such	standard	
meta-analysis	has	limitations,	since	it	does	not	take	into	account	the	correlations	among	multiple	scores	
evaluated	on	the	same	set	of	patients	141	and	it	does	not	give	a	clear	indication	of	which	prognostic	score	
performs	best.	Thus,	we	adopted	network	meta-analysis,	an	approach	that	allowed	us	to	weight	and	
then	pool	the	results	coming	from	different	cohorts.	
	
MSC	meta-analysis		
Methodological	details	are	reported	in	details	in	180.	In	brief,	we	used	an	example	of	implementation	
of	network	meta-analysis	for	treatment	effectiveness	comparison	134,	adapting	it	to	our	purposes,	
namely	to	concurrently	externally	validate	and	compare	prognostic	scores	from	individual	patient	data	
across	different	cohorts	(reference	coming	soon	and	proof	reading	already	available).	We	have	explicitly	
included	correlations	141	between	the	scores	on	a	cohort	level.	We	use	a	frequentist	two-stage	meta-
regression	model,	as	proposed	in	134:		
1. Ordinary	 meta-analysis	 (stage	 I)	 to	 obtain	 the	 direct	 estimates	 for	 pooled	 differences	 in	 AUC	
(using	 the	 inverse-variance	weighted	means	of	 the	 corresponding	 cohorts).	 The	meta-analyses	
were	 done	 within	 each	 group	 of	 cohorts	 where	 data	 for	 the	 same	 prognostic	 scores	 were	
available.	
2. In	this	stage	II,	we	merged	the	estimates	for	the	differences	in	AUC	from	the	groups	of	cohorts,	
looking	 for	 the	weighted	 least	 squares	 solution	 to	 the	 regression	problem	equation.	Based	on	
the	 direct	 estimates	 and	 their	 variances	 from	 the	 first	 stage,	 we	 estimated	 the	 pooled	
differences	in	AUC	that	obeyed	fundamental	consistency	equations.	Thus	in	stage	II,	the	Stage	I	
estimates	 for	 the	 differences	 in	 AUC	were	 combined	 across	 groups	 of	 cohorts	 to	 give	 overall	
performance	estimates	for	the	entire	network.	
In	 order	 to	 provide	 a	 ranking	 of	 the	 scores,	we	 used	 a	 frequentist	 version	 of	 the	 SUCRA	 (Surface	
Under	the	Cumulative	Ranking	Curve;	189,190)	score	showing	the	likelihood	of	score	to	be	better	than	
any	other	score	and	summarizing	relative	performances	and	confidence	intervals.		
The	last	steps	were	to	ensure	that	the	heterogeneity,	transitivity	and	consistency	assumptions	were	
met.142	 Heterogeneity	 in	 the	 MSC	 analysis	 was	 evaluated	 by	 the	 pooled	 heterogeneity	 variance	
among	 groups	 (τ2pooled).	 We	 assessed	 “transitivity”	 through	 ANOVA	 tests.	 Thus	 we	 assessed	 the	
comparability	of	the	cohorts	across	whom	the	predictive	performance	of	a	score	may	vary	because	
of	 a	 “spectrum	 effect”191	 or	 “case	 mix”	 43,46,155.	 We	 also	 assessed	 consistency	 142	 between	 direct	
evidence	 and	 MSC	 meta-analysis	 estimates	 using	 Q	 likelihood-ratio	 test	 statistic	 to	 evaluate	 the	
global	consistency	and	analysis	of	 residuals	and	 leverages	 to	evaluate	 the	 local	consistency	134.	For	
more	details,	see	“Detailed	Methods”	in	the	supplementary	material	and	180	
	
Handling	of	missing	data	
If	a	variable	was	missing	for	>30%	of	the	patients	we	discarded	the	specific	variable	for	that	
particular	specific	cohort,	since	the	effects	of	such	predictors	could	be	generally	distrusted	1.	Otherwise	
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we	performed	multiple	imputation	with	chained	equations	(the	analysis	of	the	patterns	of	missingness	
allowed	us	to	consider	the	missing	data	missing	completely	at	random	apart	from	the	dependence	on	
the	cohort)	164.	We	combined	the	estimates	of	the	30	different	analyses	(one	for	each	imputed	dataset,	
for	each	of	which	we	followed	all	the	previously	highlighted	frequentist	two-stage	meta-regression	
model	approach)	using	Rubin’s	rules.	
	
Results		
Cohort	and	participant	characteristics	
The	cohorts	varied	greatly	in	terms	of	geographic	location,	sample	size,	number	of	events	and	included	a	
broad	spectrum	of	patients	with	COPD	from	primary,	secondary	and	tertiary	care	settings	(Table	2).	
Mean	FEV1	ranged	from	30	to	70%	of	the	predicted	values,	mean	modified	Medical	Research	Council	
(mMRC)	dyspnea	scores	from	1.0	to	2.8	(the	scale	goes	from	0	to	4,	with	4	being	the	worst),	mean	
number	of	exacerbations	in	the	previous	year	(where	available)	from	0.2	to	1.7	and	mean	6-minute	walk	
distance	(where	available)	from	218	to	487	meters.		
	
Table	2	Study	characteristics	
Cohort	 #	
Event
s		
#	
patient
s	
Person	
years	
Mean	
age:	
years	
Men:	
%	
Mean	
FEV1%	
pred.	
Mean	
mMR
C	
Past	
exacerb
ators:	%	
Mean	#	
prev.	
exacer-
bations	
Current	
Smoker
:	%	
Mean	
BMI	
Mean	
6MWT:	
meters	
Mean	
SGRQ	
Mean	
CAT	
COPDgene	 337	 4484	 10603	 63	(9)	 56	 57.4	
(22.8)	
1.5	 0.16	 		 43	 27.9	
(6.1)	
376.1	
(124.1)	
36.9	
(22.9)	
		
Sevillaa	 205	 596	 1562	 66	
(10)	
95	 43.5	
(13.3)	
1	 0.25	 1.16	 24	 29.2	
(5.7)	
		 		 		
Copenhagen
b	
186	 2287	 6618	 61	(9)	 54	 70.5	
(23.7)	
1.3	 		 		 71	 25	
(4.2)	
		 		 		
Genkols	 126	 954	 2708	 65	
(10)	
61	 46.9	
(17)	
1.3	 0.15	 0.6	 47	 25.4	
(5)	
		 		 		
Zaragoza	IIa	 118	 1150	 3069	 63	(9)	 93	 62.3	
(20.3)	
1.1	 0.17	 0.91	 34	 27.5	
(4.8)	
356.2	
(153.7)	
		 		
HUNT	 116	 1571	 4583	 63	
(13)	
62	 63.8	
(18.7)	
1.3	 		 		 47	 26.4	
(4.4)	
		 		 		
Galdakaoa	 92	 543	 1497	 68	(8)	 96	 55	
(13.3)	
0.9	 0	 0.65	 21	 28.3	
(4.4)	
408.9	
(92.4)	
		 		
Barmelweidb	 79	 232	 555	 72	(9)	 60	 45.2	
(16.1)	
1.1	 		 		 21	 26	
(6.3)	
363.4	
(126.8)	
		 		
Terrassa	IIIa	 78	 181	 423	 72	
(10)	
95	 45.2	
(14.4)	
1.2	 0.31	 1.28	 23	 27.9	
(5)	
330.4	
(105.8)	
		 		
Initiatives	
BPCO	
76	 930	 1525	 64	
(10)	
77	 52.4	
(20.3)	
1.1	 0.4	 1.65	 28	 25.4	
(5.5)	
387.4	
(120.8)	
43.9	(19)	 		
Terrassa	Ia	 72	 135	 284	 72	(9)	 92	 41.3	
(13)	
1.3	 0.25	 1.03	 17	 26.3	
(4.9)	
		 		 		
SEPOCb	 61	 318	 871	 65	(9)	 100	 45	
(18.3)	
1.5	 		 		 38	 26.4	
(4.2)	
		 		 		
Requena	IIa	 52	 186	 396	 71	(9)	 99	 44.5	
(16.5)	
1	 0.16	 0.62	 17	 28.1	
(5.2)	
380.1	
(111.9)	
		 		
ICE	COLD	
ERIC	
47	 400	 1071	 67	
(10)	
57	 55.3	
(16.5)	
1.5	 0.13	 0.58	 39	 26.1	
(5.2)	
		 		 		
PAC-COPDb	 41	 342	 980	 68	(9)	 93	 52.4	
(16.2)	
1	 0.04	 		 33	 28.2	
(4.7)	
435.5	
(90.6)	
		 		
Tenerife	a	 34	 275	 653	 63	
(10)	
79	 55.8	
(21.2)	
1.2	 0.06	 0.37	 42	 27.3	
(5.1)	
487.4	
(87.5)	
		 		
Terrassa	IIa	 28	 66	 145	 72	(9)	 98	 30.2	
(12.9)	
1	 0.42	 1.81	 14	 25.7	
(4.3)	
217.7	
(76.6)	
		 		
Requena	Ia	 23	 174	 393	 72	(9)	 99	 48.1	
(16.8)	
1.2c	 0.03	 0.22	 23	 28	
(4.2)	
434.4	
(125.3)	
		 		
Zaragoza	Ia	 21	 137	 379	 66	(8)	 99	 49.8	
(17.6)	
1.1	 		 		 27	 27.7	
(4.6)	
449	
(91.9)	
		 		
Son	Espases	
Mallorca	
17	 115	 292	 70	(7)	 79	 41.5	
(13.4)	
1	 0.59	 		 27	 27.1	
(5.9)	
401.5	
(89.7)	
		 16.6	
(8.2)	
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Abbreviations:	 FEV1%	 pred.=forced	 expiratory	 volume	 in	 1	 second	 percentage	 predicted;	
mMRC=modified	 Medical	 Research	 Council	 (MMRC)	 dyspnea	 scale;	 past	 exacerbators	 are	
defined	 as	 patients	with	more	 than	 1	 exacerbation	 in	 the	 previous	 year;	mean	 #	 previous	
exacerbations	 are	 referred	 to	 the	 previous	 year;	 BMI=body-mass	 index;	 6MWT=6-minute	
walk	test;	SGRQ=Saint	George’s	Respiratory	Questionnaire;	CAT=COPD	Assessment	Test.				
	
The	 cohorts	 are	presented	 in	decreasing	order	of	number	of	events.	Most	of	 the	variables	
available	 provided	 by	 the	 3CIA	 collaboration	 for	 the	 different	 cohorts	 are	 shown.	 In	
particular,	 we	 show	 all	 the	 variables	 constituting	 the	 scores	 analyzed	 in	 our	 study.	 We	
present	 the	 standard	 deviation	 for	 all	 individual	 variables,	 whose	 distribution	 is	
approximately	 normal;	 this	 is	 not	 the	 case	 for	 count	 (with	 small	 numbers)	 or	 categorical	
variables,		like	number	of	previous	exacerbations	or	mMRC).	
aCohorts	belonging	to	the	COCOMICS	collaboration		
bCohorts	belonging	to	the	ADO		collaboration.	For	information	concerning	the	cohorts,	please	
see	40.		
c	Since	none	of	the	score	could	be	evaluated	in	the	cohort	“Requena	I”	(mainly	because	the	
variable	dyspnoea	was	missing	for	95%	of	the	patients,	i.e.	for	165	out	of	174	patients),	this	
cohort	was	excluded	from	the	analysis.		
d	Since	there	was	no	event	in	a	follow-up	of	3	years,	the	cohort	“A1ATD”	was	excluded	from	
the	analysis.		
Missing	 cells	 correspond	 to	 variables	 that	 are	 completely	 missing	 in	 the	 cohort	 of	 the	
correspondent	row.	
	
	
	
Direct	comparisons	of	prognostic	scores	for	mortality	in	patients	with	COPD	
The	direct	comparisons	are	shown	in	the	upper-right	triangle	of	Table	3,	i.e.	a	league	table	(that	
also	includes	the	Multiple	Score	Comparison	Meta-Analysis	in	the	lower-left	triangle).	Forest	plots	for	
each	pair	of	scores,	I2	and		τ2	are	shown	in	the	appendix.	41	direct	comparisons	of	the	AUC	of	prognostic	
scores	were	possible;	indeed,	no	direct	evidence	was	available	for	the	comparison	between	SAFE	and	the		
eBODE,	BODEx,	DOSE	and	B-AE-D	scores	(cells	D6,	E6,	F2,	G6,	I10	in	the	league	table	3).		
	
	
	
	
Basqueb	 16	 106	 299	 71	(9)	 98	 46.9	
(11.4)	
0.6	 		 		 23	 26.1	
(4.9)	
442.9	
(95.4)	
		 		
Japan	 15	 147	 409	 69	(7)	 100	 47.1	
(17.5)	
0.9	 		 		 22	 21	
(2.9)	
		 36.6	
(16.5)	
		
La	Princesa	
Madrid	
11	 318	 633	 71	
(10)	
74	 50	
(19.8)	
1.1	 0.18	 0.77	 19	 26.2	
(5.1)	
337.1	
(92.8)	
		 		
Pamplonaa	 7	 190	 470	 65	(8)	 84	 68.9	
(19.9)	
1.1	 		 		 37	 27	
(4.4)	
463.2	
(113.9)	
		 		
Mar	de	Plata	
Argentina	
3	 99	 147	 64	(9)	 60	 48.8	
(18.6)	
1	 0.29	 		 21	 27	
(5.6)	
353.2	
(128.7)	
		 16.1	
(7.8)	
A1ATDd	 0	 308	 834	 58	
(10)	
60	 53.1	
(25.1)	
1.2	 0.52	 		 5	 25.7	
(4.9)	
		 50.8	
(19.9)	
20.5	
(8.1)	
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Table	3	League	table	presenting	the	Multiple	Score	Comparison	(MSC)	meta-analysis	(lower-left	half	of	the	table)	
and	the	direct	random-effects	meta-analysis	(upper-right	half	of	the	table)	
Direct			meta-	
analysis	
MSC																													
meta-	
analysis	
	 GOLD	 B-AE-D	 GOLD							
(2011-
2016)	
DOSE	 BODEx	 SAFE	 eBODE	 BODE	 BODE	
updated	
ADO	
	 	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
GOLD	 A	 AUC	=	
0.613																															
(1st	Q.	
0.587-	
3rd	Q.	
0.637)	
ΔAUC	=	
0.030 																			
(-0.005,	
0.065)	
0.017														
(-0.005,
0.038)	
0.036																					
(0.008,	
0.064)	
0.054																		
(0.029,	
0.079)	
0.047																		
(0.027,	
0.068)	
0.064																				
(0.004,	
0.123)	
0.071																
(0.040,	
0.102)	
0.080																			
(0.041,	
0.119)	
0.090																			
(0.072,	
0.109)	
B-AE-D	 B	 ΔAUC	=	
0.010																								
(-0.010,	
0.031)	
	 -0.004																													
(-0.025,	
0.017)	
0.004 																			
(-0.012,	
+0.020)	
0.025 																						
(0.011,	
0.039)	
NA	 0.069																										
(-0.016,	-
0.121)	
0.079 																											
(0.004,	
0.154)	
0.082 																			
(-0.012,	-
0.152)	
0.076																												
(0.051,	
0.101)	
GOLD	 (2011-
2016)	
C	 0.012																						
(-0.001,	
0.024)	
0.001																					
(-0.019,	
0.021)	
0.009																									
(-0.002,	
0.021)	
0.028 																						
(0.017,	
0.039)	
0.055 																		
(0.038,	
0.072)	
0.047																				
(0.016,	
0.079)	
0.059																	
(0.046,	
0.073)	
0.051																		
(0.027,	
0.076)	
0.067																			
(0.053,	
0.080)	
DOSE	 D	 0.022	
(0.006,	
0.037)	
0.011																											
(-0.007,	-
0.029)	
0.010 															
(-0.005,	
0.025)	
0.018																									
(0.008,	-
0.029)	
NA	 0.039																									
(0.007,	
0.070)	
0.033 																							
(-0.000,	
0.065)	
0.043 																								
(-0.002,	
0.088)	
0.061																								
(-0.044,	-
0.079)	
BODEx	 E	 0.041	
(0.027,	
0.055)	
0.030																												
(0.014,	
0.047)	
0.029 			
(0.015,	
0.043)	
0.019																									
(0.005,	
0.033)	
NA	 0.030																										
(-0.001,	
0.061)	
0.031 																								
(-0.017,	
0.079)	
0.039 																					
(-0.028,	
0.105)	
0.050																									
(0.034,	
0.066)	
SAFE	 F	 0.061																		
(0.034,	
0.087)	
0.050																										
(0.018,	
0.082)	
0.049 					
(0.022,	
0.076)	
0.039																			
(0.010,	
0.068)	
0.020																										
(-0.009,	
0.048)	
NA	 0.011																										
(-0.000,	
0.023)	
0.005 																							
(-0.009,	
0.018)	
-0.007 																										
(-0.029,	
0.015)	
eBODE	 G	 0.065										
(0.046,	
0.085)	
0.055																									
(0.032,	
0.078)	
0.054 						
(0.034,	
0.074)	
0.044																								
(0.023,	
0.064)	
0.024 																																																																							
(0.007,	
0.042)	
0.005
(-0.025,	
0.035)	
-0.001																												
(-0.020,	
0.017)	
0.002 																			
(-0.031,	
0.034)	
0.024 																							
(-0.018,	
0.066)	
BODE	 H	 0.068											
(0.052,	
0.084)	
0.057																							
(0.034,	
0.080)	
0.056								
(0.039,	
0.074)	
0.046																								
(-0.027,	-
0.065)	
0.027 																							
(0.009,	
0.045)	
0.007 																									
(-0.019,	
0.034)	
0.003 																					
(-0.016,	
0.021)	
0.005																								
(-0.006,	
0.017)	
-0.004																											
(-0.023,	
0.016)	
BODE	upd.	 I	 0.076												
(0.058,	
0.095)	
0.066																										
(0.041,	
0.091)	
0.065 					
(0.045,	
0.085)	
0.055																													
(-0.033,	-
0.076)	
0.036 																					
(0.015,	
0.056)	
0.016 																								
(-0.012,	
0.043)	
0.011 																			
(-0.009,	
0.031)	
0.008 																										
(-0.005,	
0.022)	
-0.005																		
(-0.032,	
0.022)	
ADO	 L	 0.083												
(0.070,	
0.096)	
0.072																										
(0.052,	
0.093)	
0.071 						
(0.056,	
0.087)	
0.070																											
(-0.052,	-
0.089)	
0.042 												
(0.026,	
0.058)	
0.022																										
(-0.005,	
0.050)	
0.018 																				
(-0.003,	
0.038)	
0.015																						
(-0.002,	
0.032)	
0.007																			
(-0.012,	
0.026)	
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Abbreviations:	AUC=Area	Under	the	Curve;	The	lower-left	half	of	the	table	refers	to	the	Multiple	Score	Comparison	
meta-analysis.	 The	 upper-right	 half	 of	 the	 table	 refers	 to	 direct	 comparisons	 using	 conventional	 random	 effects	
meta-analysis.	The	first	cell	(first	row,	first	column)	gives	a	reference	value	(in	red),	namely	the	median	and	1st	and	
3rd	quartiles	of	the	AUC	of	the	GOLD	classification	across	cohorts	as	an	anchor	to	interpret	the	differences	in	AUC	
between	the	prognostic	scores.		In	each	other	cell,	each	pair	of	scores	is	compared	using	the	difference	in	AUC.	For	
the	lower-left	half	of	the	table	we	report	in	the	correspondent	cell	the	difference	between	the	AUCs	of	the	score	in	
the	 row	 and	 the	 score	 in	 the	 column;	 instead,	 for	 the	 upper-right	 half	 of	 the	 table	 we	 report	 the	 difference	
between	the	AUCs	of	the	score	in	the	column	and	the	score	in	the	row	or	the.	We	decided	for	this	representation	
to	make	a	visual	comparison	between	direct	and	MSC	comparison	easier;	indeed,	in	this	way,	it	is	enough	to	look	at	
corresponding	values	mirrored	at	the	main	diagonal.	The	95%	confidence	interval	 is	 indicated	in	parentheses.	For	
better	readability	of	the	table	the	sign	“+”	is	omitted,	while	the	sign	“-“	is	indicated.		
	
	
	
	
The	updated	BODE	score	performed	statistically	significantly	better	than	GOLD,	new	GOLD	and	
the	B-AE-D	scores	whereas	the	AUC	of	the	updated	BODE	score	was	higher	than	for	the	other	scores	but	
not	statistically	significantly	so.	We	deemed	overall	statistical	heterogeneity	of	direct	comparisons	
moderate.	In	our	MSC	meta-analysis	the	direct	comparisons	should	be	interpreted	with	caution	though,	
since	they	do	not	take	into	account	that	multiple	scores	were	evaluated	on	the	same	set	of	patients	and	
are	thus	likely	to	bias	the	interpretation	of	which	prognostic	score	performs	best	141.		
	
Groups	of	cohorts	evaluating	the	same	prognostic	scores	
Grouping	of	cohorts	where	the	same	prognostic	scores	could	be	calculated	was	the	first	step	to	
consider	correlations	introduced	by	predictions	performed	on	the	same	sample	of	patients.		Figure	1	
shows	the	grouping	of	cohorts.	In	group	1	(constituted	by	4	cohorts:	Copenhagen,	HUNT,	Japan,	SEPOC,	
as	shown	in	Figure	1)	information	on	FEV1,	age	and	dyspnea	was	available	to	calculate	the	GOLD	and	
ADO	score	for	each	participant.	In	contrast,	group	6	consisted	of	4	cohorts	(La	Princesa	Madrid	-	Requena	
II	-	Tenerife	-	Terrassa	II)	where	9	prognostic	scores	(all	except	for	the	SAFE	score)	could	be	calculated	for	
each	participant.	Figure	1	provides	a	visual	representation	of	these	groups	together	with	the	number	of	
events	(i.e.	deaths).	For	example,	the	dark	green	line	represents	group	1	where	the	GOLD	and	ADO	
scores	could	be	compared	against	each	other.	The	closed	polygons	show	the	comparisons	that	are	
possible	for	each	group	of	cohorts.	Group	6	is	represented	by	the	dark	yellow	polygon	that	includes	9	
scores.	Thus,	unlike	multiple	treatment	network	meta-analyses,	where	usually	two	or	at	most	three	
treatments	are	compared	in	each	trial,	Figure	1	shows	that	in	each	of	the	cohorts	of	our	database	we	can	
compare	between	2	and	9	prognostic	scores.	
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Figure	1	Network	representing	which	prognostic	scores	belong	to	the	different	groups.	Each	
node	represents	a	score	and	each	closed	polygon	represents	a	group	of	cohorts	where	the	same	
prognostic	scores	are	available.	The	thickness	of	the	lines	represents	the	total	number	of	deaths	in	the	
specific	group.	
	
MSC	meta-analysis	of	prognostic	scores	to	predict	3-year	mortality	in	patients	with	COPD	
The	lower-left	part	of	Table	3	shows	all	comparisons	between	the	AUCs	of	the	10	prognostic	
scores	taking	into	account	the	correlation	among	multiple	comparisons	for	the	same	patients	as	well	as	
direct	and	indirect	evidence	of	the	entire	network	(Figure	1).	The	median	AUC	of	the	GOLD	classification	
of	airflow	obstruction	severity	was	0.613	(interquartile	range	0.587	to	0.637)	and	is	shown	in	red	in	the	
upper-left	cell	as	an	anchor	to	interpret	the	differences	in	AUC	between	the	prognostic	scores.	
SAFE
newGOLDBODE
BODEupd
BODEx
eBODE
DOSE BAED
ADO
GOLD
Groups
Copenhagen*, HUNT, Japan, SEPOC* (378 deaths)
Barmelweid*, Basque*, Galdakao†, Pamplona†, Zaragoza I† (215 deaths)
Mar de Plata Argentina, PAC-COPD*, Son Espases Mallorca (61 deaths)
COPDgene (337 deaths)
Genkols, ICE COLD ERIC, Initiatives BPCO, Sevilla†, Terrassa I†, Terrassa III†, Zaragoza II† (722 deaths)
La Princesa Madrid, Requena II†, Tenerife†, Terrassa II† (125 deaths)
Number of deaths
200
400
600
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Compared	to	GOLD,	all	prognostic	scores	showed	statistically	significantly	higher	AUCs	except	for	the	B-
AE-D	and	GOLD	2011-2016	(cells	B1-L1	in	Table	3).	Compared	to	the	BODE	score	(the	most	commonly	
used	prognostic	score	in	COPD,	median	AUC	0.679	[interquartile	range	0.655	to	0.733]),	the	ADO,	
updated	BODE	and	eBODE	showed	higher	AUCs	whereas	all	other	scores	performed	worse.		
Figure	2	shows	the	comparisons	of	all	scores	against	the	BODE	score	and	that	the	ADO	score	and	
the	updated	BODE	performed	better	than	the	other	scores	(i.e.,	AUCADO	-	AUCBODE	=+0.015	[95%	CI	-0.002	
to	0.032],	p	=	0.08;	AUCBODE	updated	-	AUCBODE	=	0.008	[95%	CI	=	-0.005	to	+0.022];	p	=	0.23).	The	sensitivity	
analysis	undertaken	excluding	from	the	database	the	2	cohorts	used	in	the	large-scale	update	of	the	ADO	
index	55	shows	no	significant	differences.	
	
	
	
	
Fig.	2	Difference	in	AUC	(shown	with	confidence	interval	with	95%	confidence	level)	among	the	different	
scores	 and	 the	 BODE	 index	 (chosen	 here	 as	 the	 reference	 score)	 in	 the	 MSC	 meta-analysis.	 As	 a	
reference	we	use	the	median	of	the	AUC	of	the	BODE	score	0.679	(1st	Qu.	0.655,	3rd	Qu.	0.733).	
	
	
Heterogeneity,	transitivity	and	Inconsistency	
Global	heterogeneity	was	relatively	small	(τ2pooled	=	0.00011)	(we	did	not	use	a	τ2	for	each	group	
(τ2g)	since	this	is	not	recommended	when	there	are	groups	with	a	single	cohort	134).	The	groups	of	the	
MSC	meta-analysis	were	balanced	with	regard	to	characteristics	of	the	different	cohorts	that	may	modify	
CHAPTER	4:	Application	of	MSC	Meta-Analysis	
	
	105	
the	predictive	performance	of	the	scores	(all	a	priori	defined	characteristics	that	were	generating	case-
mix	were	not	statistically	significantly	different	across	groups)	and	we	could	thus	assume	transitivity.	
The	consistency	analyses	did	not	suggest	local	or	global	inconsistency	.	Visual	analysis	of	the	Q-Q	
plot	and	studentized	residuals	indicated	robust	local	consistency.	The	likelihood-ratio	test	statistic	
showed	overall	consistency	(Q	likelihood-ratio	test	=	25.29	≅	χ2(0.95,	16)	=	26.30,	p-value	=	0.06).		
	
Discussion	
Our	study	has	two	main	findings.	Firstly,	our	results	indicate	that	the	ADO	index	has	the	best	
ability	to	predict	3-year	mortality	in	patients	with	COPD,	followed	by	the	updated	BODE	and	eBODE	
indices.	Given	its	simplicity,	the	ADO	index	may	be	the	most	attractive	option	across	care	settings	to	
inform	patients	and	health	care	professionals	about	prognosis	and	to	inform	treatment	decisions	whose	
effectiveness	may	depend	on	life	expectancy.	Secondly,	we	presented	a	comprehensive	approach	for	
external	validation	and	concurrent	comparison	of	prognostic	scores	and	its	first	application.	MSC	meta-
analysis	is	a	method	adapted	from	network	meta-analysis	that	meets	the	call	for	new	approaches	for	
external	validation	and	concurrent	comparison	of	risk	prediction	models	and	scores	that	should	take	
advantage	of	data	sharing,	individual	patient	data	(IPD)	and	advanced	analytical	techniques	31,33,34,43,182.		
In	practice,	the	GOLD	score	using	just	lung	function	is	still	used	most	commonly	to	grade	disease	
severity,	which	is	traditionally	related	to	prognosis	as	in	other	fields	(e.g.	cancer).	FEV1%	pred.	(thus,	
GOLD	classification)	is	an	important	parameter	at	the	population-level	in	the	prediction	of	important	
clinical	outcomes	such	as	mortality	and	hospitalization.	The	revised	combined	COPD	assessment	and	
their	further	developments	integrates	the	severity	of	airflow	limitation	assessment,	providing	also	
information	regarding	symptom	burden	and	risk	of	exacerbation	50.	However,	the	results	of	our	analysis	
show	that,	when	the	aims	to	predict	mortality	in	individuals,	other	scores	such	as	ADO,	updated	BODE	
and	eBODE	are	substantially	better	than	the	GOLD	classifications	(in	our	analysis,	GOLD	and	GOLD	2011-
2016).	We	note	that	the	AUC	for	the	best	score	(ADO)	is	0.69,	a	moderately	good	discriminative	
performance;	however,	we	can	often	not	expect	a	much	higher	discriminative	performance	in	clinical	
settings	(for	instance,	see	126).	
The	predictive	performance	of	a	prognostic	score	is	important,	but	it	is	not	the	only	criterion	to	
choose	a	prognostic	score	for	practice.	Indeed,	with	an	eye	towards	applicability,	the	time,	cost	and	
burden	for	patients	and	practitioners	to	measure	the	predictors	of	a	prognostic	score	should	be	taken	
into	consideration	192.	We	deem	a	prognostic	score	such	as	ADO	to	be	easily	available	if	it	only	includes	
simple	questions,	easily	available	information	from	medical	charts	and	spirometry	(performed	for	the	
diagnosis	of	COPD)	50,52.		
Scores	to	predict	mortality	are	also	useful	beyond	estimating	prognosis.	Nowadays,	no	
treatments	to	lower	the	risk	of	mortality	are	available	for	patients	with	COPD	yet,	thus	for	this	outcome,	
prediction	scores	cannot	provide	risk-stratified	treatment	guidance.	However,	prognostic	scores	may	
help	to	make	randomized	trials	with	all-cause	mortality	as	primary	outcome	more	efficient	than	previous	
trials	by	only	including	patients	at	higher	risks	101.	Also,	prognostic	scores	for	all-cause	mortality	are	
particularly	attractive	for	multi-morbid	patients	such	as	COPD	patients,	where	cardiovascular	disease,	
diabetes,	renal	disease	and	lung	cancer,	among	other	conditions,	also	contribute	to	mortality	103,193.	
Patients	with	COPD	often	receive	less	than	optimal	prevention	and	treatment	of	cardiovascular	disease,	
which	may	partly	reflect	a	therapeutic	nihilism.	Of	course,	there	are	patients	who	are	unlikely	to	benefit	
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from	longterm	cardiovascular	prevention	because	of	short	life	expectancy.	However,	a	prognostic	score	
provides	a	better	basis	for	decisions	on	cardiovascular	prevention,	lung	cancer	screening	or	other	
treatments	and	may	limit	under-	and	over-treatment	in	COPD	1,194,195.	
Many	prognostic	models	and	scores	(as	the	models’	simplified	form)	are	never	validated	in	
practice	and	many	investigators	develop	a	second	model	instead	of	relying	on	existing	scores	at	least	as	a	
starting	point.	Such	practice	has	led	to	numerous	prognostic	scores	for	the	same	conditions	that	are	left	
without	external	validation.	Thus,	we	introduced	MSC	meta-analysis,	which	addresses	the	lack	of	
external	validation	and	comparisons	of	prognostic	scores	by	providing	a	comparison	of	their	predictive	
performance	in	external	validation	cohorts	and	simultaneously	considering	the	entire	network	of	direct	
and	indirect	comparisons.	Thereby,	it	allows	for	a	comparison	of	predictive	performance	that	is	not	
limited	by	non-comparable	spectrum	of	populations	as	it	is	commonly	the	case	when	evaluating	the	
results	of	independent	validation	studies.	MSC	meta-analysis	can	be	applied	to	any	medical	field,	with	
the	availability	of	individual	patient	data	being	the	only	major	limiting	factor.	
Strengths	of	our	study	are	the	careful	analytical	approach	to	MSC	meta-analysis	and	the	availability	of	
the	R	code	that	allow	for	widespread	use	and	potential	further	development	of	the	method.	For	the	
particular	application	of	MSC	meta-analysis	here,	a	major	strength	is	the	large	high-quality	database	of	
the	3CIA	collaboration	with	the	broadest	possible	COPD	patient	spectrum.	The	diverse	case	mix	and	
broad	patient	spectrum	greatly	increases	the	probability	that	our	results	are	generalizable	to	all	COPD	
patients.	A	limitation	of	the	study	is	that,	ideally,	a	network	meta-analysis	is	conducted	prospectively	and	
jointly	planned	for	all	of	the	cohorts	involved	to	ensure	equality	of	the	clinical	settings	and	homogeneity	
of	study	design,	conduct	and	variable	definitions.	Though,	this	will	rarely	be	the	case	in	reality.	Another	
limitation	of	our	analysis	is	that	we	only	used	AUC	as	a	performance	measure,	which	we	did	for	
theoretical	and	practical	reasons180.	In	general	improvements	in	AUC	have	to	be	interpreted	with	caution	
196.	Furthermore,	we	cannot	exclude	the	possibility	of	case-mix	effects	due	to	variables	that	were	not	
available	in	the	database	or	unknown.		
Further	research	needs	include	the	extension	of	MSC	to	include	measures	of	calibration,	which	is	
arguable	as	important	as	discrimination.	For	the	area	of	COPD,	it	would	be	attractive	to	apply	MSC	to	risk	
scores	for	exacerbations	50,197.	However,	there	are	likely	too	few	thoroughly	developed	and	externally	
validated	scores	to	predict	exacerbations	in	patients	with	COPD	126.	Finally,	given	the	large	number	of	risk	
scores	in	the	medical	field	and	the	lack	of	external	validations	and	comparisons	of	risk	scores,	there	is	a	
great	need	for	comparative	studies	that	may	use	MSC	in	order	to	inform	clinical	practice	and	research	
about	the	most	predictive	scores	126.	
	
Discussion	
Our	 study	has	 two	main	 findings.	 Firstly,	 our	 results	 indicate	 that	 the	ADO	 index	has	 the	best	
ability	 to	 predict	 3-year	mortality	 in	 patients	 with	 COPD,	 followed	 by	 the	 updated	 BODE	 and	 eBODE	
indices.	 Given	 its	 simplicity,	 the	 ADO	 index	may	 be	 the	most	 attractive	 option	 across	 care	 settings	 to	
inform	patients	and	health	care	professionals	about	prognosis	and	to	inform	treatment	decisions	whose	
effectiveness	may	 depend	 on	 life	 expectancy.	 Secondly,	 we	 presented	 a	 comprehensive	 approach	 for	
external	validation	and	concurrent	comparison	of	prognostic	scores	and	its	first	application.	MSC	meta-
analysis	 is	 a	method	adapted	 from	network	meta-analysis	 that	meets	 the	 call	 for	 new	approaches	 for	
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external	 validation	 and	 concurrent	 comparison	 of	 risk	 prediction	models	 and	 scores	 that	 should	 take	
advantage	of	data	sharing,	individual	patient	data	(IPD)	and	advanced	analytical	techniques	31,33,34,43,182.		
In	 practice,	 the	GOLD	 score	 using	 just	 lung	 function	 is	 used	most	 commonly	 to	 grade	 disease	
severity,	which	 is	 traditionally	 related	 to	 prognosis	 as	 in	 other	 fields	 (e.g.	 cancer).	 FEV1%	pred.	 (thus,	
GOLD	classification)	is	a	very	important	parameter	at	the	population-level	in	the	prediction	of	important	
clinical	 outcomes	 such	 as	 mortality	 and	 hospitalization.	 The	 revised	 combined	 COPD	 assessment	
integrates	 the	severity	of	airflow	 limitation	assessment,	providing	also	 information	regarding	symptom	
burden	 and	 risk	 of	 exacerbation	 50.	However,	 the	 results	 of	 our	 analysis	 show	 that,	when	 the	 aims	 to	
predict	mortality	 in	 individuals,	other	 scores	 such	as	ADO,	updated	BODE	and	eBODE	are	 substantially	
better	than	the	GOLD	classifications	(in	our	analysis,	GOLD	and	GOLD	2011-2016).		
The	predictive	performance	of	a	prognostic	score	is	important,	but	it	is	not	the	only	criterion	to	
choose	 a	 prognostic	 score	 for	 practice.	 Indeed,	 with	 an	 eye	 towards	 applicability,	 the	 time,	 cost	 and	
burden	 for	patients	and	practitioners	 to	measure	the	predictors	of	a	prognostic	score	should	be	taken	
into	consideration	192.	We	deem	a	prognostic	score	such	as	ADO	to	be	easily	available	if	it	only	includes	
simple	 questions,	 easily	 available	 information	 from	medical	 charts	 and	 spirometry	 (performed	 for	 the	
diagnosis	 of	 COPD)	 50,52.	We	 provide	 an	 example	 for	 how	 to	 balance	 the	 predictive	 performance	 and	
applicability	of	different	prognostic	scores	in	the	supplementary	material.		
Scores	to	predict	mortality	are	also	useful	beyond	estimating	prognosis.	Nowadays,	there	are	no	
treatments	to	lower	the	risk	of	mortality	are	available	for	patients	with	COPD	yet,	thus	for	this	outcome,	
prediction	 scores	 cannot	 provide	 risk-stratified	 treatment	 guidance.	 However,	 prognostic	 scores	 may	
help	to	make	randomized	trials	with	all-cause	mortality	as	primary	outcome	more	efficient	than	previous	
trials	 by	 only	 including	 patients	 at	 higher	 risks	 101.	 Also,	 prognostic	 scores	 for	 all-cause	 mortality	 are	
particularly	 attractive	 for	multi-morbid	 patients	 such	 as	 COPD	 patients,	where	 cardiovascular	 disease,	
diabetes,	renal	disease	and	lung	cancer	also	contribute	to	mortality	103.	Patients	with	COPD	often	receive	
less	 than	 optimal	 prevention	 and	 treatment	 of	 cardiovascular	 disease,	 which	 may	 partly	 reflect	 a	
therapeutic	 nihilism.	 Of	 course,	 there	 are	 patients	 who	 are	 unlikely	 to	 benefit	 from	 long	 term	
cardiovascular	 prevention	 because	 of	 short	 life	 expectancy.	 However,	 a	 prognostic	 score	 provides	 a	
better	basis	 for	decisions	on	cardiovascular	prevention,	 lung	cancer	screening	or	other	treatments	and	
may	limit	under-	and	over-treatment	in	COPD	1,194,195.	
Many	 prognostic	 models	 and	 scores	 (as	 the	 models’	 simplified	 form)	 are	 never	 validated	 in	
practice	and	many	investigators	develop	a	second	model	instead	of	relying	on	existing	scores	at	least	as	a	
starting	point.	Such	practice	has	led	to	numerous	prognostic	scores	for	the	same	conditions	that	are	left	
without	 external	 validation.	 Thus,	 we	 introduced	 MSC	 meta-analysis,	 which	 addresses	 the	 lack	 of	
external	validation	and	comparisons	of	prognostic	scores	by	providing	a	comparison	of	their	predictive	
performance	in	external	validation	cohorts	and	simultaneously	considering	the	entire	network	of	direct	
and	 indirect	 comparisons.	 Thereby,	 it	 allows	 for	 a	 comparison	 of	 predictive	 performance	 that	 is	 not	
limited	 by	 non-comparable	 spectrum	 of	 populations	 as	 it	 is	 commonly	 the	 case	 when	 evaluating	 the	
results	of	 independent	validation	studies.	MSC	meta-analysis	 can	be	applied	 to	any	medical	 field,	with	
the	availability	of	individual	patient	data	being	the	only	major	limiting	factor.	
Strengths	 of	 our	 study	 are	 the	 careful	 analytical	 approach	 to	 MSC	 meta-analysis	 and	 the	
availability	 of	 the	 R	 code	 that	 allow	 for	 widespread	 use	 and	 potential	 further	 development	 of	 the	
method.	 For	 the	 particular	 application	 of	MSC	meta-analysis	 here,	 a	major	 strength	 is	 the	 large	 high-
CHAPTER	4:	Application	of	MSC	Meta-Analysis	
	
	108	
quality	 database	 of	 the	 3CIA	 collaboration	 with	 the	 broadest	 possible	 COPD	 patient	 spectrum.	 The	
diverse	 case	 mix	 and	 broad	 patient	 spectrum	 greatly	 increases	 the	 probability	 that	 our	 results	 are	
generalizable	 to	all	COPD	patients.	A	 limitation	of	 the	study	 is	 that,	 ideally,	a	network	meta-analysis	 is	
conducted	 prospectively	 and	 jointly	 planned	 for	 all	 of	 the	 cohorts	 involved	 to	 ensure	 equality	 of	 the	
clinical	 settings	 and	 homogeneity	 of	 study	 design,	 conduct	 and	 variable	 definitions.	 Though,	 this	 will	
rarely	be	the	case	in	reality.	Another	limitation	of	our	analysis	is	that	we	only	used	AUC	as	a	performance	
measure,	which	we	 did	 for	 theoretical	 and	 practical	 reasons	 (see	 supplementary	material);	 in	 general	
improvements	 in	 AUC	 have	 to	 be	 interpreted	 with	 caution	 196.	 Furthermore,	 we	 cannot	 exclude	 the	
possibility	of	case-mix	effects	due	to	variables	that	were	not	available	in	the	database	or	unknown.		
Further	 research	 needs	 include	 the	 extension	 of	 MSC	 to	 include	 measures	 of	 calibration,	 which	 is	
arguable	as	important	as	discrimination.	For	the	area	of	COPD,	it	would	be	attractive	to	apply	MSC	to	risk	
scores	 for	 exacerbations	 50,197.	However,	 there	 are	 likely	 too	 few	 thoroughly	 developed	 and	externally	
validated	scores	to	predict	exacerbations	in	patients	with	COPD	126.	Finally,	given	the	large	number	of	risk	
scores	in	the	medical	field	and	the	lack	of	external	validations	and	comparisons	of	risk	scores,	there	is	a	
great	need	for	comparative	studies	that	may	use	MSC	 in	order	to	 inform	clinical	practice	and	research	
about	the	most	predictive	scores	126.	
	
Conclusions	
Borrowing	from	network	meta-analysis,	we	presented	a	comprehensive	approach	for	external	
validation	and	concurrent	comparison	of	multiple	prognostic	scores.	While	our	analyses	showed	best	
performance	for	the	ADO	and	updated	BODE	scores	to	predict	mortality	for	patients	with	COPD,	MSC	
meta-analysis	can	be	applied	to	prognostic	scores	in	any	the	medical	field	to	identify	the	best	scores,	
possibly	paving	the	way	for	stratified	medicine,	public	health	and	research.	
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State	of	the	art	
This	thesis	has	focused	on	prediction	models	with	a	practical	application	to	COPD.	Prediction	models	are	
supposed	to	help	in	clinical	practice,	public	health	management	and	medical	research.	However,	in	most	
clinical	fields,	the	path	from	model	development	to	clinical	application	still	has	a	long	way	to	go.1	Some	
medical	 fields	 are	 already	 in	 the	 stage	 of	 clinical	 application,	 being	 supported	 by	 guidelines,	 which	
strongly	 recommend	 the	use	of	prediction	models.	 For	 instance,	 in	 cardiovascular	disease,	 the	 famous	
Framingham	risk	score	 is	already	widely	accepted2–5	and	 is	used	 in	clinical	practice	 to	complement	 the	
assessment	 of	 the	 clinicians;	 for	 instance,	 in	 the	 UK	 general	 practitioners	 have	 routine	 access	 to	 risk	
score	calculators.6	In	other	fields,	like	COPD,	the	use	of	prediction	models	is	still	half	way	through;	some	
promising	models	were	developed,	but	they	are	mostly	used	in	research	but	not	widely	accepted	by	the	
medical	community	yet.	Clinicians	are	often	reluctant	to	use	models	 that	do	not	 look	 intuitive,	neither	
doctor-	nor	patient-friendly,	which	are	thus	not	easy	to	use	 in	practice.6	 In	particular,	one	of	 the	most	
famous	COPD	guidelines	reports	only	a	brief	paragraph	to	speak	about	only	one	of	the	dozens	of	models	
developed	in	the	field.7	
The	 skepticism	 of	 clinicians	 is	 in	 part	 justified,	 because	 some	 prerequisites	 for	 the	 use	 of	 prediction	
models	 are	 not	 met.	 In	 particular,	 for	 a	 model	 to	 be	 reliable	 for	 clinical	 practice,	 it	 has	 to	 satisfy	 to	
following	requirements:	
	
- To	inform	specific	decisions.	
- To	follow	a	sound	methodological	development.8,9	
- To	show	accuracy	(i.e.,	prognostic	properties	in	the	derivation	cohort	in	which	it	was	developed)	
- To	 show	 good	 reproducibility	 (i.e.,	 a	 good	 performance	 of	 the	 model	 in	 the	 same	 source	
population	of	the	derivation	cohort,	for	example	by	bootstrapping	or	cross-validation)8–13	
- To	show	good	transportability	(i.e.,	a	good	performance	of	the	model	in	a	different	population	or	
“out-of-sample”,	by	external	validation).10,14–18	
- To	be	of	proven	clinical	effectiveness	(i.e.	as	shown	by	an	impact	study).18–20	
	
This	 dissertation	 has	 addressed	 some	 of	 these	 critical	 points	 both	 from	 a	methodological	 and	 COPD-
specific	perspective	and	provides	a	basis	 from	moving	 forward	 the	use	of	prediction	model	 in	practice	
and	in	research.	
The	methodological	contribution	
We	took	up	the	challenge	(highlighted	several	times	in	top	journals)21,22	for	new	approaches	of	external	
validation	and	concurrent	comparison	of	risk	prediction	models	that	should	take	advantage	of	“big	data”	
sharing,23,24	 individual	patient	data	 (IPD)	and	advanced	analytical	 techniques.22,25–31	 Indeed,	widespread	
recognition	of	the	value	of	collaborative	initiatives,	together	with	medical	registries	(where	either	active	
or	 passive	 follow-up	 procedures	 are	 in	 place	 to	 capture	 disease	 occurrence	 or	 outcomes)	 and	
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implementation	of	medical	information	systems	(that	have	similar	data	capture	capability	as	registries)	all	
offer	great	opportunities	for	data	sharing	and	exploitation	which	counter	this	problem.		
This	 thesis	 provides	 the	 new	 methodology	 of	 MSC	 meta-analysis	 that	 allows	 for	 extensive	 external	
validation	 of	 all	 prediction	models	 that	 are	 assessed	 in	 a	 given	 number	 of	 cohort	 studies.	 Until	 now,	
prediction	 models	 were,	 if	 at	 all,	 validated	 in	 one	 or	 few	 external	 cohort	 studies.	 MSC	meta-analysis	
probably	 provides	 the	 most	 definitive	 estimates	 of	 prediction	 model	 performance	 possible	 since	 the	
estimates	 are	 based	 on	 as	many	 cohort	 studies	 that	 are	 available.	We	 had	 the	 privilege	 of	 having	 26	
cohort	studies	of	the	COPD	Cohorts	Collaborative	International	Assessment	(3CIA)	consortium32	available	
to	apply	MSC	meta-analysis	for	the	first	time.	In	addition,	MSC	meta-analysis	allows	for	the	comparison	
of	prediction	models,	which	is	rarely	done	although	of	great	importance	for	those	who	want	to	use	the	
most	accurate	and	applicable	prognostic	model.	MSC	meta-analysis	can	be	applied	 in	any	medical	 field	
and	contribute	to	a	better	evidence	base	on	the	(comparative)	performance	of	prediction	models.	
	
The	contribution	to	the	area	of	COPD	
This	 thesis	 provides	 valuable	 information	 on	 prediction	 models	 for	 exacerbations	 and	 mortality.	 The	
systematic	review	clearly	showed	that	none	of	the	prediction	models	for	exacerbations	are	ready	for	use	
yet.	Most	of	the	27	prediction	models	were	not	developed	following	rigorous	methodological	standards	
and	almost	no	one	of	them	has	been	validated.	Even	if	one	wanted	to	compare	the	performance	of	these	
prediction	 models	 great	 caution	 is	 needed	 because	 exacerbations	 were	 defined	 and	 measured	 in	
different	 ways	 and	 because	 the	 statistical	 models	 were	 so	 diverse	 that	 they	 serve	 different	 aims	 for	
predicting	exacerbations.	This	is	a	pity	since	the	prediction	of	exacerbations	would	be	much	needed	for	
risk-stratified	treatment	and	to	ultimately	improve	COPD	care	by	reducing	the	risk	for	exacerbations	that	
have	a	detrimental	effect	on	health-related	quality	of	life,	survival	and	health-care	cost.		
In	 contrast	 to	exacerbations,	 the	evidence	base	on	 the	performance	of	prediction	models	 for	death	 is	
now	 strong,	 thanks	 to	 the	 first	 application	 of	MSC	meta-analysis	 to	 a	 large	 number	 of	 COPD	 patients	
from	 diverse	 settings.	 There	 is	 clearly	 room	 for	 improving	 their	 predictive	 performance,	 but	 for	 the	
existing	prognostic	scores	evaluated	 in	this	thesis,	 there	 is	now	strong	evidence	on	their	 (comparative)	
performance.	Our	MSC	meta-analysis	 showed	 that	 the	 ADO	 and	 BODE	 updated	 index	 clearly	 perform	
best	and	the	easy	availability	of	the	three	predictors	of	the	ADO	index	speaks	for	adopting	this	score	in	
research	and	practice.33	While	 risk-stratified	 treatment	of	COPD	based	on	mortality	may	not	be	at	 the	
core	of	COPD	management,	the	prediction	of	mortality	may	guide	clinicians	in	the	use	of	other	therapies	
(e.g.	 for	cardiovascular	disease,	which	 is	highly	prevalent	 in	COPD	patients)	and	help	reducing	some	of	
the	nihilistic	approach	towards	treating	COPD	patients	beyond	COPD-specific	therapies.	Also,	it	may	help	
to	inform	the	decision	for	and	against	lung	cancer	screening,	which	is	a	relevant	issue	for	COPD	patients,	
who	are	at	substantially	higher	risk	of	lung	cancer	than	people	without	COPD:	some	guidance	currently	
suggests	 not	 to	 screen	 COPD	 patients	 because	 of	 their	 high	 risk	 for	 complications	 if	 lung	 cancer	 is	
detected	and	treated.	However,	the	clinical	manifestations	of	COPD	are	highly	heterogeneous	as	is	their	
prognosis	so	that	a	risk-stratified	approach	to	screening,	which	is	recommended	anyway	(i.e.	guided	by	
smoking	history	and	other	factors),	based	also	on	mortality	may	be	attractive.		
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Finally,	 the	ADO	and	updated	BODE	 scores	 as	 the	most	 accurate	 scores	 can	be	used	 to	 identify	COPD	
patients	 for	 trials,	 that	 have	 specific	 eligibility	 criteria	 in	 terms	 of	mortality.	 Some	 trials	may	want	 to	
identify	patients	at	low	risk	for	mortality,	whereas	other	trials	with	mortality	as	an	outcome	may	go	for	
moderate	to	high	risk	patients	 in	order	 to	make	these	trials	as	efficient	as	possible	 in	 terms	of	sample	
sizes	 needed.	 The	 prognostic	 scores	 can	 also	 be	 used	 for	 control	 of	 confounding,	 either	 through	 pre-
stratification	in	trials	or	through	statistical	adjustment	of	analysis	of	trials	or	cohort	studies.	
	
What	is	still	missing?	
Starting	from	this	thesis,	possible	future	research	projects	contributing	to	the	applicability	of	prediction	
models	are	highlighted	in	the	following	paragraphs.		
Comparison	with	a	competitor	approach	
As	we	have	seen	in	details	previously,	the	MSC	meta-analysis	approach	relies	on	a	group	structure	that	is	
defined	 by	 the	 patterns	 of	 missing	 data	 (in	 the	 same	 group	 we	 have	 cohorts	 with	 the	 same	 scores	
available,	according	to	the	variables	collected	for	each	database).	As	opposed	to	the	MSC	meta-analysis,		
a	second	promising	approach	for	external	validation	and	comparison	of	prediction	models	is	to	impute	all	
the	 missing	 data,	 not	 only	 for	 the	 variables	 existing	 in	 the	 cohort	 databases,	 but	 also	 for	 variables	
completely	 missing	 in	 individual	 databases.	 Imputing	 a	 whole	 variable	 in	 a	 cohort	 could	 sound	 not	
intuitive	 or	 not	 reliable;	 however,	 recent	 studies	 support	 the	 imputation	 or	 predictors	 even	 in	 the	
extreme	 scenario	 of	 variable	 completely	 missing.34	 With	 this	 approach,	 the	 patterns	 of	 missing	 data	
would	disappear	and	we	would	not	need	a	network	meta-analysis	approach	anymore.	At	first	glance,	the	
MSC	 meta-analysis	 should	 be	 a	 more	 conservative	 approach	 when	 several	 variables	 are	 completely	
missing	 in	several	cohorts;	 instead,	when	a	small	 fraction	of	variables	are	missing	 in	a	small	 fraction	of	
cohorts,	 the	 “whole-variable	 imputation”	 technique	 could	 be	 more	 precise	 and	 less	 computationally	
burdensome.8,35	A	need	for	medical	research	is	to	further	explore	and	compare	these	two	methodologies	
and	 to	 understand	 in	which	 case	 the	 one	 outperforms	 the	 other,	 in	 terms	 of	 precision	 and	 reliability,	
according	to	the	available	database	(in	particular	the	patterns	of	missing	data).				
A	comprehensive	assessment	of	the	performance	of	prediction	models		
It	is	of	great	importance	to	extend	the	MSC	methodology	to	calibration	properties.36,37	Indeed,	MSC	was	
initially	 developed	 to	 evaluate	 the	 discriminative	 performance.	 It	 needs	 to	 be	 extended	 to	 calibration	
properties	 (discrimination	 and	 calibration	 properties	 being	 the	 ones	 in	which	 the	 overall	 performance	
measures	of	prediction	models	can	be	decomposed;	for	instance,	this	can	be	formally	done	for	the	Brier	
score).38,39	One	possible	candidate	as	a	calibration	performance	measure	is	the	“calibration	slope”.36		
	
Concluding	remarks	
We	shed	light	on	the	current	state	of	models	predicting	exacerbations	in	patients	with	COPD,	highlighting	
that	none	of	the	twenty-seven	prediction	models	for	COPD	exacerbations	appears	to	be	ready	to	support	
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personalized	COPD	 treatment	or	 research.	 Furthermore,	we	 filled	a	main	gap	 in	 the	area	of	prediction	
models	by	developing	 the	methods	 for	MSC	meta-analysis.	Thereby,	 large-scale	external	validation	and	
comparison	of	prediction	models	become	possible.	The	application	of	MSC	meta-analysis	suggests	 that	
the	 ADO	 index	 may	 be	 the	 best	 suited	 score	 to	 use	 in	 clinical	 practice	 for	 prediction	 of	 mortality	 in	
patients	 with	 COPD	 since	 it	 performed	 best	 among	 all	 scores	 and	 since	 its	 components	 are	 easily	
available.		
	
MSC	meta-analysis	 can	 be	 applied	 to	 any	 field	 of	medicine	 and	 addresses	 the	 great	 need	 for	 external	
validation	and	comparison	of	prediction	models.	Thereby,	 the	best	prediction	models	can	be	 identified	
paving	the	way	for	risk-stratified,	personalized	medicine.	
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